i 
 SUMMARY OF CHANGES  
Protocol 
 
Protocol #: CITN -14, A4_v1.0 
NCI Protocol # : CITN -14, A4_v1.0 
Protocol Version Date : October 12, 2022  
 
I. Changes requested by  the P harmaceutical Management Branch  
# Section  Page  Comments  
1.  
8 1.1  77 Revised the Atezolizumab drug information, as requested by the 
Pharmaceutical Management Branch on October 6, 2022.  
 
 
II. Changes initiated by the Protocol Principal Investigator and CITN Coo r dinating Center  
# Section  Page  Comments  
2.  3.2.8  25 Clarified that oral prednisone > 10 mg/day or equivalent is prohibited.  
3.  
3.2.14  27 Revised criterion to align with current available  literature and standard 
language used on other immunotherapy trials. As currently written, 
exclusion criterion 3.2.14 is too prescriptive and limits enrollment of 
patients with established stability for autoimmune disease. As 
appropriate, a llowing enrollment of these patients fo llowing 
consultation with the Protocol PI and/or CITN Coordinating Center 
may help  trial accrual.   
 
III. Administrative Changes  
# Section  Page  Comments  
4.  All sections  All pages Updated version and date throughout protocol -  
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
2 Statistician: Study Coordinator: N/A 
Axio Research  
2601, 4th Avenue, Suite 200 
Seattle, WA 98121 Phone: (206) 547-2829 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
NCI-Supplied Agent(s) :  Atezolizumab (MPDL3280A; NSC 783608)  
Recombinant Human IL-7 (CYT107; NSC 767713) 
Other Agent(s): N/A 
IND #:    
IND Sponsor: DCTD, NCI  
Protocol Type / Version # / Version Date:  Amendment #4 /
  Version 1.0 / October 12, 2022 
Use of this document is governed by the terms of use on the first page of this document 

NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
3 CONTACT INFORMATION  
For regulatory 
requirements:  For patient enrollments:  For study data 
submission:  
Regulatory documentation 
must be submitted to the  
Cancer Trials Support Unit 
(CTSU ) via the Regulatory 
Submission Portal. 
Regulatory Submission Portal: 
(Sign in at 
https://www.ctsu.org , and 
select the Regulatory 
Submission sub- tab under the 
Regulatory tab.) 
Institutions with patients 
waiting that  a
re unable to use 
the Portal should alert the 
CTSU Regulatory Office 
immediately  by phone or 
email: 1-866-651- CTSU 
(2878), or CTSURegHelp@coccg.org to 
receive further instruction and support. 
Contact the CTSU Regulatory 
Help Desk at 1 -866-651- CTSU 
(2878) for regulatory 
assistance.  Please refer to the patient enrollment 
section of the protocol for instructions 
on using the Oncology Patient 
Enrollment Network (OPEN) which 
can be accessed at 
https://www.ctsu.org/OPEN SYSTEM/  
or https://OPEN.ctsu.org. 
Contact the CTSU Help Desk with any OPEN -related questions by phone or 
email:1 -888-823-5923 
ctsucontact@westat.com . Data collection for this 
study will be done exclusively through 
Medidata Rave. Please see 
the data submission section of the protocol for further 
instructions. 
The most current version of the study protocol and all supporting documents must be downloaded 
from the protocol -specific Web page of the CTSU Member Web site located at https://www.ctsu.org. 
Access to the CTSU members’ website is managed through the Cancer Therapy and Evaluation 
Program - Identity and Access Management (CTEP -IAM)  registration system and requires user log on 
with CTEP-IAM username and password. Permission to view and download this protocol and its supporting documents is restricted and is based on person and site roster assignment housed in the 
CTSU RSS.  
For clinical questions ( i.e., patient eligibility or treatment -related)  
Contact the CITN Central Operations and Statistical Center at citn@fredhutch.org  or (514) 718-2858 
For non clinical  questions ( i.e., unrelated to patient eligibility, treatment, or clinical data 
submission) Contact the CTSU Help Desk by phone or email : 
CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com .  
All calls and correspondence will be triaged to the appropriate CTSU representative. 
The CTSU Website is located at  https://www.ctsu.org . 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
4 STUDY SUMMARY  
Abbreviated Title  Urothelial Carcinoma Therapy with Atezolizumab plus CYT107  
Trial Phase  Phase II  
Clinical Indication  Locally advanced or metastatic urothelial carcinoma  
Trial Type  Randomized, controlled trial with initial Safety Run -In phase  
Safety Run -In Enrollment of 6 patients to the Experimental arm. If acceptable safety 
profile, patient randomization will begin.  
Type of control  Randomized trial with primary end point of o bjective  response rate 
(ORR). Secondary endpoint of clinical benefit rate (CBR), 
progression-free survival (PFS), Duration of Response (DOR) and 
overall survival (OS) will compare the control arm to the experimental arm.  
Randomization arm  
1 – Experimental  IL-7 (CYT107 ), 10 mcg/kg intramuscularly (IM) days 1, 8, 15 and 22 
of cycle 1 only (28- day cycle) + Atezolizumab, 1200 mg intravenously 
(IV) day 8 of cycle 1 (28-day cycle) and day 1 of subsequent cycles
(21-day cycle)
2 – Control Atezolizumab, 1200  mg intravenously (IV) day 1 of each cycle (21 -
day cycle)  
Stratification Factor  None  
Trial Blinding  None  
Number of trial patients  54 patients 
Estimated duration of trial  Trial is expected to be completed over a period of 30 months. 
Duration of Participation  Each patient will participate in the trial from the time the Informed 
Consent Form (ICF) is signed through final protocol- specified contact. 
The active study will end when the last patient reaches 2 years.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
5 
 TABLE OF CONTENTS  
STUDY SUMMARY .................................................................................................................................... 4 
TABLE OF CONTENTS  .............................................................................................................................. 5 
1. OBJECTIVES  ....................................................................................................................................... 7 
1.1 Primary Objectives  ........................................................................................................................ 7 
1.2 Secondary Objectives .................................................................................................................... 7 
1.3 Exploratory Objectives ................................................................................................................. 7 
2. BACKGROUND  .................................................................................................................................. 8 
2.1 Study Disease(s)  ............................................................................................................................ 8 
2.2 CTEP IND Agent(s) ...................................................................................................................... 8 
2.3 Other Agent(s): N/A  ................................................................................................................... 15 
2.4 Rationale  ..................................................................................................................................... 15 
2.5 Integrated Correlative Studies Background  ................................................................................ 16 
2.6 Exploratory/Ancillary Correlative Studies  .................................................................................. 19 
2.7 Special Studies  ............................................................................................................................ 22 
3. PATIENT SELECTION  ..................................................................................................................... 23 
3.1 Eligibility Criteria  ....................................................................................................................... 23 
3.2 Exclusion Criteria ....................................................................................................................... 25 
3.3 Inclusion of Women and Minorities ........................................................................................... 28 
4. REGISTRATION PROCEDURES  .................................................................................................... 28 
4.1 Investigator and Research Associate Registration with CTEP  ................................................... 28 
4.2 CTSU Registration Procedures  ................................................................................................... 29 
4.3 Delegation of Tasks Log (DTL) .................................................................................................. 31 
4.4 Patient Enrollment  ...................................................................................................................... 32 
4.5 General Guidelines ...................................................................................................................... 33 
5. TREATMENT PLAN  ......................................................................................................................... 33 
5.1 Agen
t Administration  .................................................................................................................. 34 
5.2 Safety Run- in: Definition of Dose- Limiting Toxicity  ................................................................. 37 
5.3 General Concomitant Medication and Supportive Care Guidelines ........................................... 38 
5.4 Duration of Therapy .................................................................................................................... 40 
5.5 Study Treatment beyond Disease Progression ............................................................................ 41 
5.6 Duration of Follow- Up................................................................................................................ 41 
5.7 Patient Replacement  .................................................................................................................... 42 
6. DOSING DELAYS/DOSE MODIFICATIONS ................................................................................. 42 
6.1 Atezolizumab (MPDL3280A)..................................................................................................... 42 
6.2 Recombinant Human IL-7 (CYT107) ......................................................................................... 64 
7. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  .............................................. 66 
7.1 Comprehensive Adverse Events and Potential Risks List (CAEPR)  .......................................... 66 
7.2 Adverse Event Characteristics .................................................................................................... 72 
7.3 Expedited Adverse Event Reporting ........................................................................................... 72 
7.4 Routine Adverse Event Reporting .............................................................................................. 76 
7.5 Pregnancy .................................................................................................................................... 76 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
6 
 7.6 Secondary Malignancy  ................................................................................................................ 76 
7.7 Second Malignancy  ..................................................................................................................... 76 
8. PHARMACEUTICAL INFORMATION  ........................................................................................... 77 
8.1 CTEP IND Agent(s) .................................................................................................................... 77 
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  ......................................................... 81 
9.1 Integrated Correlative Studies  ..................................................................................................... 82 
9.2 Exploratory Correlative Studies .................................................................................................. 85 
9.3 Special Studies  ............................................................................................................................ 88 
10. STUDY CALENDAR  ........................................................................................................................ 91 
11. MEASUREMENT OF EFFECT ........................................................................................................ 95 
11.1 Antitumor Effect – Solid Tumors ........................................................................................... 95 
11.2 Other Response Parameters: Immune- Related Response Criteria (irRC)  ............................. 101 
12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY REQUIREMENTS  .......... 101 
12.1 Study Oversight..................................................................................................................... 101 
12.2 Data Submission/Reporting  .................................................................................................. 101 
12.3 CTEP Multicenter Guidelines  ............................................................................................... 103 
12.4 Collaborative Agreements Language  .................................................................................... 103 
12.5 Genomic Data Sharing Plan: N/A  ......................................................................................... 105 
13. STATISTICAL CONSIDERATIONS  ............................................................................................. 105 
13.1 Responsibility for Analyses  .................................................................................................. 105 
13.2 Study Design/Objectives ....................................................................................................... 105 
13.3 Sample Size/Accrual Rate  ..................................................................................................... 106 
13.4 Stratification Factors  ............................................................................................................. 107 
13.5 Analysis of Secondary Endpoints ......................................................................................... 107 
13.6 Reporting and Exclusions  ..................................................................................................... 108 
14. REFERENCES  ................................................................................................................................. 110 
APPENDIX A  PERFORMANCE STATUS CRITERIA  ....................................................................... 113 
APPENDIX B  CTEP MULTICENTER GUIDELINES  ......................................................................... 114  
APPENDIX C  IMM UNE -R
ELATED RESPONSE CRITERIA  ............................................................ 116 
APPENDIX D  DOSE ADJUSTMENT FOR OBESE PATIENT  ........................................................... 118 
APPENDIX E  MICROBIOME SAMPLE COLLECTION  .................................................................... 120 
APPENDIX F  ABBREVIATIONS LIST  ............................................................................................... 121 
 
 
  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
7 
 1. OBJECTIVES  
The goals of this trial are to evaluate the safety and tolerability of the investigational treatment 
combination, and to determine whether the addition of CYT107 to atezolizumab improves the objective response rate achieved by atezolizumab alone in patient s with advanced/non- resectable 
bladder cancer who have recurrent disease after  platinum chemotherapy. 
1.1 Primary Objectives  
To determine the clinical efficacy of the investigational treatment combination. 
The primary endpoint will be the Objective Response Rate ( ORR ), defined by Complete 
Response (CR) or Partial Response (PR) as measured by RECIST v1.1. 
1.2 Secondary Objectives  
To determine the clinical activity  and toxicity of the investigational treatment combination.  
 The clinical benefit rate (CBR), progression -free survival (PFS), duration of response 
(DOR) , as measured by RECIST 1.1 and irRC , and overall survival (OS). 
 The CBR, PFS, DOR, and OS in all patients and patients stratified by PD -L1 expression 
levels in the tumor microenvironment. 
 The safety and toxicity of addition of CYT107 to atezolizumab. 
1.3 Exploratory Objectives 
To determine the immune correlates of the clinical activity of the investigational treatment 
combination. 
The endpoints will include the evaluation of the effect of the investigational treatment 
combination on the tumor microenvironment, based upon baseline and post- baseline tumor 
biopsy comparisons of: 
• Number, distribution, and phenotype of tumor- infiltrating cells  
• PD-L1 expression 
• Expression of Interferon γ (IFNγ) and associated inflammatory gene expression in the 
tumor microenvironment 
Explore the effect of the investigational treatment combination on the number and phenotype of 
tumor- specific T  cells in the peripheral blood. Investigate for evidence that the investigational 
treatment combination increases the exposure of bladder cancer -specific antigens ( e.g., 
Cancer/Testis Antigens or neoantigens). Investigate changes in tumor microenvironment that correlate with response or provide information on potential actionable causes for lack of clinical 
benefit.  Investigate the potential that a dministration of atezolizumab with CYT107 may perturb 
the pharmacokinetics and immunogenicity of CYT107.   
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
8 
 2. BACKGROUND 
2.1 Study Disease(s)  
The proposed clinical trial is a phase II, open-label, multicenter, randomized study of the 
administration of Atezolizumab (MPDL3280A) monotherapy or in combination with Recombinant Human IL-7 (CYT107) in patients with advanced or metastatic urothelial carcinoma.  
Urothelial carcinoma is the fifth  most common malignancy in the United States [ Siegel 2014]. 
Advanced or metastatic urothelial carcinoma carries a grim prognosis and has limited treatment options [ von der Maase 2000]. The immunogenicity of urothelial bladder cancer (UBC) was first 
demonstrated by the successful use of BCG for non- muscle  invasive bladder cancer and 
carcinoma in situ [ Kamat 2001]. More recently, antibodies blocking PD- 1/PD -L1 signaling i n 
endogenous T cells have induced dramatic and durable clinical responses in patients with metastatic urothelial carcinoma, further highlighting urothelial carcinoma as a compelling target for T -cell immunotherapy [ Powles 2014; Plimack 2017] 
Early studies with impressive response rates and durable responses led to regulatory approval of 5 different PD -1/PD-L1 antibodies. This includes atezolizumab, durvalumab, nivolumab, 
avelumab , and pembrolizumab. Survival outcomes have been assessed in randomized phase 3 
trials with atezolizumab and pembrolizumab. Pembrolizumab was successful in demonstrating improved overall survival outcomes over taxane or vinflunine chemotherapy in the post-platinum–treated advanced or metastatic UBC setting [ Bellmunt 2017]. Atezolizumab also 
demonstrated an overall survival benefit over taxane or vinflunine chemotherapy in the post-platinum–treated advanced or metastatic UBC setting in the intention to treat analysis (presentation abstract). However, the primary study endpoint was based on an enrichment biomarker approach based on PD-L1 immunohistochemical staining, and that enrichment approach failed, as the biomarker was very clearly prognostic for improved outcomes in both arms, but not predictive for improved response to atezolizumab. 
We now attempt to demonstrate improved clinically meaningful outcomes with the addition of 
CYT107 to atezoli
zumab over atezolizumab alone for patients with advanced or metastatic 
urothelial carcinoma.  
2.2 CTEP IND Agent(s)  
 Atezolizumab (MPDL3280A) 
Atezolizumab is a human immunoglobulin (Ig) G1 monoclonal antibody consisting of 2 heavy chains (448 amino acids) and 2 light chains (214 amino acids) and is produced in Chinese hamster ovary cells [Investigators's Brochure]. Atezolizumab was engineered to eliminate Fc -effector function via a single amino acid substitution (asparagine to alanine) 
at position 298 on the heavy chain, which results in a nonglycosylated antibody that has minimal binding to Fc receptors, thus eliminating detectable Fc -effector function and 
associated antibody- mediated clearance of activated effector T cells. Atezolizumab 
targets human programmed death-ligand 1 (PD-L1) and inhibits the int eraction with its  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
9 
 PD-L1 and its receptors, PD-1 and B7-1 (also known as CD80), both of which function 
as inhibitory receptors expressed on T cells. 
Atezolizumab shows antitumor activity in both nonclinical models and cancer patients 
and is being investigated as a potential therapy in a wide variety of malignancies. Atezolizumab is being studied as a single agent in the advanced cancer and adjuvant therapy settings, as well as in  combination with chemotherapy, targeted therapy, and 
cancer immunotherapy. 
Atezolizumab was  approved in the United States by the FDA in 2016 for the treatment of 
locally advanced or metastatic urothelial carcinoma and as well as metastatic non –small 
cell lung carcinoma.  In March 2021, following the review of recent Atezolizumab 
bladder cancer studies and evaluation of other available treatment options, the indication 
for Atezolizumab  in patients with urothelial carcinoma who have previously received 
platinum-based chemotherapy has been withdrawn in the United States, according to the drug’s developer, Roche. The decision to withdraw the agent for use in this patient population does not affect indications for Atezolizumab  in other diseases  including non-
small cell lung cancer, small cell lung cancer, metastatic triple -negative breast cancer, 
hepatocellular carcinoma and melanoma  or as first -line treatment in cisplatin -ineligible 
patients with locally advanced and metastatic urothelial carcinoma.   
2.2.1.1 Mechanism of A
 ction 
PD-L1 expression is prevalent in many human tumors ( e.g., lung, bladder, ovarian, 
melanoma, colon carcinoma), and its overexpression has been associated with poor prognosis in patients with several cancers [ Thompson 2006; Hamanishi 2007; 
Okazaki 2007; Hino 2010]. PD-L1 binds to 2 known inhibitory receptors expressed 
on activated T cells (PD -1 and B7.1), and receptor expression is sustained in states of 
chronic stimulation such as chronic infection or cancer [ Blank 2005; Keir 2008]. 
Ligation of PD-L1 with PD-1 or B7.1 inhibits T-cell proliferation, cytokine production, and cytolytic activity, leading to the functional inactivation or inhibition of T cells. Aberrant expression of PD-L1 on tumor cells has been reported to impede antitumor immunity, resulting in immune evasion [Blank 2007] . Therefore, 
interruption of the PD-L1/PD-1 and PD- L1/B7.1 pathway represents an attractive 
strategy to reinvigorate tumor- specific T -cell immunity.  
Blockade of PD- L1 or PD -1 wit h monoclonal antibodies has been reported to result in 
strong and often rapid antitumor effects in several mouse tumor models [ Iwai 2002; 
Strome 2003]. These data suggest that tumor- specific T cel ls may be present in the 
tumor microenvironment in an inactive or inhibited state, and blockade of the PD-L1/PD -1 pathway can reinvigorate tumor- specific T -cell responses.  
Collectively, these data establish the PD -L1/PD -1 pathwa
 y as a promising new 
therapeutic target in patients with advanced tumors. Immune- related adverse events 
(irAEs) reported from the 2 recent studies were consistent with the role of the PD-
L1/PD -1 pathway in regulating peripheral tolerance. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
10 
 2.2.1.2 Summary of Nonclinical Experience 
The safety, pharmacokinetics (PK), and toxicokinetics of atezolizumab were 
investigated in mice and cynomolgus monkeys to support intravenous (IV) administration and to aid in projecting the appropriate starting dose in humans. Given the similar binding of atezolizumab for cynomolgus monkey and human PD-L1, the cynomolgus monkey was selected as the primary and relevant nonclinical model for understanding the safety, PK, and toxicokinetics of atezolizumab. 
Overall, the nonclinical PK and toxicokinetics observed for atezolizumab supported 
entry into clinical studies, including providing adequate safety factors for the proposed phase 1 starting doses. The results of the toxicology program were consistent with the anticipated pharmacologic activity of down-modulating the PD-L1/PD -1 pathway and supported entry into clinical trials in patients. 
Refer to the Atezolizumab Investigator’s Brochure for details on the nonclinical studies. 
2.2.1.3 Summary of Cli
 nical Experience 
A summary of clinical data from company-sponsored atezolizumab trials is presented below. Details of all ongoing studies can be found in the most recent  Atezolizumab 
Investigator’s Brochure. 
2.2.1.3.1. Clinical PK and Immunogenicity 
On the basis of available preliminary PK data (0.03–20 mg/kg), atezolizumab 
shows linear PK at doses ≥1 mg/kg [Investigators's Brochure]. Based on an analysis of exposure, safety, and efficacy data, the following factors had no clinically relevant effect: age (21−89 years), body weight, gender, positive ATA status, albumin levels, tumor burden, region, or ethnicity, renal impairment, mild hepatic impairment, level of PD -L1 expression, or ECOG status. No formal PK 
drug-drug interaction studies have been conducted with atezolizumab, and the interaction potential is unknown. Further details can be found in the current Investigator’s Brochure. 
The development of anti therapeutic antibodies (ATAs) has been observed in 
patients in all dose cohorts and was associated with changes in PK for some 
patients in the lower dose cohorts (0.3, 1, and 3 mg/kg) [Investigators's Brochure]. Patients dosed at ≥10 mg/kg maintained C
min values well above the target serum 
concentration of 6 mcg/mL despite the detection of ATAs. Accordingly, the development of detectable ATAs does not appear to have a clinically significant impact on PK for doses above 10 mg/kg. To date, no relationship between the development of measurable ATAs and safety or efficacy has been observed. 
2.2.1.3.2. Clinical Safety Summary 
As of May 10, 2016, atezolizumab has been administered (alone or in 
combination with other agents) to approximately 6053 patients with solid tumors and hematologic malignancies [Investigators's Brochure] . The first -in-human 
monotherapy study PCD4989g (in patients with locally advanced or metastatic 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
11 
 solid tumors or hematologic malignancies) provides the majority of monotherapy 
safety data, with 629 safety- evaluable patients as of the data extraction date. 
Currently, no maximum tolerated dose (MTD), no dose- limiting toxicities 
(DLTs), and no clear dose- related trends in the incidence of AEs have been 
determined.  
Fatigue, decreased appetite, nausea, diarrhea, constipation, and cough were commonly reported AEs in single and combination therapy [Investigators's Brochure]. AE profiles are similar across tumor types studied, including non–small cell lung cancer (NSCLC), renal cell carcinoma (RCC), triple -negative 
breast cancer (TNBC), and urothelial carcinoma, and are consistent with the mechanism of action of atezolizumab. The overall immune- mediated AEs 
reported were considered moderate i n severity, and the majority of patients were 
able to continue on atezolizumab therapy. 
As of the data extraction date of December 15, 2015, there were 629 safety-
evaluable patients from the first- in-human phase 1a study PCD4989g 
[Investigators's Brochure]. The median age was 61 years. Of the 629 patients, 619 patients (98.4%) reported at least one AE of any grade or attribution to atezolizumab, and 316 patients (50.2%) experienced at least one grade 3 or 4 AE of any attribution. A total of 444 patients (70.6%) reported at least one treatment -
related AE, and 86 patients (13.7%) experienced at least one treatment- related 
grade 3 or 4 AE. The most frequently observed AEs of any grade and attribution (occurring in ≥ 10% of treated patients) include fatigue, decr eased appetite, 
nausea, pyrexia, constipation, cough, dyspnea, diarrhea, anemia, vomiting, asthenia, back pain, headache, arthralgia, pruritus, rash, abdominal pain, insomnia, peripheral edema, and dizziness. 
Serious AEs (SAEs) have been reported in 261 patients (41.5%) in study 
PCD4989g [Investigators's Brochure]. Reported SAEs were consistent with the underlying disease. Treatment-related SAEs (57 patients [9.1%]) included pyrexia, dyspnea, pneumonitis, malaise, fatigue, hypoxia, colitis, and bone pain. Pooled single-agent safety data from 1978 patients with UC, NSCLC, and other indications (including trial PCD4989g) indicate that the most frequent (>1% of patients) serious adverse drug reactions (regardless of grade) include dyspnea (3.0%), back pain (1.2%), and abdominal pain (1.1%). A list of AEs considered “expected” for atezolizumab is presented in Section 7.1.1.1. 
2.2.1.3.3. Immune -Related Adverse Events  
Given the mechanism of action of atezolizumab, events associated with inflammation and/or immune -mediated AEs have been closely monitored during 
the atezolizumab clinical program [ Investigators's Brochure ]. To date, immune-
related adverse events associated with atezolizumab include hepatitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency, Guillain-Barré syndrome, myasthenic syndrome/myasthenia gravis, nephritis, myocarditis, and meningoencephalitis. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
12 
 For further details, see the most recent Atezolizumab Investigator’s Brochure.  
2.2.1.3.4. Clinical Efficacy Summary  
Patients with multiple tumor types were included in study PCD4989g, with the 
largest cohorts consisting of patients with NSCLC, RCC, and UC [Investigators's Brochure]. Objective responses with atezolizumab monotherapy were observed in a broad range of malignancies, including NSCLC, RCC, melanoma, UC, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, and sarcoma. Both the preliminary and more matur e efficacy data available suggest 
that treatment with atezolizumab as a single agent or in combination with other therapeutic agents results in anti tumor activity across a range of tumor types and 
hematologic malignancies (UC, NSCLC, RCC, TNBC, melanoma, CRC, and NHL) and across lines of therapy. Clinical benefit was observed in terms of objective responses, durability of responses, and overall survival. Improved efficacy of atezolizumab was observed in the unselected patient population, as well as in patie nts with higher PD-L1 expression on TCs or ICs ( e.g., NSCLC) or 
on ICs only ( e.g., mUC, RCC).  
 Recombinant Glycosylated Human Interleukin-7 (CYT107) 
A relatively nontoxic regimen of weekly IL -7 will substantially increase the total body 
complement of T cells of all phenotypes. The current trial will test whether addition of IL-7 to atezolizumab, using an IL-7 regimen known to increase the total body 
complement of T cells, will increase the frequency and depth of clinical responses to atezolizumab.  
2.2.2.1 Mechanism of acti
 on 
IL-7 is a homeostatic growth factor for T cells that normally contributes to 
maintaining the normal number of peripheral blood T cells. IL-7 is the T- cell 
equivalent of erythropoietin and thymopoietin with multiple functions that could increase the efficacy of atezolizumab. IL -7–mediated signaling can induce 
proliferation in the absence of T- cell receptor signaling [ Swainson 2007] . IL-7 signals 
through the IL- 7 receptor (IL -7R) heterodimer composed of the common γ -chain 
(CD132) cytokine receptor and a unique IL- 7Rα (CD127). During normal conditions, 
IL-7R expression is maintained on resting T cells [ Mackall 2011] and endogenous IL -
7 is continuously available in secondary lymphoid organs as a result of stromal cell IL-7 production [ Takada 2009]. 
2.2.2.2 Summary of Nonclinical Experience 
Exogenous IL -7 induces expansion of most categories of T cells. In preclinical and 
clinical studies IL -7 has been shown to: 
1. Increase peri pheral blood T cells by several fold w ith little toxicity [ Levy 2009; 
Sportes 2010; Perales 2012 ; Tredan 2015; Sheikh 2016], 
2. Expand all categories of T cells including CD8, CD4 and memory T cells [ Sportes 
2010], 
3. Increase the total body complement of T cells including increased size of lymph nodes, spleen, liver [ Sportes 2008],  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
13 
 4. Increase T- cell receptor ( TCR ) diversity by preferentially stimulating the growth 
of TREC positive, naïve T cells [ Sportes 2008]. Continuous signaling by IL-7 
induces antiapoptotic and costimulatory responses that are essential for the 
survival of naïve T cells. 
5. Maintain effector T -cell func tion, 
6. Increase the ratio of CD8+ T cells to Tregs, as IL -7Rα expression is relatively low 
on FOXP3+ Treg cells compared with nonregulatory T- cell subsets [ Liu 2006; 
Seddiki 2006]. 
7. Increase tissue infiltration of T cells into gut mucosa (other tissues have not been examined) [ Sereti 2012]. 
8. Reverse neutrophil lymphocyte ratios [unpublished data – CITN12 -03 
([STUDY_ID_REMOVED])] 
9. Augment vaccine-induced cell responses in murine models [ Melchionda 2005] 
10. Augment immune- mediated control of both tumors and viruses [ Mackall 2011]. 
After either T -cell activation, IL -7 signaling, or both, IL- 7Rα is down-regulated on 
terminally differentiated, senescent T cells [ Fry 2003], [ Park 2004] but becomes 
reexpressed  after several days and remains expressed during the later contraction 
phase. IL -7Rα is also selectively expressed on a small minority of effector T cells that 
are destined to enter the central memory T -cell pool, thus implicating IL -7 as a 
modulator of the effector to memory cell transition [ Kaech 2003]. 
2.2.2.3 Summary of Clinical Experience 
The CYT107 dose and regimen have been established in prior clinical trials. More than 380 patients have been exposed to CYT107. Weekly CYT107 × 3 or 4 at doses of 10 to 20 µg/kg can double the number of peripheral blood T cells (CITN Immune Monitoring Lab data). Both naïve and memory T cells are expanded by CYT107 with a peak of proliferation at day 7. Repeated doses of CYT107 induce expansion of CD4+ and CD8+ T cells subsets. Importantly, there is no significant difference between the 10 and 20 mcg/kg dose levels and biological effect on CD4+ and CD8+ T-cell number increases [ Levy 2012], Figures 1A and 1B]. The increases last for 
weeks to months in some individuals [ Levy 2009]. Extrapolating from the increase in 
size of lymph nodes, spleen, and liver with FDG -PET, the total body burden of T 
cells also increased correspondingly [ Sportes 2008]. However, the 10 µg/kg dose 
level is tolerated better, with no reported serious unexpected serious adverse reactions 
(SUSARs) reported compared to 4 cases reported at the 20 µg/kg dose. Importantly, 
the 20 µg/kg dose level has been associated with autoimmune adverse events, include Henoch -Schonlein purpura, lichen planus and the emergence of neutralizing 
antibodies [CYT107 Investigator's Brochure]. 
Regimens of weekly IL-7 at the 10 µg/kg level demonstrate an acceptable safety 
profile wit
h very few grade 3 or 4 adverse events. More than 380 patients have been 
exposed to CYT107, including 236 patients in 7 phase I/IIa dose escalation studies with CYT107 in oncology, hematopoietic stem cell transplantation (HSCT), human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) infected patients and 2 phase II studies in patients with HIV. CYT107 has been well tolerated  [CYT107 Investigator's Brochure] . The most frequent adverse events are: 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
14 
 injection site reactions, lymphadenopathy, pyrexia, rash, and fatigue. A cumulative 
819 administrations of CYT107 triggered 555 injection site reactions AE, i.e.,  70% of 
CYT107 administrations led to at least one injection site reaction. The worst grade 
reported was grade 2 in 159 of 819 administrations (19.4%). No grade 3 or 4 injection site reactions were reported.  
Among the 555 injection site reactions related to CYT107: 
– 113 (20.3%) were of grade <1 
– 283 (51.0%) were of grade 1 
– 159 (28.7%) were of grade 2 
– No grade 3 or 4 injection site reactions were reported. 
Of note, this scoring was performed with reference to the DAIDS 2.0 scale which is more severe than CTCAE scoring. 
One true anaphylactic reaction and 4 acute allergic reactions have been reported, 
strictly in studies with repeated cycles of CYT107. The immunogenicity frequency and the occurrence of NADA (neutralizing antibodies) are higher with the exposure to multiple cycles of CYT107. 
Two studies analyzed the pharmacokinetics of CYT107 in patients with HIV-1 with 
CD4 T -cell counts of 101-400 cells/µL and plasma HIV RNA <50 copies/mL while 
receiving highly active antiretroviral therapy ( HAART ) for ≥12 months. Three dose 
levels of CYT107 were tested sequentially: 10, 20 and 30μg/kg. Increasing doses induced a dose response increase in peripheral blood T cells. The increases were nonlinearity  above 20µg/kg/week in the lymphopenic patients and above 
30/µg/kg/week for the non-lymphopenic pati ents. The nonlinearity  was presumed to 
be to the administered IL-7 being cleared by binding to an increased number of T cells, i.e., a "Target Mediated Drug Disposition" [CYT107 Investigator's Brochure]. 
Up to June 2013, all pre clinical and clinical studies were conducted by Cytheris S.A. 
In September 2013 all CYT107 related assets were transferred to RevImmune, the 
company now responsible for conducting CYT107 development. 
The CITN has one ongoing trial of CYT107 started with Cytheris and continued with 
RevImmune CITN is the IND sponsor. The trial is testing CYT107 in patients with metastatic castration -resistant prostate cancer after treatment with sipuleucel -T 
(PROVENGE
®, Dendreon Corporation), a prostatic acid phosphatase vaccine. The 
goal is to determine whether treatment with CYT107 can substantially increase and prolong immune responses to prostatic acid phosphatase and thereby eventually provide a novel, nontoxic regimen to prolong the survival of patients with metastatic castration -resistant prostate cancer [CITN12 -03 (Study Registry ID: [REMOVED])]. 
After  therapy with standard sipuleucel- T, patients are random ly assigned  to 
observation or administration of CYT107 10 μg/kg on days 0, 7, 14, and 21. The 
randomized trial has accrued 54 of 70 patients with half in the CYT107 arm. Results 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
15 
 to date have confirmed that CYT107 (1) increases peripheral blood CD8+ and CD4+ 
T cells, and (2) reverses the neutrophil to lymphocyte ratio. Of note, a high neutrophil to lymphocyte ratio is a poor prognostic sign in most, if not all, clinical cancer circumstances in which it’s been assessed [ Templeton 2014] including bladder cancer 
[Bhindi 2016]. No DLT have been observed. 
2.3 Other Agent(s): N/A  
2.4 Rationale 
Very few preclinical studies have combined IL -7 with PD-1 or anti- PD-L1 checkpoint blockade. 
One murine study showed the therapeutic efficacy of concomitant blockade of CTLA-4 and PD-1 relies on interdependence of IL -7 and IFN- γ signaling in T cells, predi cting the exogenous IL-7 
will boost the therapeutic efficacy [ Shi 2016]. Another study of murine sepsis showed that IL-7 
reverses immune suppression by increasing lymphocyte proliferation, expression of lymphocyte adhesion molecules, interferon-gamma production, and CD28 expression on splenic CD8+ T cells. Combined treatment with IL -7 and anti- PD-1 produced additive effects on CD28 
expression, lymphocyte proliferation, and splenic secretion of interferon- gamma [ Shindo 2015]. 
Of note, CYT107 therapy is currently being tested in human sepsis [Study Registry ID: [REMOVED]]. In a recent Science paper [ Pauken 2016] using the mouse model of chronic 
lymphocytic choriomeningitis virus (LCMV) infection explored the combined effect of IL-7 and anti-PD-L1 on the development and functionality of exhausted T cells. They confirmed that 
treatment with IL -7 starting in the effector phase can prevent development of T-cell exhaustion. 
By 8 to 11 weeks after treatment, however, the anti- PD-L1 reinvigoration of T cells was lost, and 
the quantity, proliferation, effector function, and inhibitory receptor expression of LCMV-specific CD8 T cells in the anti- PD-L1–treated mic e were comparable to those in control- treated 
mice. Interestingly at this stage the combined treatment with IL -7 and anti- PD-L1, resulted in 
more antigen -specific CD8 T cells and improved coproduction of interferon- γ and tumor necrosis 
factor –α. 
Atezolizumab induces remarkable responses in a subset of patients, yet the percentage of complete re
sponses in the “all comers” population was only 5.5% and the median OS for all 
patients was only 7.9 months [ Package Insert 2017 ]. Various mechanisms of immune escape, 
including (1) the lack of strong, tumor-specific antigens or epitopes recognized by T cells, (2) impaired or suppressed antigen presentation machinery including downregulation of major histocompatibility complex on cancer cells, (3) impaired or suppressed cytotoxic T- cell 
activation, (4) poor infiltration of T cells into the tumor microenvironment, and (5) increased immunosuppressive cytokines and cells in the tumor microenvironment prevent a large proportion of cancer patients from driving clinical benefit from anti- PD1/PD- L1 therapies [ Kim 
2016]. Thus, additional therapies to increase the frequency and depth of responses to 
atezolizumab are needed.  
Atezolizumab has induced phenomenal lifesaving responses in some patients with advanced urothelial c
arcinoma, presenting an incredible foundation for building more effective regimens. 
The current trial will determine whether, by increasing the total body complement of T cells and expanding the T-cell repertoire, the addition of CYT107 to atezolizumab will improve upon the clinical benefit provided by atezolizumab alone. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
16 
 2.5 Integrated  Correlative Studies Background  
 Evaluation of peripheral CD4+ and CD8+ T- cell counts  – Integrated Laboratory 
Correlative Study #1 
As described above, CYT107 has been shown to double the number of peripheral blood 
lymphocytes including T cells. Thus, CD4+ and CD8+ T-cell numbers are important biomarkers for the effect of CYT107 on the peripheral T-cell populations. To assess the overall  pharmacodynamic effect of atezolizumab plus CYT107 and to determine whether 
CYT107 in combination with atezolizumab results in the same, or different level, of expansion of peripheral lymphocytes, T-cell counts (both CD4+ and CD8+) will be evaluated in CLIA certified laboratories locally at each site. CD4+ and CD8+ T -cell 
counts will be evaluated at baseline, during treatment, and at end of therapy. 
Hypothesis : The combination of atezolizumab with CYT107 will result in similar levels 
of peripheral blood T-cell expansion as with CYT107 alone. 
 
 Slide-Based Immune Phenotype Panel -- Multispectral  IHC  – Integrated Laboratory 
Correlative Study #2 
Because tumor -infiltrating immune cells are associated with clinical outcomes, infiltrates 
from pre -treatment  tumor tissue and from biopsies taken during treatment will be 
assessed by IHC to determine extent and the nature of T- cell infiltration and of the 
overall immune milieu of the tumor microenvironment (TME).  
Paired baseline and post- baseline tumor biopsies will be evaluated using quantitative 
multicolor immunohistochemistry (IHC) with Perkin -Elmer’s Vectra IHC platform. This 
platform employs spectral deconvolution imaging to separate optical signals from each 
antibody together with state-of–the- art image analysis capabilities to facilitate robust 
quantitative slide -based immunophenotyping. Using the Vectra multi spectral  imaging 
platform (PerkinElmer), adjacent tumor sections will be stained and imaged with a se ries 
of 5-6 antibodies per section simultaneously to investigate the spatial relationship 
between key immunomodulatory cell types and molecules. The antibodies will include, but are not limited to, the following: pancytokeratin (AE1/AE3), CD8, CD4, PD-1, PD-L1, CD68, CD163, FOXP3, arginase, and pan -MHC class I and class II. Data will be 
generated in the form of total positive cells, positive cells/mm2, percentage positive cells in a population, ratios of cells and molecules of interest ( e.g., PD -L1:CD8 or 
FOXP3+CD4+:CD8). Additionally, tumors may also be assayed by IHC for a variety of other markers including CD80, IFN-gamma CD3, CD5, TIA-1, CD20, CD11b, CD137, CD45RO, CD301CD56 and CD16 ( natural killer [ NK] and NK T cells), CD79a (B cells), 
GITR, TIM -3, FOXP3, LAG3. Furthermore, quantitative analysis of tumor- infiltrating 
lymphocyte (TIL) distribution ( i.e., stromal, and interface/invasive margin) will be 
performed. Anti- PD-L1 immunohistochemical staining will be performed  at HistoGeneX 
(Naperville, IL) with  the SP142 clone, in addition to the multispectral IHC (msIHC) to 
serve as both an independent test and control for the reproducibility of the msIHC assay. The study is intended to evaluate for changes in the immune profile of the tumor microenvironment. If sufficient archival tumor tissue collected before therapy is not  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
17 
 available, a baseline biopsy will be obtained before enrolling in the study as part of this 
protocol. 
IHC studies will be performed under the direction of Dr.  at the Fred 
Hutchinson Cancer Research Center (Fred Hutch)  Experimental Histopathology 
Laboratory, Seattle, WA, or other agreed upon investigator. Hypothesis : The combination of atezolizumab with CYT107 will alter the TME (tumor 
microenvironment) towards a pro inflammatory  phenotype. 
 
 Assessment of tumor biopsy by gene expression analysis -- Interferon γ (INFγ) Gene 
Expression Signature - NanoString® nCounter® Human Immunology V2 Panel and the 
nCounter® PanCancer Immune Profiling Panel – Integrated Laboratory Correlative 
Study #3 
To identify potential signatures correlating with tumor T -cell infiltration patterns and 
clinical response Tumor tissue will be tested for gene expression using NanoString® 
technology on unstained tissue formalin -fixed paraffin -embedded ( FFPE ) slide material. 
Specifically, slides will be analyzed using both a 770-gene panel (nCounter® PanCancer 
Immune Profiling Panel) which contains markers for 24 different immune cell types and 
populations, 30 common cancer antigens and genes that representing immune responses including checkpoint blockade genes as well as the NanoString
® nCounter® Human 
Immunology V2 Panel which contain genes associated with the INFγ Gene Expression Signature. These gene expression profiles may provide an additional detailed phenotype to guide correlative investigation. 
NanoString
®-based gene expression analysis, specifically for the IFN γ Signature, will be 
used to test the hypothesis that the investigational study treatment regimen, CYT107 plus 
atezolizumab, will promote a proinflammatory  antitumor immune response. The IFN γ 
Signature, which is comprised of IDO1, CXCL10, CXCL9, HLA-DRA, STAT1 and IFNγ, has previously been shown to correlate with anti -PD1 response and nonresponse. 
RNA will be extracted from all paraffin -embedded tumor samples and analyzed using the 
NanoString
® nCounter Immunology V2 Profiling Pane, which includes the 
aforementioned genes of the IFN γ Signature, as well as over 700 other genes associated 
with inflammation. The samples used will be taken from tissue sections adjacent to those stained for multispectral  IHC to facilitate comparison between these analysis sets. 
Samples will consist of matched pre - and post- treatment  FFPE biopsies. 
These analyses will be performed in coordination with NanoString
® Technologies in 
Seattle, WA, and analyzed using qualified analytic tools at the immunopathology lab of the Fred Hutch . 
Hypotheses : The combination of Atezolizumab with CYT107 will alter the TME towards 
a pro  inflammatory  GEP phenotype, and distinct gene expression patterns will be 
identified that may correlate with clinical outcomes.   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
18 
 
 T-Cell Receptor Repertoire Analysis -- TCR sequencing – Integrated Laboratory 
Correlative Study #4 
We will perform TCR sequencing where pretreatment and post- treatment  biopsies are 
available. TCR repertoire analysis will be performed on RNA extracted from FFPE 
biopsies, and T cells isolated from PBMCs from the research blood collections throughout study participation. TCR repertoire analysis has been standardized and commercialized by Adaptive Biosciences. The TCR sequences will also specifically be queried for sequences already known to encode for TCRs reactive to shared antigens often expressed in urot helial transitional cell carcinoma ( e.g., MAGE -A3, NY- ESO -1, 
LAGE -1, and PRAME).  
Samples will be analyzed at Adaptive Bioscience in Seattle, WA , or other agreed upon 
vendor or collaborator. 
Hypothesis : The combination of Atezolizumab with CYT107 will result in emergence 
and/or increased prevalence of specific TCR sequences reflecting the clonal expansion of 
antitumor T cells, and expansion of those specific T- cell clones in TILs  (exhibited by 
higher TCR clonality) will be associated with improved response to therapy. 
 
 Tumor- Associated Neo -antigen discovery --  Whole Exome Sequencing and RNAseq and 
Antigen Prediction – Integrated Laboratory Correlative Study #5 
In order to investigate the role of T- cell–mediated immunity directed towards tumor -
specific mutant antigens, genomic sequencing and RNAseq of tumor cells from baseline 
tumor biopsy relative to non-tumor cells from whole blood (PBMC) will be performed to: i) identify tumor -associated neoantigen s; and ii) identify the genomic variances that may 
contribute to response or disease progression and provide an understanding of molecular abnormalities.  
DNA and RNA will be extracted from baseline or archival FFPE tumor biopsies will be sequenced to identify overexpressed known “shared” tumor- associated antigens (TAAs) 
and nonsynonymous expressed mutations using available and standard-of- practice 
technologies. For example, a computational approach (BIMAS and SYFPEITHI algorithms) can be utilized to analyze and prioritize these mutation -derived “virtual” 
antigens in terms of their likelih ood to bind to/be presented by MHC I alleles (HLA-A2, 
A3, A24). Potential antigens can be encoded in tandem minigene constructs with intervening P2A viral sequences to allow for equimolar expression of multiple “long” (~27 amino acids) peptides centered on the putative antigenic mutational sites. These neoantigen ic libraries will be cloned into an appropriate expression vectors to allow for in 
vitro - transcription of neoantigen -encoding mRNA for use in ELISPOT assays to detect 
neoantigen  immune responses. RNAseq will also identify whether common “shared” 
antigens are also expr essed, including MAGE- A3, NY- ESO -1, LAGE-1, and  PRAME. 
Common epitopes sequences from these shared antigens will also be transduced as above. Quantitation of mutation burden may also be important for urothelial carcinoma, where  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
19 
 immunogenicity and/or responses to PD-1/PD- L1 axis -directed therapies may be 
associated with a high mutation burden. 
These analyses will be performed using qualified analytes and analytic tools at the 
immunopathology lab at the Fred Hutch  or at a vendor, to be determined. 
Hypothesis : Clinical outcomes will correlate with neo antigen  and mutational burden. 
 
 Antitumor Immune T -cell Responses – ELISPOT  – Integrated Laboratory Correlative 
Study #6 
If there are positive clinical responses, antigen -specific T -cell responses may be assessed 
by IFNγ enzyme -linked immunospot (ELISPOT) assay to provide information regarding 
the effect of the atezolizumab and CYT107 regimen on antigen- specific T -cell–functional 
antitumor responses. The ability of the investigational treatment to induce a tumor antigen -specific immune response will be assessed using ex vivo incubation of PBMC-
derived T cells with autologous PBMC either pulsed with peptide antigens or recombinant proteins representing known ongoing and nascent antitumor responses 
(PRAME, NY- ESO -1, MAGE -A3 and/or p53), or neoantigen s described above. Memory 
viral responses (influenza A, CEF) will also be assessed as controls. We will quantitate the strength of the antigen- specific T -cell responses and compare baseline and post-
baseline T-cell responses for each putative antigen. The absolute change in ELISPOT responses for antigens will be compared between the SFC/million PBMC at baseline (before treatment initiation) and at designated time points post- treatment . 
Assays will be performed in the C ITN Immune Monitory L aboratory (CIML) at the Fred 
Hutch  under the direction of Dr. , or an agreed upon vendor or collaborator. 
Hypothesis : The combination of atezolizumab with CYT107 will result in increased T-
cell responses to known and/or neoantigens. 
 
2.6 Exploratory/Ancillary Correlative Studies  
 Assessment of PD -L1 expression at Baseline and Post- treatment -- 
Immunohistochemistry (IHC)  – Exploratory Laboratory Correlative Study #1 
PD-L1 has been identified as an important correlative biomarker for clinical response to 
anti-PD-L1 and anti- PD-1 therapies. In particular, given that the function of atezolizumab 
is to block binding of PD-1 to PD-L1, expression of PD- L1 will be quantitate d by IHC in 
baseline formalin -fixed paraffin -embedded tumor specimens, and from biopsies obtained 
after treatment. This is an important part of the correlative studies to explore whether this 
marker which correlates with response in other circumstances also correlates with response in this protocol population. For baseline samples, formalin- fixed, paraffin-
embedded tissue block(s) from tumor obtained before treatment will be obtained by the clinical site either from archival samples obtained from the releva nt pathology 
laboratories where they were processed and stored, or from baseline biopsy as part of this  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
20 
 protocol (core, punch, or excisional). Post- treatment, formalin -fixed paraffin -embedded 
tumor specimens will b e obtained from biopsy at week 11 (core, punch, or excisional) as 
part of this protocol. 
PD-L1 expression will be tested by IHC at HistoGeneX (Naperville, IL) with the PD -L1 
SP142 clone assay , or at other agreed upon vendor. 
Hypothesis : PD-L1 expression at baseline will correlate with clinical responses to 
atezolizumab and atezolizumab in combination with CYT107. In addition, atezolizumab 
administration may alter PD -L1 expression to an unknown extent. 
 
 Evaluation of the effect of atezolizumab with and without CYT107 on circulating 
Lymphocyte and Monocyte numbers and Phenotype – Exploratory Laboratory 
Correlative Study #2 
We will assess the effects of the atezolizumab with and without CYT107 on the frequency and phenotypic character of PBMC subsets including dendritic cells (DCs), monocyte populations, T cells, NK cells, and B cells. The effect on these immune cell subtypes of checkpoint inhibitors, and other immune modulators is being investigated in other CITN trials and may provide important correlative information on the success or failure of combination immunotherapy. 
A 14 -color whole blood immunophenotyping assay will quantify in one panel the 
absolute number and proportion of T cells (both CD8+ and CD4+), NK cells 
(CD56+CD3 -), NKT cells (CD56+CD3+), B cells (CD19+/CD20+), monocytes 
(CD16+), neutrophils (CD15+), as well as both myeloid DCs (CD45+HLA-DR+CD11c+CD123-) and plasmacytoid DCs (CD45+HLA- DR+CD11c -CD123+). In 
addition, myeloid-derived suppressor cells (MDSC) will be measured using antibodies to HLA-DR, CD11b, and CD33 in this same multiparameter flow cytometric assay. 
Multiparameter flow cytometry on whole blood with a 12-color panel may also be used in parallel to further define the phenotype of T cells and to identify activated T cells, T- cell 
subsets (including regulatory T cells). This validated panel includes the markers CD45, CD3, CD4, CD8, CD45RA, CD197 (CCR7), CD28, CD127, CD25, HLA-DR, CD279 (PD-1), CD278. 
Assays will be performed under the direction of Dr.  in the CIML at the Fred 
Hutch . 
Hypothesis : The combination of atezolizumab with CYT107 will perturb circulating 
lymphocyte and monocyte numbers and phenotypes to a yet unknown extent. 
 
 Multiplex Cytokines -- Multiplex ELISA  – Exploratory Laboratory Correlative Study #3 
Perturbations in cytokines, chemokines, and growth factors have been associated with cancers and changes in plasma cytokine concentrations of proinflammatory and immunosuppressive cytokines may correlate with clinical responses to therapy. Measureable chan ges in serum and plasma cytokines have been associated with 
checkpoint blockade therapies. Comparison of baseline plasma cytokines, chemokines  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
21 
 and growth factors to longitudinal measurements during therapy may improve our 
understanding of the immunologic effects of the combination of atezolizumab plus CYT107 on cancer. Furthermore, these assays will be used to explore whether reactive changes in cytokine levels correlates with toxicity and/or efficacy of atezolizumab and CYT107. Longitudinally collected plasma samples will be evaluated using commercial multiplex immunoassays that are quantified by immunochemiluminescence detection or other appropriate technology. 
Assays will be performed at the Fred Hutch Shared Resources, or at other agreed upon 
vendor. 
Hypothesis : The combination of atezolizumab with CYT107 will perturb cytokines, 
chemokines, and growth factors to a yet unknown extent. 
 
 Kynurenine and tryptophan (Kyn/Trp) ratios and plasma Arginine levels  – Exploratory 
Laboratory Correlative Study #4 
Over expression of indoleamine 2,3-dioxygenase (IDO) is known to result in increases in 
the Kyn/Trp ratio in blood and within some tumor microenvironments. Increases in Kyn/Trp ratios result in the subsequent suppression of T- cell responses and is a major 
mechanism of immune control. IDO is expressed by some tumors, but probably more importantly, it is expressed by lymphocytes as a normal mechanism and important mechanism to dampen immune responses. Expression of IDO (with subsequent increased Kyn/Trp ratio) may be one likely mechanism of checkpoint blockade and other immunotherapy failures. Thus, we will measure Kyn/Trp ratios in plasma taken at baseline, during treatment, and at end of treatment in this protocol to analyze, in patients who have failed clinical response to Atezolizumab plus IL -7 treatment, failure may be 
associated with increased Kyn/Trp levels.  
In addition, another important mechanism of immune control and suppression is through the changing concentrations of arginine insofar as decreased levels of arginine in plasma (ie arginine depletion) is associated with decreases in CD4 and CD8 T- cell proliferation 
and Th1 functions. Arginine depletion can occur by the release by MDSCs of arginase which converts L-arginine to ornithine. This may be another mechanism of tumor evasion as myeloid suppressor cells with high arginase activity are found in tumors. Thus, we will also measure arginine levels in the same plasma samples taken at baseline, during treatment, and at end of treatment in this protocol to analyze, in patients who have failed clinical response to Atezolizumab plus IL- 7 treatment, whether failure may be associated 
with increased arginine levels in plasma.  
All assays will be performed at  an agreed upon collaborator or vendor to be determined. . 
Hypothesis : Failure to respond to atezolizumab plus CYT107 treatment may be 
associated with increased Kyn/Trp ratios and/or increased plasma arginine levels in some patients.  
  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
22 
 
 Microbiome Analyses – Exploratory Laboratory Correlative Study #5 
Recent reports in preclinical  mouse tumor models suggest that the gut microbiome has an 
effect on response to checkpoint blockade immunotherapy, and there is growing evidence 
that the intestinal microbiome may have major influences on antitumor immune responses. The microbiota has long been known to have profound effects on innate and adaptive immunity. However, the impact and importance of the gut microbiome in human cancer patients’ responses to immunotherapy has not yet been well- characterized and will 
be important to determine. To begin to understand the role of the microbiome in responses to immunotherapy in this protocol, we will collect microbiome samples from patients at baseline and perform taxonomic profiling via 16 S rRNA gene sequencing and metagenomic whole- genome shotgun (WGS) sequencing. Fecal samples will be collected 
and stored using standard, at home stool-collection procedures, and we will assess the landscape of the gut microbiome. Sequencing data will be analyzed and compared to clinical responses to determine whether response or nonresponse to atezolizumab plus CYT107 can be correlated with specific microbiota. 
Assays will be performed in collaboration with Dr.  at Fred Hutch or 
other agreed upon collaborator. Hypothesis : The gut microbiome profile will affect the clinical response to the 
combination of atezolizumab with CYT107 to a yet unknown extent.  
2.7 Special Studies  
 Assessment of Immunogenicity and Pharmacokinetics  
The known and predicted activities of these two immunotherapeutic agents in enhancing 
immune responses may, in combination, influence pharmacokinetics and immunogenicity. In particular CYT107 is pharmacologically targeting lymphocytes and subject to a PK target mediated clearance (like many other blood growth factors). This is the cas e for G -CSF and other factors. We have validated methods to measure CYT107 
blood samples for PK analysis a s well as  to detect and measure the presence of binding 
and neutralizing antibodies. We will thus measure CYT107 blood levels before the first 
and fourth administrations of CYT107, and at specified intervals a fter administration of 
CYT107. This would enable detection of any potential significant interference of the concomitant immunotherapies on CYT107 PK. Similarly, we will measure anti-CYT107 binding antibodies before any CYT107 administration and after the last CYT107 administration. Any subject presenting with binding antibodies will be further tested for the presence of anti -CYT107 neutralizing antibodies. While the number of patients will 
be too small to draw definitive conclusions, this might lead to a potential interference in the combination therapy deserving a further exploration.
 
  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
23 
 3. PATIENT SELECTION  
3.1 Eligibility Criteria  
 Patients must have histologically or cytologically documented locally 
advanced/inoperable or metastatic UBC, including renal pelvis, ureters, urinary bladder, and urethra. 
Note : Mixed histology tumors allowed if predominant histology is urothelial carcinoma. 
Note : Small cell or neuroendocrine carcinoma is not allowed if predominant. 
 Patient s must have recurrent disease after any prior platinum -based chemotherapy 
regimen .  
 Patients must have measurable disease per RECIST 1.1 assessed by computed tomography ( CT) scan or MRI. See 
Section 11 for the evaluation of measurable disease.  
 Patients must be ≥18 years of age on day of signing informed consent document. 
Because no dosing or adverse event data are currently available on the use of atezolizumab in combination with CYT107 in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials. 
 ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A ) 
 Patients must have a life expectancy of greater or equal to 12 weeks  
 Patients must have normal organ and marrow function as defined below: 
– leukocytes ≥2,500/mcL  
– absolute neutrophil count ≥1,000/mcL  
– platelets  ≥100,000/mcL  
– hemoglobin ≥8 g/dL 
– total bilirubin  ≤1.5 × institutional upper limit of normal (ULN) 
(however, patients with known Gilbert’s disease who have serum bilirubin level ≤ 3 × ULN may 
be enrolled) 
– AST(SGOT)/ALT(SGPT)  ≤3 × ULN (AST and/or ALT ≤ 5 × ULN for 
patients with liver involvement)  
– alkaline phosphatase  ≤2.5 × ULN (≤ 5 x ULN for patients with 
documented liver involvement or bone metastases)  
– creatinine clearance  ≥30 mL/min/1.73  m
2 by Cockcroft -Gault: 
 (140 −  age) × (weight in kg) × (0.85 if female) 
72 × (serum creatinine in mg/dL)  
  
 
 
 
 
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
24 
 At the discretion of the treating physician, a 24-
hour urine creatinine clearance could be obtained and utilized as the gold standard if creatinine clearance by Cockcroft -Gault is <30, and 
prevents patient enrollment on the trial.  
 
– INR and aPTT  ≤1.5 × ULN (This applies only to patients who 
do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low- molecular -weight heparin or 
warfarin, should be on a stable dose.) 
 Patients must provide tissue from an archival tumor sample (obtained within 2 years from 
screening visit)  or newly obtained core, punch, or excisional biopsy of a tumor lesion if 
deemed relatively safe and technically feasible.  
 Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of study agent(s). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 
Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. CYT107 has not been tested for reproductive toxicity yet and may expose to the same risk. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before  study entry, for the duration of study participation, 
and for 5 months (150 days) after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 
 Patients must have the ability to understand and the willingness to sign a written informed consent document. 
 Patients positive for HIV are allowed on study, but HIV-positive patients must have: 
a. A stable regimen of HAART  
b. No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections 
c. A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR- based tests   
 
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
25 
 3.2 Exclusion Criteria  
 Patients with prior allogeneic bone marrow transplantation or prior solid organ 
transplantation. 
 Patients who have had chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatment.  
 Patients who have received more than 2 systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma.  
Note : Prior perioperative chemotherapy is allowed and is not counted as a line of therapy 
if patient relapsed ≥12 months later and received additional platinum- based 
chemotherapy for metastatic disease. 
 Patients who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier ( i.e., have residual toxicities > Grade 1). 
However, the following therapies are allowed: 
• Hormone- replacement therapy or oral contraceptives  
• Herbal therapy ≥1 week before  initiation of study treatment (herbal therapy intended 
as anticancer therapy must be discontinued at least 1 week before  initiation of study 
treatment)  
• Palliative radiotherapy for bone metastases >2 weeks before  initiation of study 
treatment  
 Patients who have received prior treatment with anti- PD-1, or anti- PD-L1 therapeutic 
antibody, or pathway -targeting agents. 
• Patients who have received prior treatment with anti- CTLA -4 may be enrolled, 
provided the following requirements are met: 
– Minimum of 12 weeks from the first dose of anti- CTLA -4 and >6 weeks from 
the last dose 
– No history of severe immune- related adverse effects from anti -CTLA -4 (NCI 
CTCAE Grade 3 and 4) 
 Patients who have received treatment with any other investigational agent within 4 weeks before initiation of study treatment.  
 Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]- α or interleukin [IL]-2) within 6 weeks 
before  initiation of study treatment.  
 Patients who have received treatment with systemic immunosuppressive medications (including, but not limited to, oral prednisone (> 10 mg/day or equivalent), 
cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor [anti -TNF] agents) within 2 weeks before  initiation of study treatment.  
• Patients who have received acute, low dose, systemic immunosuppressant  
 
 
 
 
 
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
26 
 medications ( e.g., a one- time dose of dexamethasone for nausea) may be enrolled.  
• The use of inhaled corticosteroids, and mineralocorticoids ( e.g., fludrocortisone) for 
patients with orthostatic hypotension or adrenocortical insufficiency is allowed. 
 Patients taking bisphosphonate therapy for symptomatic hypercalcemia. 
Note: Use of bisphosphonate therapy for other reasons ( e.g., bone metastasis or 
osteoporosis) is allowed. 
 Patients with known primary central nervous system (CNS) malignancy or symptomatic 
CNS metastases are excluded, with the following exceptions: 
• Patients with asymptomatic untreated CNS disease may be enrolled, provided all of 
the following criteria are met: 
– Evaluable or measurable disease outside the CNS  
– No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 
10 mm of the optic apparatus (optic nerves and chiasm) 
– No history of intracranial hemorrhage or spinal cord hemorrhage 
– No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted. 
– No neurosurgical resection or brain biopsy within 28 days before initiation of 
study treatment 
• Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: 
– Radiographic demonstration of improvement upon the completion of CNS 
directed therapy and no evidence of interim progression between the 
completion of CNS directed therapy and the screening radiographic study 
– No stereotactic radiation or whole-brain radiation within 28 days before  
initiation of study treatment 
– Screening CNS radiographic study ≥ 4 weeks from completion of radiotherapy 
and ≥ 2 weeks from discontinuation of corticosteroids 
Note : Patients with CNS metastases enrolled on trial must also have a brain MRI 
imaging at all standard radiologic evaluation timepoints (refer to Section 10) 
 Patients with known hypersensitivity to Chinese hamster ovary cell products or other 
recombinant human antibodies. 
 Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins 
 Patients with known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver/NAFLD/NASH; and inherited liver disease.  
• Patients with past or resolved hepatitis B infection (defined as having a negative 
hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to  
 
 
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
27 
 hepatitis B core antigen] antibody test) are eligible.  
• Patients positive for HCV antibody are eligible only if polymerase chain reaction 
(PCR) is negative for HCV RNA.  
 Patients with active underlying autoimmune disease requiring systemic 
immunosuppressive medication ( oral prednisone >10 mg/day or equivalent). Topical, 
inhaled, or intraarticular steroids or physiologic endocrine replacement (insulin, levothyroxine, etc.) are permitted. Patients with a history of autoimmune disease that is not currently active require consultation with the Protocol PI and/or CITN Coordinating Center.  
 
   
 Patients who have a history of idiopathic pulmonary fibrosis, pneumonitis (including 
drug induced), organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia, etc. ), or evidence of active pneumonitis on screening chest CT scan. History 
of radiation pneumonitis in the radiation field (fibrosis) is permitted . 
 Patients who have known additional malignancies other than UBC within 2 years before  
initiation of study treatment.  
Exceptions  include malignancies with a negligible risk of metastasis or death and treated 
with expected curative outcome ( e.g., non–melanomatous skin cancers), or localized 
prostate cancer treated with curative intent and absence of prostate- specific antigen 
(PSA) relapse or incidental prostate cancer.  
 Patients with active tuberculosis (TB).  
 Patients who have leptomeningeal disease.  
 Patients who have severe infections within 4 weeks before  initiation of study treatment, 
including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.  
Exception : Uncomplicated urinary tract infection will not be considered as a severe 
infection in these patients.  
 Patients who have signs or symptoms of infection within 2 weeks before  initiation of 
study treatment.  
 Patients who have received oral or IV antibiotics within 2 weeks before  initiation of study 
treatment. Patients receiving prophylactic antibiotics ( e.g., for prevention of a urinary 
tract infection or chronic obstructive pulmonary disease) are eligible. 
 Patients who have major surgical procedure, other than for diagnosis, within 28 days before  initiation of study treatment or anticipation of need for a major surgical procedure  
 
 
 
 
 
 
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
28 
 during the course of the study. 
 Patients who have had a live, attenuated vaccine within 4 weeks before initiation of study 
treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab. 
• Influenza vaccination should be given during influenza season only (approximately 
October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks before  initiation of study treatment or at any time during the study. 
 Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive 
heart failure (New York Heart Association Class III or IV), unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction (within the last 6 months), or ps ychiatric 
illness/social situations that would limit compliance with study requirements.  
 Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical ( e.g., infectious) illness.  
3.3 Inclusion of Women and Minorities  
Both men and women of all races and ethnic groups are eligible for this trial. 
4. REGISTRATION PROCEDURES  
4.1 Investigator and Research Associate Registration with CTEP 
 CTEP Registration Procedures 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) 
policy require all investigators participating in any NCI- sponsored clinical trial to register 
and to renew their registration annually. To register, all individuals must ob tain a Cancer 
Therapy Evaluation Program (CTEP) Identity and Access Management (IAM) account (https://ctepcore.nci.nih.gov/iam ). In addition, persons with a registration type of 
Investigator (IVR), Non-Physician Investigator (NPIVR), or Associate Plus (AP) must complete their annual registration using CTEP’s web -based Registration and Credential 
Repository (RCR) (https://ctepcore.nci.nih.gov/rcr).  
RCR utilizes five person registration types. 
• IVR — MD, DO, or i
nternational equivalent; 
• NPIVR — advanced practice providers (e.g., NP or PA) or graduate level researchers 
(e.g., PhD); 
• AP — clinical site staff (e.g., RN or CRA) with data entry access to CTSU applications such as the Roster Update Management System [ RUMS], OPEN, Rave, 
acting as a primary site contact, or with consenting privileges; 
• Associate (A) — other clinical site staff involved in the conduct of NCI-sponsored trials; and  
• Associate Basic (AB) — individuals (e.g., pharmaceutical company employees) with limited access to NCI -supported systems.  
 
 
 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
30 
 continue to submit Research Ethics Board (REB) approval to the CTSU Regulatory Office 
following country-specific regulations.  
Sites participating with the NCI CIRB must submit the Study Specific Worksheet (SSW) 
for Local Context to the CIRB using IRBManager to indicate their intent to open the study locally. The NCI CIRB’s approval of the SSW is automatically communicated to the CTSU Regulatory Office, but sites are required to contact the CTSU Regulatory Office at CTSURegPref@ctsu.coccg.org  to establish site preferences for applying NCI 
CIRB approvals across their Signatory Network. Site preferences can be set at the network or protocol level. Questions about establishing site preferences can be addressed to the CTSU Regulatory Office by ema il or calling 1 -888-651-CTSU (2878). 
In addition, the Site-Protocol Principal Investigator (PI) (i.e. the investigator on the 
IRB/REB approva
l) must meet the following criteria in order for the processing of the 
IRB/REB approval record to be completed: 
• Holds an active CTEP status;  
• Active status at the site(s) on the IRB/REB approval ( applies to US and Canadian 
sites only ) on at least one participating organization’s roster; 
• If using NCI CIRB, active on the NCI CIRB roster under the applicable CIRB 
Signatory Institution(s) record; 
• Includes the IRB number of the IRB providing approval in the Form FDA 1572 in the 
RCR profile;  
• Lists all sites on the IRB/REB approval as Practice Sites in the Form FDA 1572 in the 
RCR profile; and 
• Holds the appropriate CTEP registration type for the protocol.  
Additional Requirements  
Additional site requirements to obtain an approved site registration status include:  
• An active Federal Wide Assurance (FWA) number  
• An active roster affiliation with the Lead  Protocol Organization (LPO) or a 
participating organization (PO); and  
• An active roster affiliation with the NCI CIRB roster under at least one CIRB 
Signatory Institution (US sites only); and  
• Compliance with all protocol- specific requirements  (PSRs) . 
 Downloading Site Registration Documents 
Download the site registration forms from the protocol- specific page located on the 
CTSU members’ website. Permission to view and download this protocol and its 
supporting documents is restricted to the institutions and its associated investigators and staff on a participating roster. To view/download site registration forms:   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
31 
 • Log in to the CTSU members’ website ( https://www.ctsu.org)  using your CTEP- IAM 
username and password; 
• Click on Protocols  in the upper left of your screen; 
• Either enter the protocol number in the search field at the top of the protocol tree, or 
• Click on the By Lead Organization folder to expand, then select CITN , and protocol 
CITN -14. 
• Click on Documents , Protocol Related Documents, and use the Document Type  filter and 
select Site Registration  to download and complete the forms provided. (Note: For 
sites under the CIRB, IRB data will load automatically to the CTSU.)  
 
 Submitting Regulatory Documents 
Submit required forms and documents to the CTSU Regulatory Office using the 
Regulatory Submission Portal on the CTSU members’ website.  
To access the Regulatory Submission Portal log in to the CTSU members’ website, go to 
the Regulatory  section and select Regulatory Submission. 
Institutions with patients waiting that are unable to use the  Regulatory Submission Portal 
should alert the CTSU Regulatory Office immediately by phone or email: 1-866-651-
CTSU (2878), or CTSURegHelp@coccg.org  in order to receive further instruction and 
support. 
 Checking Site Registration Status 
Site registration status may be verified on the CTSU members’ website.  
• Click on Regulatory  at the top of your screen; 
• Click on Site Registration ; and   
• Enter your 5-character CTEP Institution Code and click on Go; 
o Additional filters are available to sort by Protocol, Registration Status, Protocol Status, and/or IRB Type.  
Note : The status shown only reflects institutional compliance with site registration  
requirements as outlined within the protocol. It does not reflect compliance with protocol 
requirements for individuals participating on the protocol or the enrolling investigator’s status with the NCI or their affiliated networks.  
4.3 Delegation of Tasks Log (DTL) Each site must complete a protocol -specific Delegation of Tasks Log (DTL) using the 
DTL application in the Delegation Log section on the CTSU members’ website. The 
Clinical Investigator (CI) is required to review and electronically sign the DTL prior to the site receiving an approved site registration status and enrolling patients to the study. 
To maintain an approved site registration status the CI must re -sign the DTL at least 
annually and when a new version of the DTL is released; and to activate new task  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
32 
 assignments requiring CI sign-off. Any individual at the enrolling site on a participating 
roster may initiate the site DTL. Once the DTL is submitted for CI approval, only the designated DTL Administrators or the CI may update the DTL. Instructions on completing the DTL are available in the Help Topics button in the DTL application and 
include a Master Task List, which describes DTL task assignments, CI signature, and CTEP registration requirements.  
 
4.4 Patient Enrollment  
 OPEN  
The Oncology Patient Enrollment Network ( OPEN) is a web -based registration system 
available to users on a 24/7 basis. OPEN is integrated with CTSU regulatory and roster 
data and with the LPOs registration/randomization systems or the Theradex Interactive Web Response System (IWRS) for retrieval of patient registration/randomization assignment. OPEN will populate the patient enrollment data in NCI’s clinical data management system, Medidata Rave.  
Requirements for OPEN access:   
• A valid CTEP -IAM account ; 
• To perform enrollments or request slot reservations: Must be on an LPO roster, 
ETCTN corresponding roster, or participating organization roster with the role of Registrar. Registrars must hold a minimum of an Associate Plus (AP) registration type; 
• If a Delegation of Tasks Log (DTL) is required for the study, the registrars must hold 
the OPEN Registrar task on the DTL for the site; and 
• Have an approved site registration for the protocol prior to patient enrollment. 
 
To assign an Investigator (IVR) or Non- Physician Investigator (NPIVR) as the treating, 
crediting, consenting, drug shipment (IVR only), or receiving investigator for a patient transfer in OPEN, the IVR or NPIVR must list the IRB number used on the site’s I RB 
approval on their Form FDA 1572 in RCR. If a DTL is required for the study, the IVR or NPIVR must be assigned the appropriate OPEN- related tasks on the DTL.  
Before  accessing OPEN, site staff should verify the following: 
• Patient has met all eligibility criteria within the protocol stated timeframes ; and  
• All patients have signed an appropriate consent form and Health Insurance Portability 
and Accountability Act ( HIPAA ) authorization form (if applicable). 
Note : The OPEN system will provide the site with a printable confirmation of registration 
and treatment information. Please print this confirmation for your records. 
Access OPEN at https://open.ctsu.org or from the OPEN link on the CTSU member’s 
website. Further instructional information is on the OPEN section  of the CTSU website at  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
33 
 https://www.ctsu.org or at https://open.ctsu.org. For any additional questions contact the 
CTSU Help Desk at 1 -888-823-5923 or ctsucontact@westat.com . 
Patient enrollment for this study will be facilitated using the Slot Reservation System in 
conjunction with the registration system in OPEN. Prior to discussing protocol entry with the patient, all site staff must use the CTSU OPEN Slot Reservation System to ensure that a slot on the protocol is available to the patient. Once a slot reservation confirmation is obtained, site staff may then proceed to enroll the patient to this study.   
4.5 General Guidelines  
After  registration, patients should begin protocol treatment within 5 business days. Issues that 
would cause treatment delays should be discussed with the PI . If a patient does not receive 
protocol therapy after registration, the patient’s registration on the study may be canceled. The 
Clinical Research Site (CRS) must notify the CITN Coordinating Center of cancellations as soon as possible. 
Except in very unusual circumstances, each participating institution will order DCTD-supplied 
agents directly from CTEP. 
5. TREATMENT PLAN  
This is a phase II trial of atezolizumab (MPDL3280A) plus recombinant human IL-7 (CYT107) 
in patients with locally advanced or metastatic urothelial carcinoma. The trial follows a randomized, controlled trial design, with an initial ‘Safety Run- In’ phase d esigned to evaluate 
the acute safety profile of the investigational treatment combination.  
During the Safety Run-In phase, 6 patients will be assign ed to the experimental arm 
(atezolizumab + CYT107)  with staggered enrollment. This will be accomplished with an initial 3 
patient enrollment. All adverse events will be assessed by the Toxicity Evaluation Committee. If 0-1 patient experiences a protocol- defined DLT (refer to Section 5.2) after completion of the 4-
week DLT window, an additional 3 patients will be enrolled. Once all 6 patients have completed the 4 -week DLT window, the Toxicity Evaluation Committee  will again assess all adverse 
events . If, at any time,  2 or more patients experience a protocol -defined DLT, further enrollment 
into the trial will be suspended. 
If the treatment combination of the experimental arm demonstrates an acceptable safety profile 
in the Safet
y Run- In (one or fewer patient experiences a protocol -defined DLT), randomized 
enrollment into the trial will begin.  
Patients will be randomly assigned to either the control arm (a tezolizumab mon otherapy) or 
experimental arm (a tezolizumab + CYT107) of the trial.  
The first 6 subjects enrolled in the run-in phase of the study will have PK sampling done at baseline (prior to CYT107 administration), and at week 4 prior to CYT107 administration and at 2 hours, 4 hours and 6 hours after the fourth CYT107 administration. 
Anti-drug antibody testing (ADA testing) will be done on all subjects who receive CYT107. 
Testing will be done at baseline (prior to CYT107 administration) and at week 8, (1 month after 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
35 
 For anaphylaxis precautions, see the management guidelines below . Atezolizumab 
infusions will be administered per the instructions outlined in the Table below. 
First Infusion  Subsequent Infusions 
• No premedication is permitted prior to the 
atezolizumab infusion.  
• Vital signs (pulse rate, respiratory rate, blood 
pressure, and temperature) should be measured 
within 60 minutes prior to the infusion. 
• Atezolizumab should be infused over 60 ( ±15) 
minutes.  
• If clinically indicated, vital signs should be 
measured every 15  (±5) minutes during the 
infusion and at 30 ( ±10) minutes after the 
infusion. 
• Patients should be informed about the 
possibility of delayed post-infusion symptoms 
and instructed to contact their study physician if 
they develop such symptoms. • If the patient experienced an infusion −related 
reaction with any previous infusion, 
premedication with antihistamines, antipyretics, and/or analgesics may be 
administered for subsequent doses at the 
discretion of the investigator.  
• Vital signs should be measured within 60 minutes prior to the infusion. 
• Atezolizumab should be infused over 
30 (±10) minutes if the previous infusion was 
tolerated without an infusion- related reaction, 
or 60 (±15) minutes if the patient experienced 
an infusion- related reaction with the previous 
infusion. 
• If the patient experienced an infusion− related 
reaction with the previous infusion or if 
clinically indicated, vital signs should be 
measured during the infusion and at 
30 (± 10) minutes after the infusion.  
 
For anaphylaxis precautions, use the following procedure: 
 Equipment Needed 
• Monitoring devices: ECG monitor, blood pressure monitor, oxygen saturation 
monitor, and thermometer 
• Oxygen 
• Epinephrine for subcutaneous, IV, intramuscular, and/or endotracheal use in 
accordance with standard practice  
• Antihistamines  
• Corticosteroids 
• Intravenous infusion solutions, tubing, catheters, and tape 
Procedures  
In the event of a suspected anaphylactic reaction during atezolizumab infusion, the 
following procedures should be performed:  
• Stop the study drug infusion. 
• Call for additional medical assistance.  
• Maintain an adequate airway.  
• Ensure that appropriate monitoring is in place, with continuous ECG and pulse 
oximetry monitoring, if possible. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
36 
 • Administer antihistamines, epinephrine, or other medications as required by patient 
status and directed by the physician in charge. 
• Continue to observe the patient and document observation. 
All patients randomly assigned to the experimental treatment arm in Part 2 will also 
receive CYT107 in addition to atezolizumab. 
 Recombinant Human IL- 7 (CYT107)  
Patients enrolled in the Safety Run-in phase and patients randomly assigned to the experimental arm of the trial will receive recombinant human IL -7 (CYT107). The 
patients will receive 10 mc g/kg of IL-7 (CYT107) IM on days 1, 8, 15 and 22 of Cycle 1 
only. The CYT107 dose must be administered before atezolizumab on Day 8 of Cycle 1.  
For patient with a Body Mass Index (BMI) >30, an adjusted body weight will be used to 
calculate the final dose the patient will receive. Please refer to Appendix D  for details on 
the adjusted body weight calculation. 
Patients receiving CYT107 will have their vital signs (heart rate, respiratory rate, blood 
pressure, and te
mperature) determined within 60 minutes before the first CYT107 
injection on day 1, and 2 hours  (±15 minutes ) after the injection.  
On day 8, vital signs will be monitored as described above ( Section 5.1.1) following the 
guidelines for the first atezolizumab infusion. 
On days 15 and 22, vital signs will be determined within 60 minutes before and within 30 
minutes after the
 injection.  
Patients will be informed about the possibility of the development of an allergic reaction to CYT107 (hives, bronchospasm, rash, etc. ) and instructed to contact their study 
physician if they develop such symptoms. 
 Other Procedures: Biopsy (core needle, punch or excisional)  
The rationale for the biopsy/tissue collection is to investigate changes in the tumor microenvironment that may correlate with response or provide information on potential actionable causes for lack of benefit.  
A pre -treatment biopsy/tissue collection  will be obtained before the first dose of study 
treatment (atezolizumab or CYT107) assuming this can be carried out safely. 
Note:  If an archival tumor sample (at least 0.5 × 0.5 × 0.5 cm) obtained within 2 years 
from screening visit is available, the pre -treatment biopsy is not required.  
A post- treatment tumor biopsy/tissue  collection will be obtained if deemed relatively safe 
and technically feasible (core biopsy, punch biopsy or excisional biopsy). The tumor 
biopsy/tissue collection will be obtained prior to dosing on Cycle 4, Day 1 or at the end of 
treatment visit, whichever occurs first.   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
37 
 The biopsies will be done according to clinical site S tandard O perating P rocedures 
(SOP s). 
 Other procedures:  Microbiome Sample Collection 
Pre-treatment  and post- treatment  microbiome samples will be collected  by patients using 
standard, at home stool-collection procedures using standardized fecal swab/storage 
devices.  The samples will be stored froz en at home by patient and returned to the clinical 
research site at their next study visit.    
Patients  will be provided with fecal swab/storage devices and instructions (refer to 
Appendix E ) at the screening visit and at the Cycle 3, Day 1  visit.  
5.2 Safety Run -in: Definition of Dose -Limiting Toxicity  
Dose -limiting toxicity is defined as any adverse event (AE) occurring within the first 28 days 
(i.e., from Week 1 Day 1 through Week 4 Day 7), that is considered to be  at least possibly  
related  to the protocol treatment (atezolizumab, CYT107 or both), and that meets at least one of 
the non-hematologic or hematologic criteria below: 
 Hematologic toxicity  
The standard NCI Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 
criteria will be replaced by these criteria:  
 
• Any Grade 4 event, including laboratory electrolyte abnormalities, that is not easily 
reversed without sequelae 
• Grade 4 neutropenia (Absolute Neutrophil Count (ANC) <0.5 × 109/L) 
• Grade 3 febrile neutropenia (ANC <1.0 × 109/L with a fever ≥38.3ºC)  
• Grade 4 thrombocytopenia (<25.0 × 109/L) lasting >4 days or that requires platelet 
transfusion 
• Grade ≥3 thrombocytopenia (<50.0–25.0 × 109/L) associated with Grade ≥3 bleeding 
• Grade 2 concurrent AST or ALT >3xULN and total bilirubin > 2xULN without evidence of cholestasis  
• Any toxicity resulting in death ( i.e., Grade 5)  
Note : Peripheral lymphocytopenia after the first CYT107 injection is not a sign of 
toxicity; it reflects the lymphocytes “homing effect” of rh IL-7. Lymphocyte counts 
usually come back to baseline 5 to 7 days after the first injection. 
 Non-hematologic toxicity  
Any Grade ≥3 non-hematologic toxicity (CTCAE v 5.0), except  for the following, which 
will not constitute DLTs:  
• Grade ≥3 nausea or vomiting lasting ≤72 hours with the use of adequate/maximal medical intervention and/or prophylaxis  
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
38 
 • Grade 3 diarrhea lasting ≤72 hours with the use of adequate/maximal medical 
intervention and/or prophylaxis 
• Grade 3 fatigue lasting ≤7 days  
• Grade 3 injection site reaction (unless operative intervention is required) 
• Grade 3 hyperglycemia lasting ≤72 hours with standard anti diabetic  therapy  
• Grade 3 increases in liver transaminases (>5.0 –20.0 × ULN) in patient with liver 
metastases  
• Clinical laboratory abnormalities that are reversible to ≤Grade 1 or baseline status within 72 hours with outpatient care and/or monitoring, or that are considered not 
clinically significant by the treating physician  
Management and dose modifications associated with the above AEs  are outlined in 
Section 6 . 
The AEs  will be assessed by the Toxicity Evaluation Committee, which includes the 
PI(s), study sponsor(s), CTEP and the CITN Central Operating and Statistical Center 
(COSC).  
The patients must complete the full 4 -week DLT window to be considered evaluable for 
DLTs. Patients who discontinue from the study before completion of the full 4- week 
DLT window for reasons other than the occurrence of a DLT ( e.g., withdrawal of 
consent, rapid tumor progression, death due to rapid tumor progression, AE that does not 
meet DLT criteria) will not be considered evaluable for DLTs and will be replaced.  
All randomly assigned patients will be monitored for occurrence of DLT. Monitoring of all safety and toxicity data is done by the PI, the study Sponsor(s) and the CITN COSC on a real -time basis as data are entered into Medidata Rave using the Web Reporting 
Module . All participating sites must notify the P I and CITN COSC when a DLT has 
occurred.  
A delay  due to toxicity in receiving the second cycle of therapy of >14 days will be 
considered a DLT in subj ects enrolled in the safety run -in phase of the study. This does 
not apply to subsequent subjects enrolled in the randomized component of the study. 
5.3 General Concomitant Medication and Supportive Care Guidelines  
Because there is a potential for interaction of Atezolizumab and CYT107 with other concomitantly administered drugs, the case report form must capture the concurrent use of all other drugs, over-the- counter medications, or alternative therapies. The P I should be alerted if 
the patient is taking any agent known to affect or with the potential for drug interactions. The study team should check a frequently updated medical reference for a list of drugs to avoid or minimize use of.  
Atezolizumab General Concomitant Medication Guidelines  
Concomitant therapy includes any prescription medications or over- the-counter 
preparations used by a patient between the 7 days preceding the baseline evaluation and 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
39 
 the treatment discontinuation visit.  
Patients who experience infusion- associated symptoms may be treated symptomatically 
with acetaminophen, ibuprofen, diphenhydramine, and/or cimetidine or another H2 
receptor antagonist, as per standard practice (for sites outside the United States, equivalent medications may be substituted per local practice). Serious infusion- associated 
events manifested by dyspnea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or respiratory distress should be managed with supportive therapies as clinically indicated ( e.g., supplemental oxygen and β
2-adrenergic agonists; 
see Section 5.1.1).  
Systemic corticosteroids and TNF α inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab but may be administered at the discretion of the treating physician. If feasible, alternatives to corticosteroids should be considered. Premedication may be administered for Cycles ≥2 at the discretion of the treating physician. The use of inhaled corticosteroids and mineralocorticoids ( e.g., 
fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. Megestrol administered as appetite stimulant is acceptable while the patient is enrolled in the study. 
Patients who use oral contraceptives, hormone- replacement therapy, prophylactic or 
therapeutic anticoagulation therapy (such as low- molecular -weight heparin or warfarin at 
a stable dose level) should continue their use. Males and females of reproductive 
potential should use highly effective means of contraception. 
 Atezolizumab Excluded Therapies 
Any concomitant therapy intended for the treatment of cancer, whether health authority approved or experimental, is prohibited unless it is specifically included in the treatment regimen described in this protocol. This includes but is not limited to the following: 
• Chemotherapy, hormonal therapy, immunotherapy, radiotherapy, investigational 
agents, or herbal therapy (except for maintenance therapies outlined in Section 5.3.1).  
– After Cycle 1, certain forms of radiotherapy may be considered for pain palliation if patients are deriving benefit ( e.g., treatment of known bony 
metastases); atezolizumab administration may be suspended during radiotherapy. 
• Herbal therapy intended as anticancer therapy must be discontinued ≥ 1 week before 
initiation of study treatment; the ingredients of many herbal medicines are not fully studied, and their use may result in unanticipated drug-drug interactions that may cause, or confound assessment of, toxicity. 
Initiation or increased dose of granulocyte colony stimulating factors ( e.g., granulocyte 
colony stimulating factor, granulocyte/macrophage colony stimulating factor, and/or 
pegfilgrastim) is prohibited.   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
40 
 Patients are not allowed to receive immunostimulatory agents, including, but not limited 
to, IFN- α, IFN -γ, or IL -2, during the entire study. These agents, in combination with 
atezolizumab, could potentially increase the risk for autoimmune conditions. 
Patients should also not be receiving immunosuppressive medications, including, but not 
limited to, cyclophosphamide, azathioprine, methotrexate, and thalidomide. These agents could potentially alter the activity and the safety of atezolizumab.  
 Recombinant Human IL- 7 (CYT107)  
The excluded therapies listed above ( Section 5.3.1) also apply to CYT107. 
Immunostimulatory and immunosuppressive agents are prohibited.  
Topical corticosteroids to treat injection site reaction are allowed.  
Studies perfo
rmed to investigate the potential of CYT107 to inhibit or to act as a time 
dependent inhibitor of hepatic microsomal cytochrome P450 isozym es (see Investigator 
Brochure) concluded that at the concentration investigated, it is unlikely that CYT107 
will be involved in drug-drug interactions and CYT107 is not expected to cause clinically significant P450 inhibition or induction. However, the case report form ( CRF ) must 
capture the concurrent use of all other drugs, over-the-counter medications, or alternative therapies including vitamins and nutritional supplements. 
5.4 Duration of Therapy 
In the absence of treatment delays due to AE (s), treatment may continue for up to 2 years  or until 
one of the following criteria applies:  
• Disease progression warranting alternative systemic therapy,  
Note : Patients with radiographic progressive disease (PD) who are otherwise stable 
without symptomatic progression may continue Atezolizumab until the next radiographic imaging time point (within 9 weeks) to assess for possible pseudoprogression. 
• Intercurrent illness that prevents further administration of treatment,  
• Unacceptable AE (s), 
• Patient decides to withdraw from the study, 
• General or specific changes in the patient's condition render the patient unacceptable 
for further treatment in the judgment of the investigator, 
• Patient noncompliance, 
• Dosing interruption lasting >12 weeks (see Section 6.1.1),  
• Pregnancy  
– All women of child -bearing potential should be instructed to contact the 
investigator immediately if they suspect they might be pregnant ( e.g., missed 
or late menstrual period) at any time during study participation. 
– The investigator must immediately notify CTEP in the event of a confirmed pregnancy in a patient participating in the study.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
41 
 • Termination of the study by sponsor(s), or 
• The drug manufacturer can no longer provide the study agent 
The reason(s) for protocol therapy discontinuation, the reason(s) for study removal, and the 
corresponding dates must be documented in the CRF. 
All patients who tolerate the protocol regimen and with either complete tumor response (CR), 
partial response ( PR), or stable disease (SD) will be permitted to continue treatment with 
atezolizumab until confirmed disease progression or for up to 2 years. 
Discontinuation of treatment may be considered, at the discretion of the treating physician, for 
patients who have attained a confirmed CR that have been treated for at least 24 weeks with atezolizumab and had at least 2 treatments beyond the date when the initial CR was declared.  
5.5 Study Treatment beyond Disease Progression  
Immunotherapeutic agents such as atezolizumab may produce antitumor effects by potentiating endogenous cancer-specific immune responses. The response patterns seen with such an approach may extend beyond the typical time course of responses seen with cytotoxic agents and  
can manifest as a clinical response after an initial increase in tumor burden or even the appearance of new lesions. 
Patients with radiographic PD who are otherwise stable without symptomatic progression may 
continue trial treatment as long as they meet the following criteria  (following consultation with 
Protocol PI and/or CITN Coordinating Center):  
• Investigator- assessed clinical benefit  
• Tolerance of study treatment 
• Absence of signs and symptoms (including worsening of laboratory values) indicating 
disease progression 
• No decline in ECOG performance status 
• Absence of rapid progression of disease or threat to vital organs 
• Absence of progressive tumor at critical anatomical sites ( e.g., cord compression) 
requiring urgent alternative medical intervention 
Patients should remain on the trial and continue to receive monitoring according to the Study 
Calendar ( Section 10).   
5.6 Duration of Follow- Up 
The active study will end when the last patient reaches 2 years.  
Disease status and overall survival data will be collected and reported every 12  weeks, either by 
in-person visit or by telephone assessment. 
Upon discontinuation of study treatment in patients without documented progression, every effort should be made to continue monitoring disease status by radiologic imaging at the investigative site or locally. Imaging will be collected and evaluated per RECIST 1.1. Patients will be followed for disease assessment for up to 2 years  after discontinuation of study treatment.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
42 
 Standard of care disease assessments will be collected until disease pro gression, start of new 
anticancer treatment, death or end of study, whichever occurs first.  
After disease progression or start of new anticancer treatment, patient will be fol lowed for 
overall survival only. Survival follow-up will continue until death or the end of the study, 
whichever occurs first.   
Patients removed from study for unacceptable AE (s) will be followed until resolution or 
stabilization of the AE ; in addition, the patients will be followed for dise ase status and overall 
survival, as described above.  
5.7 Patient Replacement  
All randomly assigned patients who receive at least one dose of the investigational treatment will 
be considered evaluable for safety and included in the overall safety analysis. 
During the Safety Run-in Phase, patients who discontinue from the study before  completion of 
the full 4 -week DLT window for reasons other than the occurrence of a DLT ( e.g., withdrawal of 
consent, rapid tumor progression, death due to rapid tumor progression, AE that does not meet 
DLT criteria) will not be considered evaluable for DLTs and will be replaced.  
6. DOSING DELAYS/DOSE MODIFICATIONS  
The NCI CTCAE Version 5.0 will be used to grade AEs . Patients enrolled in this study will be 
evaluated clinically and with standard laboratory tests before and at regular intervals during their participation in this study as specified in this section.  
Patients will be evaluated for AEs  (all grades), serious AEs , and AEs  requiring study drug 
interruption or discontinuation at each study visit for the duration of their participation in the study. 
6.1 Atezolizumab (MPDL3280A) 
 General AE Management and Dose Modification Guidelines  
There will be no dose reduction for atezolizumab in this study. Patients may temporarily suspend study treatment for up to 84 days (12 weeks) beyond 
the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If atezolizumab is held because of AEs for >84 days beyond the scheduled date of infusion, the patient will be discontinued from atezolizumab and will be followed for safety and efficacy as specified in this protocol. If the AE resolves within 84 days and the patient is receiving corticosteroid ther apy for the event, 
atezolizumab may be held for longer than 84 days (up to 4 weeks) in order to allow tapering of the steroid dose to ≤10 mg oral prednisone or equivalent. 
Dose interruptions for reasons other than toxicity, such as surgical procedures, may be 
allowed. The acceptable length of interruption will be at the discretion of the study PI in consultation with CTEP.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
43 
 For detailed information regarding management of AEs  associated with atezolizumab, 
please refer to the most current version of the Atezolizumab Investigator’s Brochure and 
the FDA product label. 
The primary approach to grade 1 to 2 irAEs is supportive and symptomatic care with 
continued treatment with atezolizumab; for higher -grade irAEs, atezolizumab should be 
withheld and oral and/or parenteral steroids administered. Recurrent grade 2 irAEs may also mandate withholding atezolizumab or the use of steroids. Assessment of the benefit-risk balance should be made by the investigator, with consideration of the totality of information as it pertains to the nature of the toxicity and the degree of clinic al benefit a 
given patient may be experiencing before  further administration of atezolizumab. 
Atezolizumab should be permanently discontinued in patients with life-threatening irAEs. 
Patients should be assessed clinically (including review of laboratory values) for toxicity 
before , during, and after each infusion. If unmanageable toxicity due to atezolizumab 
occurs at any time during the study, treatment with atezolizumab should be discontinued. 
 Management of Specific AEs 
Management of certain AEs of concern, including immune- related pneumonitis, hepatitis, 
colitis, endocrinopathies, pancreatitis, neuropathies, meningoencephalitis, and potential ocular toxicities are presented in the Atezolizumab Investigator’s Brochure. See Section 
5.1.1, including the ‘ Administrati on of First and Subsequent Atezolizumab 
Infusions ’ table  for guidelines for the management of Infusion- Related Reactions and 
Anaphylaxis. 
Atezolizumab has been associated with risks such as the following: IRRs and 
immune−related hep
atitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, 
hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, Guillain- Barré 
syndrome, myasthenic syndrome or myasthenia gravis, meningoencephalitis, 
myocarditis, nephritis, myositis, and severe cutaneous adverse reactions. Immune-mediated reactions may involve any organ system and may lead to hemophagocytic lymphohistiocytosis and macrophage activation syndrome. 
6.1.2.1 Pulmonary events 
 
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltrates have been associated with the administration of atezolizumab. Patients will be assessed for pulmonary signs and symptoms throughout the study and will have computed tomography (CT) scans of the chest performed at every tumor assessment. 
All pulmonary events should be thoroughly evaluated for other commonly reported etiologies 
such as pneumonia or other infection, lymphangitic carcinomatosis, pulmonary embolism, heart failure, chronic obstructive pulmonary disease, or pulmonary hypertension. Management guidelines for pulmonary events are provided in the table below.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
44 
 Event  Management  
Pulmonary event, 
Grade 1  • Continue atezolizumab and monitor closely.  
• Re-evaluate on serial imaging. 
• Consider patient referral to pulmonary specialist.  
• For Grade 1 pneumonitis, consider withholding atezolizumab.  
Pulmonary event, 
Grade 2  • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to pulmonary and infectious disease specialists and 
consider bronchoscopy or BAL. 
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day oral 
prednisone. 
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding atezolizumab, permanently discontinue atezolizumab.
 c 
• For recurrent events, or events with no improvement after 48–72 hours 
of corticosteroids, treat as a Grade 3 or 4 event.  
Pulmonary event, 
Grade 3 or 4 • Permanently discontinue atezolizumab. c 
• Bronchoscopy or BAL is recommended. 
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day IV 
methylprednisolone. 
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥1 month.  
BAL   =  bronchoscopic alveolar lavage.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to the equivalent of ≤ 10 
mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or 
appropriate delegate). 
6.1.2.2 Hepatic events  
 
Immune- mediated hepatitis has been associated with the administration of atezolizumab.  
Patients eligible for study treatment must have adequate liver function, as manifested by measurements of total bilirubin and hepatic transaminases, and liver function will be monitored throughout study treatment.  Management guidelines for hepatic events are provided in the table below.  Patients with right upper-quadrant abdominal pain and/or unexplained nausea or vomiting should 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
46 
 Event  Management  
AST/ALT is within 
normal limits 
at baseline and 
increases to 
>3×ULN to 
≤10×ULN 
or 
AST/ALT is >ULN 
to ≤3×ULN 
at baseline and 
increases to 
>5×ULN to 
≤10×ULN 
or 
AST/ALT is >3×ULN to 
≤5×ULN at baseline 
and increases to >8×ULN to 
≤10×ULN • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Monitor LFTs more frequently until return to baseline values.  
• For events of > 5 days' duration, consider initiating treatment 
with corticosteroids equivalent to 1 −2 mg/kg/day oral 
prednisone. 
• If event resolves to baseline or to Grade 1 or better, resume 
atezolizumab. b 
• If event does not resolve to baseline or to Grade 1 or better while withholding atezolizumab, permanently discontinue atezolizumab.
 c 
AST or ALT 
increases to 
> 10  × ULN or total 
bilirubin increases to >
 3× ULN • Permanently discontinue atezolizumab. c 
• Consider patient referral to gastrointestinal specialist for 
evaluation and liver biopsy to establish etiology of hepatic 
injury.  
• Initiate treatment with corticosteroids equivalent to 1 -2 
mg/kg/day oral prednisone. 
• If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to baseline, taper corticosteroids over ≥1 
month.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
47 
 Event  Management  
LFT  =  liver function test.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on an 
assessment of benefit −risk by the investigator and in alignment with the protocol requirements 
for the duration of treatment and documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to the equivalent 
of ≤10 mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- mediated event.  The decision to re −challenge patients with 
atezolizumab should be based on investigator's assessment of benefit −risk and documented by 
the investigator (or an appropriate delegate). 
6.1.2.3 Gastrointestinal events  
 
Immune- mediated colitis has been associated with the administration of atezolizumab.  
Management guidelines for diarrhea or colitis are provided in the table  below . 
 
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies.  For events of significant duration or magnitude or associated with signs of systemic 
inflammation or acute- phase reactants ( e.g., increased C -reactive protein, platelet count, or 
bandemia): Perform sigmoidoscopy (or colonoscopy, if appropriate) with colonic biopsy, with 
three to five specimens for standard paraffin block to check for inflammation and lymphocytic infiltrates to confirm colitis diagnosis.  
 
Event  Management  
Diarrhea or colitis, 
Grade 1  • Continue atezolizumab.  
• Initiate symptomatic treatment.  
• Endoscopy is recommended if symptoms persist for > 7 days. 
• Monitor closely.  
Diarrhea or colitis, 
Grade 2  • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Initiate symptomatic treatment.  
• Patient referral to GI specialist is recommended.  
• For recurrent events or events that persist  >5 days, initiate treatment 
with corticosteroids equivalent to 1 −2 mg/kg/day oral prednisone.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
48 
 Event  Management  
Diarrhea or colitis, 
Grade 3  • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to GI specialist for evaluation and confirmatory biopsy. 
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day IV 
methylprednisolone and convert to 1− 2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Diarrhea or colitis, 
Grade 4  • Permanently discontinue atezolizumab. c 
• Refer patient to GI specialist for evaluation and confirmation biopsy. 
• Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1-2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
• If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids over ≥1 
month.  
GI = gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of ≤10 
mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate).  
 
6.1.2.4 Endocrine disorders 
 
Thyroid disorders, adrenal insufficiency, diabetes mellitus, and pituitary disorders have been 
associated with the administration of atezolizumab. Management guidelines for endocrine events are provided in the table  below  
Patients with unexplained symptoms such as headache, fatigue, myalgias, impotence, 
constipation, or mental status changes should be investigated for the presence of thyroid, 
pituitary, or adrenal endocrinopathies. The patient should be referred to an endocrinologist if an endocrinopathy is suspected. Thyroid stimulating hormone (TSH) and free triiodothyronine ( T3) 
and thyroxine ( T4) levels should be obtained to determine whether thyroid abnormalities are 
present. Pituitary hormone levels and function tests ( e.g., TSH, growth hormone, luteinizing 
hormone, follicle-stimulating hormone, testosterone, prolactin, adrenocorticotropic hormone 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
49 
 [ACTH] levels, and ACTH stimulation test) and magnetic resonance imaging (MRI) of the brain 
(with detailed pituitary sections) may help to differentiate primary pituitary insufficiency from primary adrenal insufficiency.
 
Event  Management  
Asymptomatic 
hypothyroidism • Continue atezolizumab.  
• Initiate treatment with thyroid replacement hormone. 
• Monitor TSH closely.  
Symptomatic 
hypothyroidism • Withhold atezolizumab.  
• Initiate treatment with thyroid replacement hormone.  
• Monitor TSH closely. 
• Consider patient referral to endocrinologist.  
• Resume atezolizumab when symptoms are controlled and thyroid 
function is improving.  
Asymptomatic 
hyperthyroidism TSH ≥0.1 mU/L and <0.5 mU/L:  
• Continue atezolizumab. 
• Monitor TSH every 4 weeks. 
• Consider patient referral to endocrinologist.  
 
TSH <0.1 mU /L: 
• Follow guidelines for symptomatic hyperthyroidism. 
• Consider patient referral to endocrinologist.  
Symptomatic 
hyperthyroidism • Withhold atezolizumab.  
• Initiate treatment with anti- thyroid drug such as methimazole or 
carbimazole as needed.  
• Consider patient referral to endocrinologist.  
• Resume atezolizumab when symptoms are controlled and thyroid 
function is improving. 
• Permanently discontinue atezolizumab. c 
Symptomatic adrenal 
insufficiency, Grade 2 −4 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to endocrinologist. 
• Perform appropriate imaging.  
• Initiate treatment with corticosteroids equivalent to 1 -2 
mg/kg/day IV methylprednisolone and convert to 1-2 mg/kg/day oral prednisone or equivalent upon improvement. 
• If event resolves to Grade 1 or better and patient is stable on replacement therapy, resume atezolizumab. 
b 
• If event does not resolve to Grade 1 or better or patient is not stable on replacement therapy while withholding atezolizumab, 
permanently discontinue atezolizumab. c 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
50 
 Hyperglycemia, Grade  1 
or 2 • Continue atezolizumab.  
• Investigate for diabetes.  In the absence of corticosteroids or 
diabetes medication non- adherence may be an indication of beta-
cell destruction and atezolizumab-induced diabetes.  If patient 
has Type 1 diabetes ( e.g. new- onset diabetes in the absence of 
corticosteroids or another inciting medication), treat as a Grade 3 event.   
• Exercise caution in utilizing non-insulin hypoglycemic agents in 
this setting, as new -onset hyperglycemia in the absence of 
corticosteroids may be an indication of beta-cell destruction and 
atezolizumab -induced diabetes.  After a thorough investigation of 
other potential causes which may involve a referral to an endocrinologist, follow institutional guidelines. 
• Monitor for glucose control.  
Hyperglycemia, Grade  3 
or 4 • Withhold atezolizumab.  
• Initiate treatment with insulin.  
• Monitor for glucose control. 
• Strongly consider referral to endocrinologist, particularly if 
patient is deemed to have atezolizumab -induced diabetes; if so, 
obtain C-peptide level paired with glucose, autoantibody levels 
(e.g. GAD65, islet cell autoantibodies), and hemoglobin A1C 
level.  
• If patient is found to have diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome, treat as per institutional guidelines with appropriate management and laboratory values ( e.g. anion gap, 
ketones, blood pH, etc.) reported.   
• Resume atezolizumab when symptoms resolve and glucose levels 
are stable.  
Hypophysitis (pan -
hypopituitarism), Grade 2 
or 3 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to endocrinologist. 
• Perform brain MRI (pituitary protocol). 
• Initiate treatment with corticosteroids equivalent to 1 -2 
mg/kg/day IV methylprednisolone and convert to 1-2 mg/kg/day 
oral prednisone or equivalent upon improvement. 
• Initiate hormone replacement if clinically indicated.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding atezolizumab, permanently discontinue atezolizumab. 
c 
• For recurrent hypophysitis, treat as a Grade 4 event.  
Hypophysitis (pan -
hypopituitarism), Grade 4 • Permanently discontinue atezolizumab. c 
• Refer patient to endocrinologist. 
• Perform brain MRI (pituitary protocol). 
• Initiate treatment with corticosteroids equivalent to 1 -2 
mg/kg/day IV methylprednisolone and convert to 12 mg/kg/day oral prednisone or equivalent upon improvement. 
• Initiate hormone replacement if clinically indicated.  
MRI  = magnetic resonance imaging; TSH  = thyroid -stimulating hormone.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
51 
 a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of ≤10 
mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate). 
6.1.2.5 Ocular Events  
 
An ophthalmologist should evaluate visual complaints ( e.g., uveitis, retinal events).  
Management guidelines for ocular events are provided in the table  below . 
Event  Management  
Ocular event, 
Grade 1  • Continue atezolizumab.  
• Patient referral to ophthalmologist is strongly recommended.  
• Initiate treatment with topical corticosteroid eye drops and topical 
immunosuppressive therapy.  
• If symptoms persist, treat as a Grade 2 event.  
Ocular event, 
Grade 2  • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Patient referral to ophthalmologist is strongly recommended.  
• Initiate treatment with topical corticosteroid eye drops and topical immunosuppressive therapy.  
• If event resolves to Grade 1 or better, resume atezolizumab.
 b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Ocular event, 
Grade 3 or 4 • Permanently discontinue atezolizumab. c 
• Refer patient to ophthalmologist.  
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day oral 
prednisone.   
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥1 month.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of ≤10 
mg/day oral prednisone before atezolizumab can be resumed. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
52 
 c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate).  
6.1.2.6 Immune -mediated Myocarditis 
 
Immune- mediated myocarditis has been associated with the administration of atezolizumab.  
Immune-mediated myocarditis should be suspected in any patient presenting with signs or 
symptoms suggestive of myocarditis, including, but not limited to, laboratory ( e.g., B-type 
natriuretic peptide) or cardiac imaging abnormalities, dyspnea, chest pain, palpitations, fatigue, decreased exercise tolerance, or syncope.  Myocarditis may also be a clinical manifestation of myositis and should be managed accordingly.  Immune-mediated myocarditis needs to be distinguished from myocarditis resulting from infection (commonly viral, e.g., in a patient who 
reports a recent history of gastrointestinal illness), ischemic events, underlying arrhythmias, exacerbation of preexisting cardiac conditions, or progression of malignancy.   
All patients with possible myocarditis should be urgently evaluated by performing cardiac 
enzyme assessment, an ECG, a chest X -ray, an echocardiogram, and a cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist should be consulted.  An endomyocardial biopsy may be considered to enable a definitive diagnosis and appropriate treatment, if clinically 
indicated.  
Patients with signs and symptoms of myocarditis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in the table  below . 
Event  Management  
Immune -mediated 
myocarditis, Grade 2− 4 • Permanently discontinue atezolizumab. a 
• Refer patient to cardiologist. 
• Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as appropriate. 
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day 
IV methylprednisolone and convert to 1 −2 mg/kg/day oral 
prednisone or equivalent upon improvement. 
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids 
over ≥1 month.  
ECMO  = extracorporeal membrane oxygenation; VAD  = ventricular assist device.  
a Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate). 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
53 
 6.1.2.7 Infusion-Related Reactions and Cytokine- Release Syndrome  
 
No premedication is indicated for the administration of Cycle 1 of atezolizumab.  However, 
patients who experience an infusion-related reaction (IRR) or cytokine- release syndrome (CRS) 
with atezolizumab may receive premedication with antihistamines, anti-pyretics, and/or analgesics ( e.g., acetaminophen) for subsequent infusions.  Metamizole (dipyrone) is prohibited 
in treating atezolizumab -associated IRRs because of its potential for causing agranulocytosis. 
IRRs are known to occur with the administration of monoclonal antibodies and have been reported with atezolizumab.  These reactions, which are thought to be due to release of cytokines and/or other chemical mediators, occur within 24 hours of atezolizumab administration and are generally mild to moderate in severity.  
 CRS is defined as a supraphysiologic response following administration of any immune therapy that results in activation or engagement of endogenous or infused T cells and/or other immune effector cells.  Symptoms can be progressive, always include fever at the onset, and may include hypotension, capillary leak (hypoxia), and end-organ dysfunction (Lee et al ., 2019).  CRS has 
been well documented with chimeric antigen receptor T- cell therapies and bispecific T -cell 
engager antibody therapies but has also been reported with immunotherapies that target PD-1 or PD-L1 (Rotz et al ., 2017; Adashek and Feldman, 2019), including atezolizumab. 
 There may be significant overlap in signs and symptoms of IRRs and CRS, and in recognition of the challenges in clinically distinguishing between the two, consolidated guidelines for medical management of IRRs and CRS are provided in the table  below. 
 Severe COVID -19 appears to be associated with a CRS involving the inflammatory cytokines 
interleukin (IL)- 6, IL -10, IL-2, and IFN- γ (Merad and Martin, 2020).  If a patient develops 
suspected CRS during the study, a differential diagnosis should include COVID- 19, which 
should be confirmed or refuted through assessment of exposure history, appropriate laboratory testing, and clinical or radiologic evaluations per investigator judgment.  If a diagnosis of COVID-19 is confirmed, the disease should be managed as per local or institutional guidelines.  
Event  Management  
Grade 1 a 
Fever b with or 
without 
constitutional symptoms  • Immediately interrupt infusion.  
• Upon symptom resolution, wait for 30 minutes and then restart infusion 
at half the rate being given at the time of event onset. 
• If the infusion is tolerated at the reduced rate for 30 minutes, the infusion 
rate may be increased to the original rate.  
• If symptoms recur, discontinue infusion of this dose. 
• Administer symptomatic treatment, c including maintenance of IV fluids 
for hydration. 
• In case of rapid decline or prolonged CRS ( >2 days) or in patients with 
significant symptoms and/or comorbidities, consider managing as per Grade 2. 
• For subsequent infusions, consider administration of oral premedication with antihistamines, anti-pyretics, and/or analgesics, and monitor closely 
for IRRs and/or CRS.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
54 
 Event  Management  
Grade 2 a 
Fever b with 
hypotension not 
requiring 
vasopressors  
and/or  
Hypoxia requiring low-flow oxygen
 d 
by nasal cannula or 
blow-by • Immediately interrupt infusion.  
• Upon symptom resolution, wait for 30 minutes and then restart infusion 
at half the rate being given at the time of event onset. 
• If symptoms recur, discontinue infusion of this dose. 
• Administer symptomatic treatment. c 
• For hypotension, administer IV fluid bolus as needed. 
• Monitor cardiopulmonary and other organ function closely (in the ICU, if 
appropriate).  Administer IV fluids as clinically indicated, and manage constitutional symptoms and organ toxicities as per institutional practice.  
• Rule out other inflammatory conditions that can mimic CRS (e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this appendix. 
• Consider IV corticosteroids ( e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours). 
• Consider anti- cytokine therapy.  
• Consider hospitalization until complete resolution of symptoms.  If no improvement within 24 hours, manage as per Grade 3, that is, hospitalize 
patient (monitoring in the ICU is recommended), permanently 
discontinue atezolizumab.
 e 
• If symptoms resolve to Grade 1 or better for 3 consecutive days, the next dose of atezolizumab may be administered.  For subsequent infusions, 
consider administration of oral premedication with antihistamines, 
anti-pyretics, and/or analgesics and monitor closely for IRRs and/or 
CRS.  
• If symptoms do not resolve to Grade 1 or better for 3 consecutive days, 
contact the investigator.  
Grade 3 a 
Fever b with 
hypotension 
requiring a 
vasopressor (with or 
without vasopressin)  
and/or  
Hypoxia requiring 
high-flow oxygen d 
by nasal cannula, 
face mask, non-rebreather 
mask, or Venturi mask  • Permanently discontinue atezolizumab. e 
• Administer symptomatic treatment. c 
• For hypotension, administer IV fluid bolus and vasopressor as needed. 
• Monitor cardiopulmonary and other organ function closely; monitoring 
in the ICU is recommended.  Administer IV fluids as clinically indicated, 
and manage constitutional symptoms and organ toxicities as per 
institutional practice.  
• Rule out other inflammatory conditions that can mimic CRS (e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this 
appendix. 
• Administer IV corticosteroids ( e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours). 
• Consider anti- cytokine therapy.  
• Hospitalize patient until complete resolution of symptoms.  If no 
improvement within 24 hours, manage as per Grade 4, that is, admit 
patient to ICU and initiate hemodynamic monitoring, mechanical 
ventilation, and/or IV fluids and vasopressors as needed; fo r patients who 
are refractory to anti -cytokine therapy, experimental treatments may be 
considered at the discretion of the investigator.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
55 
 Event  Management  
Grade 4 a 
Fever b with 
hypotension 
requiring multiple 
vasopressors (excluding vasopressin)  
and/or  
Hypoxia requiring 
oxygen by positive 
pressure (e.g., CPAP, BiPAP, intubation and 
mechanical 
ventilation) • Permanently discontinue atezolizumab. e 
• Administer symptomatic treatment. c 
• Admit patient to ICU and initiate hemodynamic monitoring, mechanical 
ventilation, and/or IV fluids and vasopressors as needed.  Monitor other 
organ function closely.  Manage constitutional symptoms and organ 
toxicities as per institutional practice.  
• Rule out other inflammatory conditions that can mimic CRS (e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this appendix. 
• Administer IV corticosteroids ( e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours). 
• Consider anti-cytokine therapy.  For patients who are refractory to anti-cytokine therapy, experimental treatments
 f may be considered at the 
discretion of the investigator.  
• Hospitalize patient until complete resolution of symptoms. 
ASTCT =  American Society for Transplantation and Cellular Therapy; BiPAP =  bi-level positive airway 
pressure; CAR  = chimeric antigen receptor; CPAP  = continuous positive airway pressure; 
CRS  = cytokine- release syndrome; CTCAE  = Common Terminology Criteria for Adverse Events; 
eCRF  = electronic Case Report Form; HLH = hemophagocytic lymphohistiocytosis; ICU =  intensive care 
unit; IRR =  infusion -related reaction; MAS  = macrophage activation syndrome; NCCN =  National Cancer 
Comprehensive Network; NCI  = National Cancer Institute.  
Note:  These management guidelines have been adapted from NCCN guidelines for management of CAR 
T-cell−related toxicities (Version 2.2019). 
a Grading system for these management guidelines is based on ASTCT consensus grading for CRS.  NCI 
CTCAE v5.0 should be used when reporting severity of IRRs, CRS, or organ toxicities associated with 
CRS on the Adverse Event eCRF.  Organ toxicities associated with CRS should not influence overall 
CRS grading. 
b Fever is defined as temperature ≥ 38°C not attributable to any other cause.  In patients who develop CRS 
and then receive anti -pyretic, anti-cytokine, or corticosteroid therapy, fever is no longer required when 
subsequently determining event severity (grade).  In this case, the grade is driven by the presence of hypotension and/or hypoxia. 
c Symptomatic treatment may include oral or IV antihistamines, anti- pyretics, analgesics, bronchodilators, 
and/or oxygen.  For bronchospasm, urticaria, or dyspnea, additional treatment may be administered as per institutional practice.  
d Low flow is defined as oxygen delivered at ≤6 L/min, and high flow is defined as oxygen delivered at 
>6 L/min.  
e Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
56 
 should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate).  For subsequent infusions, administer oral premedication with antihistamines, anti-
pyretics, and/or analgesics, and monitor closely for IRRs and/or CRS.  Premedication with corticosteroids 
and extending the infusion time may also be considered after assessing the benefit −risk ratio.  
f Refer to Riegler et al. (2019). 
 
6.1.2.8 Pancreatic Events  
 
Symptoms of abdominal pain associated with elevations of amylase and lipase, suggestive of 
pancreatitis, have been associated with the administration of atezolizumab.  The differential diagnosis of acute abdominal pain should include pancreatitis.  Appropriate workup should 
include an evaluation for ductal obstruction, as well as serum amylase a nd lipase tests .  
Management guidelines for pancreatic events, including pancreatitis, are provided in the 
table  below . 
Event  Management  
Amylase and/or lipase 
elevation, Grade 2  Amylase and/or lipase >1.5−2.0 × ULN:  
• Continue atezolizumab. 
• Monitor amylase and lipase weekly.  
• For prolonged elevation ( e.g., >3 weeks), consider treatment 
with corticosteroids equivalent to 10 mg/day oral prednisone.  
 
Asymptomatic with amylase and/or lipase >2.0−5.0 × ULN:  
• Treat as a Grade 3 event.  
Amylase and/or lipase 
elevation, Grade 3 or 4 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to GI specialist.  
• Monitor amylase and lipase every other day.  
• If no improvement, consider treatment with corticosteroids 
equivalent to 1 −2 mg/kg/day oral prednisone. 
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while 
withholding atezolizumab, permanently discontinue 
atezolizumab. c 
• For recurrent events, permanently discontinue atezolizumab. c 
Immune -mediated pancreatitis, 
Grade 2 or 3 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to GI specialist.  
• Initiate treatment with corticosteroids equivalent to 
1−2 mg/kg/day IV methylprednisolone and convert to 
1−2 mg/kg/day oral prednisone or equivalent upon 
improvement.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while 
withholding atezolizumab, permanently discontinue 
atezolizumab. c 
• For recurrent events, permanently discontinue atezolizumab. c 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
57 
 Event  Management  
Immune -mediated pancreatitis, 
Grade 4  • Permanently discontinue atezolizumab. c 
• Refer patient to GI specialist.  
• Initiate treatment with corticosteroids equivalent to 
1−2 mg/kg/day IV methylprednisolone and convert to 
1−2 mg/kg/day oral prednisone or equivalent upon 
improvement.  
• If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids 
over ≥1 month.  
GI = gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of ≤10 
mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate).  
 
6.1.2.9 Dermatologic Events 
 
Treatment -emergent rash has been associated with atezolizumab.  The majority of  cases of rash 
were mild in severity and self -limiting, with or without pruritus.  Although uncommon, cases of 
severe cutaneous adverse reactions such as Stevens -Johnson syndrome and toxic epidermal 
necrolysis have been reported with atezolizumab.  A dermatologist should evaluate persistent and/or severe rash or pruritus.  A biopsy should be considered unless contraindicated.  Management guidelines for dermatologic events are provided in the table  below.  
 
Event  Management  
Dermatologic event, 
Grade 1  • Continue atezolizumab.  
• Consider treatment with topical corticosteroids and/or other 
symptomatic therapy ( e.g., antihistamines).  
Dermatologic event, 
Grade 2  • Continue atezolizumab.  
• Consider patient referral to dermatologist for evaluation and, if 
indicated, biopsy. 
• Initiate treatment with topical corticosteroids.  
• Consider treatment with higher- potency topical corticosteroids if event 
does not improve.  
• If unresponsive to topical corticosteroids, consider oral prednisone 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
58 
 0.5 mg/kg/day.  
Dermatologic event, 
Grade 3  • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to dermatologist for evaluation and, if indicated, biopsy. 
• Initiate treatment with corticosteroids equivalent to 10 mg/day oral 
prednisone, increasing dose to 1 −2 mg/kg/day if event does not 
improve within 48− 72 hours. 
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Dermatologic event, 
Grade 4  • Permanently discontinue atezolizumab. c 
Stevens -Johnson 
syndrome or toxic 
epidermal necrolysis (any grade)  Additional guidance for Stevens -Johnson syndrome or toxic epidermal 
necrolysis:  
• Withhold atezolizumab for suspected Stevens -Johnson syndrome or 
toxic epidermal necrolysis.  
• Confirm diagnosis by referring patient to a specialist (dermatologist, 
ophthalmologist, or urologist as relevant) for evaluation and, if indicated, biopsy. 
• Follow the applicable treatment and management guidelines above.  
• If Stevens-Johnson syndrome or toxic epidermal necrolysis is 
confirmed, permanently discontinue atezolizumab.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of ≤10 
mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate).  
 
6.1.2.10 Immune -mediated  Meningoencephalitis 
 
Immune- related meningoencephalitis is an identified risk associated with the administration of 
atezolizumab. Immune -related meningoencephalitis should be suspected in any patient 
presenting with signs or symptoms suggestive of meningitis or encephalitis, including, but not 
limited to, headache, neck pain, confusion, seizure, motor or sensory dysfunction, and altered or depressed level of consciousness. Encephalopathy from metabolic or electrolyte imbalances needs to be distinguished from potential meningoencephalitis resulting from infection (bacterial, viral, or fungal) or progression of malignancy, or secondary to a paraneoplastic process. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
59 
 All patients being considered for meningoencephalitis should be urgently evaluated with a CT 
scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or edema. If deemed safe by the treating physician, a lumbar puncture should be performed,  and a neurologist should 
be consulted. 
Patients with signs and symptoms of meningoencephalitis, in the absence of an identified 
alternate etiology, should be treated according to the guidelines in the table below. 
Event  Management  
Immune -mediated 
meningoencephalitis, 
all grades  • Permanently discontinue atezolizumab. a 
• Refer patient to neurologist. 
• Initiate treatment with corticosteroids equivalent to 1 −2 
mg/kg/day IV methylprednisolone and convert to 
1−2 mg/kg/day oral prednisone or equivalent upon 
improvement.  
• If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥1 month.  
a Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- mediated event.  The decision to re −challenge patients with 
atezolizumab should be based on investigator's assessment of benefit −risk and documented by the 
investigator (or an appropriate delegate).  
 
6.1.2.11 Neurologic disorders 
 
Myasthenia gravis and Guillain- Barré syndrome have been observed with single- agent 
atezolizumab. Patients may present with signs and symptoms of sensory and/or motor 
neuropathy. Diagnostic work- up is essential for an accurate characterization to differentiate 
between alternative etiologies.  Management guidelines for neurologic disorders are provided in 
table  below . 
Event  Management  
Immune -mediated 
neuropathy, Grade 1 • Continue atezolizumab.  
• Investigate etiology. 
Immune -mediated 
neuropathy, Grade 2 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Investigate etiology and refer patient to neurologist. 
• Initiate treatment as per institutional guidelines.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Immune -mediated 
neuropathy, Grade 3 
or 4 • Permanently discontinue atezolizumab. c  
• Refer patient to neurologist. 
• Initiate treatment as per institutional guidelines.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
60 
 Myasthenia gravis and 
Guillain -Barré 
syndrome (any grade) • Permanently discontinue atezolizumab. c 
• Refer patient to neurologist. 
• Initiate treatment as per institutional guidelines. 
• Consider initiation of corticosteroids equivalent to 1 −2 mg/kg/day 
oral or IV prednisone.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of ≤10 
mg/day oral prednisone before atezolizumab can be resumed. 
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate). 
 
6.1.2.12 Renal Events  
 
Immune-mediated nephritis has been associated with the administration of atezolizumab.  Eligible patients must have adequate renal function.  Renal function, including serum creatinine, should be monitored throughout study treatment.  Patients with abnormal renal function should be evaluated and treated for other more common etiologies (including prerenal and postrenal causes, and concomitant medicati ons such as non- steroidal anti-inflammatory drugs).  Refer the 
patient to a renal specialist if clinically indicated.  A renal biopsy may be required to enable a definitive diagnosis and appropriate treatment.  Patients with signs and symptoms of nephritis, in the absence of an identified alternate etiology, should be treated according to the guidelines in the table  below . 
 
Event  Management  
Renal event, Grade  1 • Continue atezolizumab.  
• Monitor kidney function, including creatinine and urine protein, 
closely until values resolve to within normal limits or to baseline 
values.  
Renal event, Grade  2 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to renal specialist.  
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day 
oral prednisone. 
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
61 
 Renal event, Grade  3 
or 4 • Permanently discontinue atezolizumab.  
• Refer patient to renal specialist and consider renal biopsy.  
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day 
oral prednisone. 
• If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥1 month.  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator. 
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of 
≤10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate). 
 
6.1.2.13 Immune -Mediated Myositis 
 
Immune-mediated myositis has been associated with the administration of atezolizumab.  
Myositis or inflammatory myopathies are a group of disorders sharing the common feature of inflammatory muscle injury; dermatomyositis and polymyositis are among the most common disorders.  Initial diagnosis is based on clinical (muscle weakness, muscle pain, skin rash in dermatomyositis), biochemical (ser um creatine kinase increase), and imaging 
(electromyography/MRI) features, and is confirmed with a muscle biopsy.  Patients with possible myositis should be referred to a rheumatologist or neurologist.  Patients with possible myositis should be monitored for signs of myocarditis. 
Patients with signs and symptoms of myositis, in the absence of an identified alternate etiology, 
should be treated according to the guidelines in the table  below  
Event  Management  
Immune -mediated 
myositis, Grade 1 • Continue atezolizumab.  
• Refer patient to rheumatologist or neurologist.  
• Initiate treatment as per institutional guidelines.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
62 
 Event  Management  
Immune -mediated 
myositis, Grade 2 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to rheumatologist or neurologist.  
• Initiate treatment as per institutional guidelines.  
• Consider treatment with corticosteroids equivalent to 1 −2 mg/kg/day 
IV methylprednisolone and convert to 1 −2 mg/kg/day oral prednisone 
or equivalent upon improvement. 
• If corticosteroids are initiated and event does not improve within 
48 hours after initiating corticosteroids, consider adding an 
immunosuppressive agent.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab. c 
Immune -mediated 
myositis, Grade 3 • Withhold atezolizumab for up to 12  weeks after event onset. a 
• Refer patient to rheumatologist or neurologist.  
• Initiate treatment as per institutional guidelines.   
• Respiratory support may be required in more severe cases.  
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day IV 
methylprednisolone, or higher-dose bolus if patient is severely 
compromised ( e.g., cardiac or respiratory symptoms, dysphagia, or 
weakness that severely limits mobility); convert to 1 −2 mg/kg/day oral 
prednisone or equivalent upon improvement. 
• If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade 1 or better while withholding atezolizumab, permanently discontinue atezolizumab.
 c 
• For recurrent events, treat as a Grade 4 event.  
Immune -mediated 
myositis, Grade 4 • Permanently discontinue atezolizumab. c 
• Refer patient to rheumatologist or neurologist.  
• Initiate treatment as per institutional guidelines.  
• Respiratory support may be required in more severe cases.  
• Initiate treatment with corticosteroids equivalent to 1 −2 mg/kg/day 
IV methylprednisolone, or higher -dose bolus if patient is severely 
compromised ( e.g., cardiac or respiratory symptoms, dysphagia, or 
weakness that severely limits mobility); convert to 1 −2 mg/kg/day oral 
prednisone or equivalent upon improvement. 
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent. 
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥1 month.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
63 
 Event  Management  
a Atezolizumab may be withheld for a longer period of time ( i.e., >12 weeks after event onset) to allow 
for corticosteroids (if initiated) to be reduced to the equivalent of ≤ 10 mg/day oral prednisone.  The 
acceptable length of the extended period of time must be based on an assessment of benefit −risk by the 
investigator and in alignment with the protocol requirements for the duration of treatment and 
documented by the investigator.  
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the equivalent of 
≤10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -mediated event.  The decision to re −challenge patients with atezolizumab 
should be based on investigator's assessment of benefit −risk and documented by the investigator (or an 
appropriate delegate).  
 
6.1.2.14 Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome 
 
Immune-mediated reactions may involve any organ system and may lead to hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), which are considered to be potential risks for atezolizumab.    Patients with suspected HLH should be diagnosed according to published criteria by McClain and Eckstein (2014).  A patient should be classified as having HLH if five of the following eight criteria are met:  
• Fever ≥ 38.5°C 
• Splenomegaly 
• Peripheral blood cytopenia consisting of at least two of the following: 
− Hemoglobin < 90 g/L (9  g/dL) (<100 g/L [10 g/dL] for infants < 4 weeks old) 
− Platelet count < 100 ×  109/L (100,000/mcL) 
− ANC < 1.0 ×  109/L (1000/mcL) 
• Fasting triglycerides > 2.992 mmol/L (265 mg/dL) and/or fibrinogen < 1.5 g/L 
(150 mg/dL) 
• Hemophagocytosis in bone marrow, spleen, lymph node, or liver 
• Low or absent natural killer cell activity  
• Ferritin > 500 mg/L (500 ng/mL) 
• Soluble interleukin 2 (IL-2) receptor (soluble CD25) elevated ≥  2 standard deviations 
above age-adjusted laboratory- specific norms  
 Patients with suspected MAS should be diagnosed according to published criteria for systemic juvenile idiopathic arthritis by Ravelli et al . (2016).  A febrile patient should be classified as 
having MAS if the following criteria are met:  
• Ferritin > 684 mg/L (684 ng/mL) 
• At least two of the following: 
− Platelet count ≤ 181 ×  109/L (181,000/mcL) 
− AST ≥ 48 U/L  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
64 
 − Triglycerides > 1.761 mmol/L (156 mg/dL) 
− Fibrinogen ≤ 3.6 g/L (360 mg/dL) 
 
Patients with suspected HLH or MAS should be treated according to the guidelines in the table  below . 
 
Event  Management  
Suspected HLH or 
MAS  • Permanently discontinue atezolizumab.  
• Consider patient referral to hematologist.  
• Initiate supportive care, including intensive care monitoring if 
indicated per institutional guidelines.  
• Consider initiation of IV corticosteroids, an immunosuppressive agent, and/or anti -cytokine therapy. 
• If event does not respond to treatment within 24 hours, initiate treatment as appropriate according to published guidelines (La Ros ée 
2015; Schram and Berliner 2015; La Ros ée et al ., 2019). 
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥1 month.  
HLH  = hemophagocytic lymphohistiocytosis; MAS  = macrophage activation syndrome.  
 
6.2 Recombinant Human IL -7 (CYT107) 
There will be no dose reduction for CYT107 in this study. 
Delays in dosing will be allowed for delays such as weather factors resulting in delays getting to 
the clinic or hospital, travel delays, clinic schedules, or emergencies. A delay of up to 72 hours  
will be allowed on one occasion during the course of a treatment cycle. 
Patients will come off protocol therapy if any CYT107 or treatment- related grade 3 or 4 A Es by 
CTCAE Version 5.0 criteria occur with the exception  of transient lymphopenia. Three cases of 
Grade 3 lymphopenia have been documented with CYT107. Peripheral lymphopenia after the 
first CYT107 injection is a sign of CYT107 activity; reflecting the rh IL-7 ‘homing effect’ of 
lymphocytes to deep tissues. 
For purposes of this trial, since peripheral lymphopenia is a transient event, a Grade 3 
‘lymphocyte count decrease’ to <500- 200 cells/mm3 and a Grade 4 ‘lymphocyte count decrease’ 
to <200 cells/mm3 will not require patients coming off protocol provided the lymphocyte count 
returns to a minimum of 500 cells/mm3 by the time of the scheduled start of the next weekly dose 
within the treatment phase. A Grade 3 or 4 ‘lymphocyte count decrease’ will require patients 
coming off protocol if the count fails to retur n to a minimum of 500 cells/mm3 by the time of the 
scheduled start of the next weekly dose. 
Dose modifications for Adverse Events : Substantial AEs are not expected and thus dose 
modifications are not planned or recommended. In all human trials with CYT107, AEs  were 
frequent, but transient and grade 2 or less (as noted in the Adverse Event list, Section 7.1.2). 
These include injection site reactions, lymphadenopathy, pyrexia, rash, and  fatigue.  
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
72 
 
 Adverse Event List(s) for Commercial Agent(s) : N/A 
7.2 Adverse Event Characteristics  
• CTCAE term (AE description) and grade : The descriptions and grading scales 
found in the revised NCI CTCAE version 5.0 will be utilized for AE reporting. All 
appropriate treatment areas should have access to a copy of the CTCAE version 5.0. 
A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
• For expedited reporting purposes only : 
– AEs for the agent that are bold and italicized in the CAEPR ( i.e., those listed 
in the SPEER column, Section 7.1.1) sh ould be reported through CTEP- AERS 
only if the grade is above the grade provided in the SPEER. 
– Other AEs for the protocol that do not require expedited reporting are outlined 
in Section 7.3.4
. 
• Attribution  of the AE: 
– Definite – The AE is clearly related  to the study treatment.  
– Probable – The AE is likely related  to the study treatment.  
– Possible – The AE may be related  to the study treatment.  
– Unlikely – The AE is doubtfully related to the study treatment.  
– Unrelated – The AE is clearly NOT related  to the study treatment.  
7.3 Expedited Adverse Event Reporting  
 Rave- CTEP- AERS Integration 
The Rave Cancer Therapy Evaluation Program Adverse Event Reporting System (CTEP-
AERS) Integration enables evaluation of Adverse Events (AE) entered in Rave to determine whether they require expedited reporting and facilitates entry in CTEP- AERS 
for those AEs requiring expedited reporting. Sites must initiate all AEs for this study in Medidata Rave .  
 Treatment -emergent AEs: All AEs that occur after start of treatment are collected in 
Medidata Rave using the Adverse Event form, which is available for entry at each treatment course or reporting period and is used to collect AEs that start during the period or persist from the previous reporting period. AEs that occur 30 Days after the Last Administration of the Investigational Agent/Intervention are collected using the Late Adverse Event form.  Prior to sending AEs through the rules evaluation process, site staff should verify the following on the Adverse Event form in Rave: 
• The reporting period (course/cycle) is correct; and 
• AEs are recorded and complete (no missing fields) and the form is query free.    
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
73 
 The CRA reports AEs in Rave at the time the Investigator learns of the event. If the CRA 
modifies an AE, it must be re -submitted for rules evaluation.  
 Upon completion of AE entry in Medidata Rave, the CRA submits the AE for rules evaluation by completing the Expedited Reporting Evaluation form. Both NCI and protocol- specific reporting rules evaluate the AEs submitted for expedited reporting. A 
report is initiated in CTEP -AERS using information entered in Medidata Rave for AEs 
that meet reporting requirements. The CRA completes the report by accessing CTEP-AERS via a direct li nk on the Medidata Rave Expedited Reporting Evaluation form. 
Contact the CTSU Help Desk at 1 -888-823-5923 or by email at ctsucontact@westat.com  
if you have any issues submitting an expedited report in CTEP- AERS.  
 In the rare occ
urrence that internet connectivity is lost, a 24-hour notification is to be 
made to CTEP by telephone at 301-897-7497. Once internet connectivity is restored, the 24-hour notification that was phoned in must be entered immediately into CTEP- AERS 
using the direct link from Medidata Rave.  Additional information about the CTEP-AERS integration is available on the CTSU members’ website:  
• Study specific documents:   Protocols > Documents> Protocol Related Documents> Adverse Event Reporting, and   
• Additional resources: Resources > CTSU Operations Information> User Guides & Help Topics . 
 NCI requirements for SAE reporting are available on the CTEP website:   
• NCI Guidelines for Investigators:  Adverse Event Reporting Requirements is available at https://ctep.cancer.gov/protocolDevelopment/electronic applications/docs/aeguid
elines.pdf . 
 
 Distribution of Adverse Event Reports 
CTEP -AERS is programmed for automatic electronic distribution of reports to the 
following individuals: PI and Adverse Event Coordinator(s) (if applicable) of the Corresponding Organization or Lead Organization, the local treating physician, and the Reporter , and Submitter. CTEP -AERS provides a copy feature for other email  recipients.  
 Expedited Reporting Guidelines  
Use the NCI protocol number and the protocol- specific patient ID assigned during trial 
registration on all reports. 
Note: A death on study requires both  routine and ex pedited reporting, regardless of 
causality. Attribution to treatment or other cause must be provided.   
 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
75 
 
 Additional Protocol- Specific Expedited Adverse Event Reporting Exclusions : N/A 
 Adverse Events of Special Interest in Atezolizumab Studies 
The following AEs are considered of special interest in patients receiving atezolizumab 
and must be reported expeditiously through CTEP-AERS, irrespective of regulatory seriousness criteria:  
• Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s 
Law and based on the following observations:  • Treatment -emergent ALT or AST > 3 x ULN (or > 3 x baseline value in disease 
states where LFTs may be elevated at baseline)  in combination with total bilirubin 
> 2 x ULN (of which ≥ 35% is direct bilirubin)   
• Treatment -emergent ALT or AST > 3 x ULN (or > 3 x baseline value in disease 
states where LFTs may be elevated at baseline) in combination with clinical 
jaundice    
• Suspected transmission of an infectious agent by the study treatment, as defined 
below:  
• Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical sy mptoms or laboratory findings that indicate an infection 
in a patient exposed to a medicinal product. This term applies only when a contamination of study treatment is suspected. 
• Pneumonitis 
• Colitis  
• Endocrinopathies: diabetes mellitus, pancreatitis, hyperthyroidism, hypophysitis, and adrenal insufficiency  
• Hepatitis, including AST or ALT >10 x ULN  
• Systemic lupus erythematosus 
• Neurological disorders: Guillain -Barré syndrome, myasthenic syndrome or 
myasthenia gravis, and meningoencephalitis 
• Events suggestive of hypersensitivity, cytokine release syndrome, influenza- like 
illness, systemic inflammatory response syndrome, systemic immune activation, or infusion- related reactions  
• Nephritis  
• Ocular toxicities ( e.g., uveitis, retinitis , optic neuritis) 
• Myositis  
• Myopathies, including rhabdomyolysis 
• Grade ≥2 cardiac disorders ( e.g., atrial fibrillation, myocarditis, pericarditis)  
• Vasculitis  
• Autoimmune hemolytic anemia   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
76 
 • Severe cutaneous reactions (e.g., Stevens -Johnson syndrome, dermatitis, bullous, toxi 
epidermal necrolysis) 
7.4 Routine Adverse Event Reporting  
All A Es must  be reported i n routine study data submissions. AEs reported expeditiously 
through CTEP -AERS must also be reported in routine study data submissions.  
AE data collection and reporting, which are required as part of every clinical trial, are done to 
ensure the safety of patients enrolled in the studies as well as those who will enroll in future studies using similar agents. AEs are reported in a routine manner at scheduled times during the trial using Medidata Rave. For this trial the Adverse Event CRF is used for routine AE reporting in Rave.  
7.5 Pregnancy  
Although not an adverse event in and of itself, pregnancy as well as its outcome must be documented via CTEP -AERS . In addition, the Pregnancy Information Form  included within 
the NCI Guidelines for Adverse Event Reporting Requirements must be completed and submitted to CTEP. Any pregnancy occurring in a patient or patient’s partner from the time of consent to 150 days after the last dose of study drug must be reported and then followed for outcome. Newborn infants should be followed until 30 days old. Please see the “NCI Guidelines for Investigators: Adverse Event Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs” (at http://ctep.cancer.gov/protocolDevelopment/adverse effects.htm ) for more 
details on how to report pregnancy and its outcome to CTEP. 
7.6 Secondary Malignancy 
A secondary mal
ignancy  is a cancer caused by treatment for a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation , or chemotherapy). A secondary 
malignancy is not considered a metastasis of the initial neoplasm. 
CTEP requires all secondary malignancies that occur after  treatment with an agent under an NCI 
IND/IDE be reported expeditiously via CTEP- AERS. Three options are available to describe the 
event:  
• Leukemia secondary to oncology chemotherapy ( e.g., acute myelocytic leukemia [AML])  
• Myelodysplastic syndrome (MDS) 
• Treatment -related secondary malignancy  
Any malignancy possibly related to cancer treatment (including AML/MDS) should also be 
reported via the routine reporting mechanisms outlined in each protocol. 
7.7 Second Malignancy  
A second malignancy  is one unrelated to the treatment of a prior malignancy (and is NOT  a 
metastasis from the initial malignancy). Second malignancies require ONLY routine AE 
reporting unless otherwise specified. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
77 
 8. PHARMACEUTICAL INFORMATION 
A list of the AEs  and potential risks associated with the investigational agents administered in 
this study can be found in Section 7.1. 
8.1 CTEP IND Agent(s)  
 Atezolizumab (NSC 783608)  
Other Names : TecentriqTM, MPDL3280A 
Classification : monoclonal antibody 
M.W.: 150 KD 
Mode of Action : anti- PD-L1 
Description : 
Atezolizumab is a humanized IgG1 monoclonal antibody consisting of 2 heavy chains 
(448 amino acids) and 2 light chains (214 amino acids). Atezolizumab targets human PD-L1 and inhibits its interaction with its receptor PD -1. Atezolizumab also blocks the 
binding of PD-L1 to B7.1, an interaction that is reported to provide additional inhibitory signals to T cells (Butte et al. 2007). 
How Supplied : 
Atezolizumab is provided by Genentech/F.Hoffmann-La Roche LTD and distributed by 
the Pharmaceutical Management Branch, CTEP, NCI. The agent is supplied in a single-use, 20- mL glass vial as a colorless -to-slightly -yellow, sterile, preservative -free clear 
liquid solution intended for IV administration. Each 20 mL vial contains 1200 mg of atezolizumab and is formulated in glacial acetic acid (16.5 mg), L-histidine (62 mg), polysorbate 20 (8 mg), and sucrose (821.6 mg), with a pH of 5.8. The vial is designed to 
deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated 
volume to enable delivery of the entire 20  mL volume. 
Preparation : 
The prescribed dose of atezolizumab should be diluted 0.9% NaCl to a concentration between 3.2 mg/mL and 16.8 mg/mL and infused with or without a low-protein binding 0.2 or 0.22 micrometer in -line filter. The IV bag may be constructed of polyvinyl 
chloride ( PVC ), polyolefin ( PO), or polyethylene (PE).The prepared solution may be 
stored at 2°C –8°C for up to 24 hours or at ambient ≤ 25°C (77°F) for 6 hours from the 
time of preparation. If the dose solution is stored at 2°C –8°C (36°C –46°F) , it should be 
removed from refrigeration and allowed to reach room temperature prior to administration. These times include the storage and administration times for the infusion. Do not shake or freeze infusion bags containing the dose solution.  
Storage : 2°C –8°C (36°F–46°F). Vial contents should not be frozen or shaken and should 
be protected from direct sunlight.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
78 
 If a storage temperature excursion is identified, promptly return atezolizumab to 2°C- 8°C 
(36°F-46°F) and quarantine the supplies. Provide a detailed report of the excursion 
(including documentation of temperature monitoring and duration of the excursion) to PMBAfterHours@mail.nih.gov for determination of suitability.  
Stability : Stability studies are ongoing. 
CAUTION: No preservative is used in atezolizumab; therefore, the vial is intended for single use only. Discard any unused portion of drug remaining in a vial. 
Route of Administration : IV infusion 
Method of Administration : 
Atezolizumab is administered as an IV infusion over 60 minutes. If the first infusion is 
tolerated, all subsequent infusions may be delivered over 30 minutes. Do not administer 
atezolizumab as an IV push or bolus. No premedication is indicated for administration of 
Cycle 1 of atezolizumab. Patients who experience an infusion- related reaction with Cycle 
1 of atezolizumab may receive premedication with subsequent infusions. 
Potential Drug Interactions : 
Cytochrome P450 enzymes as well as conjugation/glucuronidation reactions are not 
involved in the metabolism of atezolizumab. No drug interaction studies for atezolizumab have been conducted or are planned. There are no known interactions with other medicin al products or other form of interactions. 
Patient Care Implications : 
Male patients and female patients of childbearing potential should utilize contraception and take active measures to avoid pregnancy while undergoing atezolizumab treatment and for at least 5 months (150 days) after the last dose of atezolizumab. 
Availability : 
Atezolizumab is an investigational agent supplied to investigators by the Division of 
Cancer Treatment and Diagnosis (DCTD), NCI.  
Atezolizumab is provided to the NCI under a Collaborative Agreement between the Pharmaceutical Collaborator and the DCTD, NCI (see Section 12.4).  
 CYT107 (Recombinant Glycosylated Human Interleukin -7) (NSC 767713)  
Other Names : Human Interleukin-7, Lymphopoietin-1, rHuIL-7  
Classification : Cytokine 
M.W.: 22kDa 
Mode of Action:  Multifunctional cytokine critical for T -cell development and 
homeostasis.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
79 
 Description : 
Glycosylated 152 amino acid recombinant protein containing three N-glycosylation sites 
and one O- glycosylation site , with 3 disulfide bridges: Cys2- Cys 92, Cys 34- Cys 129, 
and Cys 47- Cys 141. CYT107 is produced using a Chinese Hamster Ovary cell line. 
How Supplied : CYT107 is supplied by RevImmune and distributed by the 
Pharmaceutical Management Branch, CTEP, DCTD, NCI.  Each single- use 0.6 mL vial 
contains 1200 mcg of CYT107 at a concentration of 2000 mcg/mL, as a sterile, clear, 
colorless solution containing 10mM Sodium Acetate, 100mM Sodium chloride, 50mM Glutamic acid, 50mM Arginine, pH approximately 5.  CYT107 is provided to the NCI under a Collaborative Agreement between the Pharmaceutical Collaborator and the DCTD, NCI (see Section 12.4).  
Preparation : Do not shake vials. Remove number of vials required for dose preparation 
from the freezer and thaw at refrigerated temperature (2 -8°C) for 1 hour prior to dose 
preparation. Once thawed, inspect vials for any visible particulate matter. If observed, discard  vials. Aseptically withdraw the required dose volume into a syringe for 
administration.   Storage : Store vials in their original box frozen at -20°C. 
 If a storage temperature excursion is identified, promptly return CYT107 vials  to -20°C 
freezer  and quarantine the supplies. Provide a detailed report of the excursion (including 
documentation of temperature monitoring and duration of the excursion) to PMBAfterHours@mail.nih.gov for determination of suitability.  
Stability : Stability studies of the intact vials are ongoing. Do not re- freeze thawed vials. 
Intact vials may be removed from the freezer and kept at refrigerated temperature for a maximum of 12 hours prior to dose administration. Once dose is withdrawn into a syringe, administer immediately. If necessary, prepared syringes may be stored refrigerated for up to 6 hours prior to administration. Vials are for single-use only. Destroy any remaining contents following dose preparation.   Route  and Method of Administration : Intramuscular (IM) injection . Inject slowly (over 
10-20 seconds) into Deltoid muscle or muscle of the thighs or buttocks, away from joints, nerves or bones. Rotate injection sites with each injection.  
Potential Drug Interactions: In -vitro , CYT107 did not inhibit isoenzymes CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. In 
vitro , CYT107 did not induce isoenzymes CYP1A, CYP2B6 and CYP3A4. At 
concentrations tested, it is unlikely CYT107 will cause drug-drug interactions.   Patient Care Implications : Advise study participants to use effective contraception 
while receiving study treatment and for at least 2 months after the last dose.   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
80 
 For patient with a Body Mass Index (BMI) >30, an adjusted body weight will be used to 
calculate the final dose to be administered. Please refer to Appendix D  for details on the 
adjusted body weight calculation. 
 
 Agent Ordering and Agent Accountability 
NCI-supplied agents may be requested by the PI (or their authorized designee) at each 
participating institution. Pharmaceutical Management Branch (PMB) policy requires that 
agent be shipped directly to the institution where the patient is to be treated. PMB does not permit the transfer of agents between institutions (unless prior approval from PMB is obtained). The CTEP-assigned protocol number must be used for ordering all CTEP-supplied investigational agents. The responsible investigator at each participating institution must be registered with CTEP, DCTD through an annual submission of FDA Form 1572 (Statement of Investigator), Biosketch/Curriculum Vitae, Supplemental Investigator Data Form (IDF), and Financial Disclosure Form (FDF). If there are several participating investigators at one institution, CTEP -supplied investigational agents for the 
study should be ordered under the name of one lead investigator at that institution. 
Active CTEP -registered investigators and investigator-designated shipping designees and 
ordering designees can submit agent requests through the PMB Online Agent Order 
Processing (OAOP) application. Access to OAOP requires the establishment of a CTEP IAM a ccount and the maintenance of an “active” account status and a “current” 
password. For questions about drug orders, transfers, returns, or accountability, call or email PMB any time. Refer to the PMB’s website for specific policies and guidelines related to agent management.  
8.1.3.1 Agent Inventory Records 
The investigator, or a responsible party designated by the investigator, must maintain 
a careful record of the receipt, dispensing and final disposition of all agents received from the PMB using the appropriate NCI Investigational Agent (Drug) Accountability Record (DARF) available on the CTEP forms page. Store and maintain separate NCI Investigational Agent Accountability Records for each agent, strength, formulation, and ordering investigator on this protocol. 
 Investigator Brochure Availability 
The current versions of the IBs for the agents will be accessible to site investigators and research staff through the PMB OAOP application. Access to OAOP requires the establishment of a CTEP -IAM account and the maintenance of an “active” account status 
and a “current” password. Questions about IB access may be directed to the PMB IB Coordinator via email. 
 Useful Links and Contacts 
• CTEP Forms, Templates, Documents: http://ctep.cancer.gov/forms/  
• NCI CTEP Investigator Registration: RCRHelpDesk@nih.gov  
 
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
81 
 • PMB policies and guidelines: 
http://ctep.cancer.gov/branches/pmb/agent_management.htm   
• PMB Online Agent Order Processing (OAOP) application: https://eapps -
ctep.nci.nih.gov/OAOP/pages/login.jspx 
• CTEP Identity and Access Management (IAM) account: https://ctepcore.nci.nih.gov/iam/ 
• CTEP IAM account help: ctepreghelp@ctep.nci.nih.gov 
• IB Coordinator: IBCoordinator@mail.nih.gov 
• PMB email: PMBAfterHours@mail.nih.gov 
• PMB phone and hours of service: (240) 276-6575 Monday through Friday between 8:30 am and 4:30 pm (ET) 
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  
Specimens will be collected for several planned correlative studies. Many samples will be 
processed and stored to be run in batches. The CITN Immune Monitoring Laboratory will provide lab kits and shipping supplies. Specific instructions on numbers and types of tubes required for each visit are provided in the CITN-14 Laboratory Manual.  
When blood volume or specimen material is limit ed, the correlative studies will be considered 
secondary to tests needed to make clinical decisions. Prioritization of secondary tests will be 
made based on technical considerations, total amount of sample from each individual subject, total number of samples acquired, total number of each assay performed, and information gained from the assays performed to date. The anticipated priority correlatives are: 
Plasma/serum -based  studie
 s 
1. Multiplex Cytokines – Multiplex ELISA  
2. Kynurenine and tryptophan (Kyn/Trp) ratios and  
Cell associated studies  
1. Evaluation of peripheral CD4+ and CD8+ T-cell counts 
2. T-Cell Receptor Repertoire Analysis – TCR sequencing 
3. Evaluation of the effect of atezolizumab with and without CYT107 on circulating 
Lymphocyte and Monocyte numbers and Phenotype 
4. Tumor-Associated Neoantigen discovery – Whole Exome Sequencing and RNAseq and Antigen Prediction 
5. Antitumor Immune T -cell Responses  
Biopsy associated studies 
1. Slide -Based Immune Phenotype Panel – Multispectral IHC  
2. Assessment of tumor biopsy by gene expression analysis -- Interferon γ (INFγ ) Gene 
Expression Signature - NanoString® nCounter® Human Immunology V2 Panel and the 
nCounter® PanCancer Immune Profiling Panel 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
82 
 3. Assessment of PD -L1 expression at Baseline and Post- treatment – 
Immunohistochemistry (IHC) 
4. Tumor-Associated Neoantigen discovery – Whole Exome Sequencing and RNAseq and 
Antigen Prediction 
9.1 Integrated  Correlative Studies  
 Evaluation of peripheral CD4+ and CD8+ T- cell counts – Integrated Laboratory 
Correlative Study #1 
9.1.1.1 Collection of Specimen(s)  
Blood draws will be performed by venipuncture on study subjects in Red-Top or Gold SST or other blood draw tubes as specified per local site SOP. 
9.1.1.2 Handling of Specimens(s)  
Blood Samples will be collected at room temperature and shipped ambient to the local clinical lab.  
9.1.1.3 Shipping of Specimen(s)  
Blood collection tubes will be shipped at ambient temperature to the designated local clinical, CLIA compliant laboratory the same day as the blood draw. 
9.1.1.4 Site(s) Performing Correlative Study  
Assays will be performed at each local clinical site. Assays are to be performed at each site by a CLIA compliant laboratory. The specific technique is not specified in the protocol. 
 
 Slide-Based Immune Phenotype Panel – Multispectral IHC – Integrated Laboratory 
Correlative Study #2 
9.1.2.1 Collection of Specimen(s)  
Formalin -fixed, paraffin -embedded archival tissue block(s) from tumor obtained 
within 2 years from the screening visit will be identified by the clinical site at the relevant pathology laboratories where they were processed and stored. Tissue blocks are preferred, however FFPE slides can substitute if blocks are unavailable. Alternatively, patients will undergo a pre -treatment biopsy (core, punch, or 
excisional)  as part of this protocol. Patient will undergo a post-treatment biopsy (core, 
punch, or excisional)  if deemed relatively safe and technically feasible as part of this 
protocol.  
9.1.2.2 Handling of Specimens(s)  
Formalin -fixed, paraffin -embedded archival tumor blocks will be requested by fax 
and phone by the clinical site from the relevant pathology laboratory by providing the patient’s name, consent form, and date of collection. If patients undergo biopsy as part of this protocol, tissue will be placed in formalin  for overnight shipping to the 
CIML.   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
83 
 9.1.2.3 Shipping of Specimen(s)  
For archival samples, clinical sites will arrange for the formalin -fixed, paraffin -
embedded tumor blocks or FFPE slide to be shipped at ambient temperature to the 
CIML . For biopsies done as part of this protocol, tissue in formalin will be shipped 
overnight at ambient temperature to the CIML. Clinical sites will utilize a web -based 
specimen system (BSI -Web) to communicate with the CIML. After  sectioning at the 
CIML, the CIML will coordinate shipment of unst ained slides to Dr. at 
Fred Hutch . 
9.1.2.4 Site(s) Performing Correlative Study  
Assays will be performed by Dr. at Fred Hutch . 
 
 Assessment of tumor biopsy by gene expression analysis -- Interferon γ (INFγ) Gene 
Expression Signature - NanoString® nCounter® Human Immunology V2 Panel and the 
nCounter® PanCancer Immune Profiling Panel – Integrated Laboratory Correlative 
Study #3 
9.1.3.1 Collection of Specimen(s)  
Formalin -fixed, paraffin -embedded archival tissue block(s) from tumor obtained 
within 2 years from the screening visit will be identified by the clinical site at the relevant pathology laboratories where they were processed and stored. Alternatively, patients will undergo a pre- treatment biopsy (core, punch, or excisional) as part of 
this protocol. Patients will undergo a post- treatment biopsy  (core, punch, or 
excisional) if deemed relatively safe and technically feasible as part of this protocol. 
9.1.3.2 Handling of Specimens(s)  
Formalin -fixed, paraffin -embedded archival tumor blocks will be requested by fax 
and phone by the clinical site from the relevant pathology laboratory by providing the patient’s name, consent form, and date of collection. If patients undergo biopsy as part of this protocol, tissue will be placed in formalin  for overnight shipping to the 
CIML.  
9.1.3.3 Shipping of Specimen(s)  
For archival samples, clinical sites will arrange for the formalin -fixed, paraffin -
embedded tumor blocks (preferred) or FFPE slide s (if blocks are unavailable)  to be 
shipped at ambient temperature to the CIML . For biopsies done as part of this 
protocol, tissue in formalin will be shipped overnight at ambient temperature to the CIML. Clinical sites will utilize a web -based specimen system (BSI -Web) to 
communicate with the CIML. After  sectioning at the CIML, the CIML will 
coordinate shipment of unstained slides  (or RNA) to NanoString
®. Depending on the 
specific contract, RNA will be extracted from FFPE slides, either at NanoString® or 
the CIML, using established protocols (MAN-10050-02 Preparing Nucleic Acid from FFPE Samples for Use with nCounter
® Assays).   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
84 
 9.1.3.4 Site(s) Performing Correlative Study  
Assays will be performed by NanoString® Technologies in Seattle, WA, and analyzed 
using qualified analytic tools at the immunopathology lab of Fred Hutch . 
 T-Cell Receptor Repertoire Analysis – TCR sequencing – Integrated Laboratory 
Correlative Study #4 
9.1.4.1 Collection of Specimen(s)  
Specimens will include archived and prospectively obtained tumor biopsies and blood 
samples. Blood draws will be performed by venipuncture. 
9.1.4.2 Handling of Specimens(s)  
Biopsy samples will be placed in formalin and shipped to the CIML. Blood collection tubes will be shipped on day of blood draw for overnight delivery to the CIML. 
9.1.4.3 Shipping of Specimen(s)  
Whole blood and biopsies in formalin will be shipped ambient to the CIML. Blood will be processed to PBMC as described above. Clinical sites will utilize a web -based 
specimen system (BSI -Web) to communicate with the CIML. The CIML will 
coordinate shipment of samples to Adaptive Biosciences.  
9.1.4.4 Site(s) Performing Correlative Study  
Samples will be analyzed at Adaptive Bioscience in Seattle, WA , or other agreed 
upon vendor or collaborator. 
 
 Tumor- Associated Neo antigen discovery – Whole Exome Sequencing and RNAseq and 
Antigen Prediction – Integrated Laboratory Correlative Study #5 
9.1.5.1 Collection of Specimen(s)  
Specimens will include archived  tumor blocks (or FFPE slides) and prospectively 
obtained tumor biopsies and blood samples. Blood draws will be performed by 
venipuncture. 
9.1.5.2 Handling of Specimens(s)  
For archival samples, clinical sites will arrange for the formalin -fixed, paraffin 
embedded tumor specimens to be shipped at ambient temperature to the CIML. For 
biopsies done as part of this protocol, tissue in formalin will be shipped overnight at 
ambient temperature to the CIML where they will be embedded in paraffin. Paraffin blocks (or FFPE slides) will be stored at 4
oC under desiccant.  
Blood collection tubes will be shipped on day of blood draw for overnight delivery to the CIML.  Blood will be processed to PBMC as described above and stored in liquid 
nitrogen. Nucleic acid will be extracted from PBMC and from biopsy specimens using vendor-specific protocols.   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
85 
 9.1.5.3 Shipping of Specimen(s)  
Whole blood, archival tumor blocks (or FFPE slides) and biopsies in formalin will be 
shipped ambient to the CIML. Clinical sites will utilize a web -based specimen system 
(BSI -Web) to communicate with the CIML. The CIML will coordinate shipment of 
samples to the Fred Hutch immunopathology lab and/or agreed upon vendor. 
9.1.5.4 Site(s) Performing Correlative Study  
These analyses will be performed using qualified analytes and analytic tools at the immunopathology lab and shared resources of the Fred Hutch  or at a vendor to be 
determined.  
 
 Antitumor Immune T -cell Responses -- ELISPOT – Integrated Laboratory Correlative 
Study #6 
9.1.6.1 Collection of Specimen(s)  
Blood draws will be performed by venipuncture on study subjects just before, during, and at end of treatment.  
9.1.6.2 Handling of Specimens(s)  
Blood collection tubes (for subsequent PBMC isolation) will be shipped on day of blood draw for overnight delivery to the CIML. 
9.1.6.3 Shipping of Specimen(s)  
Blood collection tubes will be shipped overnight at ambient temperature to the CIML using CIML established SOPs. Clinical sites will utilize a web -based specimen 
system (BSI -Web) to communicate with the CIML. The CIML will coordinate 
shipment via cryoport of cryopreserved PBMC in the event that a vendor or collaborator performs these studies. 
9.1.6.4 Site(s) Performing Correlative Study  
Assays will be performed in the CIML at Fred Hutch  under the direction of Dr. 
 or an agreed upon vendor or collaborator. 
9.2 Exploratory Correlative Studies 
 Assessment of PD -L1 expression at Baseline and Post- treatment -- 
Immunohistochemistry (IHC) – Exploratory Laboratory Correlative Study #1 
9.2.1.1 Collection of Specimen(s)  
Formalin -fixed, paraffin -embedded archival tissue block(s) from tumor obtained 
within 2 years from the screening visit will be identified by the clinical site at the relevant pathology laboratories where they were processed and stored. Tissue blocks are preferred, however FFPE slides can substitute if blocks are unavailable. Alternatively, patients will undergo a pre -treatment biopsy (core, punch, or 
excisional) as part of this protocol. Patients will undergo a post- treatment biopsy   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
86 
 (core, punch, or excisional) if deemed relatively safe and technically feasible as part 
of this protocol. 
9.2.1.2 Handling of Specimens(s)  
Formalin -fixed, paraffin -embedded archival tumor blocks will be requested by fax 
and phone by the clinical site from the relevant pathology laboratory by providing the patient’s name, consent form, and date of collection. If patients undergo biopsy as part of this protocol, tissue will be placed in formalin for overnight shipping to the 
CIML.  
9.2.1.3 Shipping of Specimen(s)  
For archival samples, clinical sites will arrange for the formalin -fixed, paraffin -
embedded tumor blocks (preferred) or FFPE slide s (if blocks are unavailable)  to be 
shipped at ambient temperature to the CIML. For biopsies done as part of this protocol, tissue in formalin will be shipped overnight at ambient temperature to the CIML. Clinical sites will utilize a web -based specimen system (BSI -Web) to 
communicate  with the CIML. After sectioning at the CIML, the CIML will 
coordinate shipment of unstained slides to HistoGeneX (Naperville, IL) or other 
agreed  upon vendor. 
9.2.1.4 Site(s) Performing Correlative Study  
Assays will be performed by HistoGeneX or other agreed upon vendor. Samples would be run in batches. 
 
 Evaluation of the effect of atezolizumab with and without CYT107 on circulating 
Lymphocyte and Monocyte numbers and Phenotype – Exploratory Laboratory 
Correlative Study #2 
9.2.2.1 Collection of Specimen(s)  
Blood draws will be performed by venipuncture on study subjects just before, during, and at end of treatment.  
9.2.2.2 Handling of Specimens(s)  
Blood Samples will be collected at room temperature and shipped ambient to the CIML the same day as the blood draw. The sample must be received at the CIML within 24 hours of blood draw. 
9.2.2.3 Shipping of Specimen(s)  
Blood collection tubes will be shipped at ambient temperature to the CIML. Clinical sites will utilize a web -based specimen system (BSI -Web) to communicate with the 
CIML.  
9.2.2.4 Site(s) Performing Correlative Study  
Quantification of PBMC and T-cell subsets will be performed under the direction of Dr.  in the CIML at Fred Hutch.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
87 
  
 Multiplex Cytokines -- Multiplex ELISA – Exploratory Laboratory Correlative Study #3 
9.2.3.1 Collection of Specimen(s)  
Whole blood will be collected into red-top tubes by venipuncture. 
9.2.3.2 Handling of Specimens(s)  
Blood samples will be processed to frozen serum at the local labs and stored frozen at 
-80°C. 
9.2.3.3 Shipping of Specimen(s)  
Frozen serum vials will be shipped from clinical sites to the CIML. Clinical sites will utilize a web -based specimen system (BSI -Web) to communicate with the CIML. The 
CIML will coordinate shipments of serum to the Fred Hutch Shared Resource facility or other collaborator, as needed. 
9.2.3.4 Site(s) Performing Correlative Study  
Assays will be performed at the Fred Hutch Shared Resource facility or other agreed upon collaborator or vendor. 
 
 Kynurenine and tryptophan (Kyn/Trp) Ratios and Plasm a Arginine levels – Exploratory 
Laboratory Correlative Study #4 
9.2.4.1 Collection of Specimen(s)  
Blood draws will be performed by venipuncture on study subjects at time points before, during, and after treatment. 
9.2.4.2 Handling of Specimens(s)  
Plasma will be isolated by the local laboratory and frozen at - 80°C.  
9.2.4.3 Shipping of Specimen(s)  
Plasma samples will be batch shipped overnight on dry ice to the CIML. Sites will utilize a web -based specimen system (BSI -Web) to communicate with the CIML. The 
CIML will coordinate the shipment of samples to the agreed upon collaborator or vendor. 
9.2.4.4 Site(s) Performing Correlative Study  
Kynurenine and tryptophan and Arginine levels will be assessed at an agreed upon collaborator or vendor to be determined.  
   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
88 
 
 Microbiome Analyses – Exploratory Laboratory Correlative Study #5 
9.2.5.1 Collection of Specimen(s)  
Fecal samples will be collected by patients pre- treatment and post- treatment  using 
standard, at home stool-collection procedures using standardized fecal swab/storage 
devices.  
9.2.5.2 Handling of Specimens(s)  
Samples will be initially stored frozen at home by patients and returned to the clinical research site at their next study visit and stored at the local site at - 80°C.  
9.2.5.3 Shipping of Specimen(s)  
Frozen samples will be batch shipped overnight on dry ice to the CIML. Sites will utilize a web -based specimen system (BSI -Web) to communicate with the CIML. The 
CIML will coordinate the shipment of samples to Dr.  at Fred Hutch . 
9.2.5.4 Site(s) Performing Correlative Study  
Assays will be performed in collaboration with Dr.  at Fred Hutch or 
other collaborator. 
9.3 Special Studies  
 Immunogenicity Testing 
The formation of anti-drug antibodies (ADA) and neutralizing anti -drug antibodies  
(NADA) to  glyco- rhIL-7 (CYT107) will be evaluated in  the Safety Run -In/Experimental 
Arm subjects only, on Cycle 1, Day 1 before the first CYT107 injection and on Cycle 3, Day 1. If positive on Cycle 3, Day 1, immunogenicity  testing  will be repeated at the end 
of the study.  
9.3.1.1 Collection of specimen(s)  
Blood draws will be performed by venipuncture on study subjects before, during and at end of treatment.   
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
89 
 9.3.1.2 Handling of specimen(s)    
Plasma will be isolated by the local laboratory and frozen at -80C. 
9.3.1.3 Shipping of Specimen(s)   
Plasma s amples will be batch shipped overnight on dry ice to the CIML (Seattle, 
WA). Sites will utilize a web -based specimen system (BSI -Web) to communicate 
with the CIML. The CIML will coordinate the shipment of samples to the agreed 
upon collaborator or vendor.  
9.3.1.4  Site(s) Performing Immunogenicity Testing 
ADA and NADA to glyco- rhIL-7 (CYT107)  will be performed by Eurofins Scientific 
(Vergeze, France ) who will perform both ELISA Binding (non-neutralizing) and 
neutralizing antibody assays according to their Standard Operating Procedure.  
 
 CYT107 Pharmacokinetics 
The pharmacokinetic profile of CYT107 levels will be assessed to determine if 
Atezolizumab has an effect on CYT107 PK levels. The samples will be collected before 
CYT107 treatment on Cycle 1, Day 1 and again on Cycle 1, Day 22.  
9.3.2.1 Collection of specimen(s)   
Blood draws will be performed by venipuncture on study subjects before and during 
study treatment.  
Table 9.3.2 Pharmacokinetics timepoints   
Cohort  Pharmacokinetic timepoints for CYT107   
Safety Run -in subjects  Day 1, Immediate Pre -dose CYT107  
Safety Run -in subjects  Day 1, 2 hours (± 15  mins) after CYT107 administration is complete  
Safety Run -in subjects  Day 1, 4 hours (± 15 mins) after CYT107 administration is complete  
Safety Run -in subjects  Day 1, 6 hours (± 15 mins) after CYT107 administration is complete  
Safety Run -in subjects  Day 22 , Immediate Pre -dose CYT107 and Atezolizumab  
Safety Run -in subjects  Day 22 , 2 hours (± 15  mins)  after CYT107 administration  is complete * 
Safety Run -in subjects  Day 22 , 4 hours (± 15  mins)  after CYT107 administration  is complete * 
Safety Run -in subjects  Day 22 , 6 hours (± 15  mins)  after CYT107 administration  is complete * 
*Blood draws are timed after CYT107 administration is complete, not completion of Atezolizumab 
infusion.  
 
9.3.2.2 Handling of Specimens(s)  
Plasma  will be isolated by the local laboratory and frozen at - 80°C.   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
90 
 9.3.2.3 Shipping of Specimen(s)  
Plasma  samples will be batch shipped overnight on dry ice to the CIML (Seattle, 
WA). Sites will utilize a web -based specimen system (BSI -Web) to communicate 
with the CIML. The CIML will coordinate the shipment of samples to the agreed 
upon collaborator or vendor. 
9.3.2.4 Site(s) Performing Pharmacokinetics Testing  
PK of glyco- rhIL-7 (CYT107) will be performed by Eurofins Scientific (Vergeze, 
France) who will perform assays according to their Standard Operating Procedures.  
 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
95 11. MEASUREMENT OF EFFECT  
11.1 Antitumor Effect – Solid Tumors 
For the purposes of this study, patients should be re- evaluated for response every 9 weeks.  
Response and progression will be evaluated in this study using the new international criteria 
proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [ Eisenhauer 2009]. Changes in the largest diameter (unidimensional measurement) 
of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.  
This study will also evaluate response and progression using immune- related respons
 e criteria 
(irRC) [ Wolchok 2009] . See Appendix C  for a detailed description of the evaluation criteria. 
 Definitions  
Evaluable for toxicity. All patients will be evaluable for toxicity from the time of their 
first treatment with atezolizumab and/or CYT107.  
Evaluable for objective response. Only those patients  who have measurable disease 
present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response. These patients will have their 
response classified accord ing to the definitions stated below. (Note: Patients who exhibit 
objective disease progression  before  the end of cycle 1 will also be considered evaluable.) 
Evaluable Non- Target Disease Resp
 onse. Patients who have lesions present at baseline 
that are evaluable but do not meet the definitions of measurable disease, have received at least one cycle of therapy, and have had their disease re- evaluated will be considered 
evaluable for non- target disea se. The response assessment is based on the presence, 
absence, or unequivocal progression of the lesions. 
 Disease Parameters  
Measurable disease. Measurable lesions are defined as those that can be accurately 
measured in at least one dimension (longest diameter to be recorded) as ≥20 mm (≥2  cm) 
by chest x- ray or as ≥10 mm (≥1  cm) with CT scan, MRI, or calipers by clinical exam. 
All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters).  
Note : Tumor lesions that are situated in a previously irradiated area might or might not 
be considered m
easurable.  
Malignant lymph nodes. To be considered pathologically enlarged and measurable, a 
lymph node must be ≥15 mm (≥1.5 cm) in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm [0.5 cm]). At baseline and in follow-up, only the short axis will be measured and followed.  
 ------
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
96 Non-measurable disease. All other lesions (or sites of disease), including small lesions 
(longest diameter <10  mm [<1  cm] or pathological lymph nodes with ≥10 to <15 mm [≥1 
to <1.5 cm] short axis), are considered non- measurable disease. Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis 
cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non- measurable. 
Note : Cystic lesions that meet the criteria for radiographically defined simple cysts 
should not be conside
red as malignant lesions (neither measurable nor non- measurable ) 
since they are, by definition, simple cysts. 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if noncystic  lesions are present in the same patient, these are preferred for selection as 
target lesions.  
Target lesions . All measura
 ble lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs, should be identified as target lesions  and recorded and measured at baseline. Target lesions should be selected on the 
basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does  not lend itself 
to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected. A sum of the diameters (longest for nonnodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported 
as the baseline sum diameters. If lymph nodes are to be included in the sum, then only the 
short axis is added into the sum. The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.  
Non-target lesions . All other lesi
 ons (or sites of disease) including any measurable 
lesions over and above the 5 target lesions should be identified as non- target lesions  and 
should also be recorded at baseline. Measurements of these lesions are not required, but the presence, absence, or in rare cases unequivocal progression of each should be noted throughout follow-up. 
 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers. All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow- up. Imaging- based 
evaluation is preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.   
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
97 Clinical lesions  Clinical lesions will only be considered measurable when they are 
superficial ( e.g., skin nodules and palpable lymph nodes) and ≥10 mm (≥1  cm) diameter 
as assessed using calipers ( e.g., skin nodules). In the case of skin lesions, documentation 
by color photography, including a ruler to estimate the size of the lesion, is 
recommended.  
Chest x -ray Lesions on ches t x-ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung. However, CT is preferable. 
Conventional CT and MRI This guideline  has defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is 5 mm (0.5 cm) or less. If CT 
scans have slice thickness greater than 5 mm (0.5  cm), the minimum size for a 
measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations ( e.g., for body scans). 
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal resolution; how
ever, there are many image acquisition variables involved in MRI, which 
greatly impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI is variable globally. As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease. Furthermore, as with CT, the modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the image 
acquisition protocol should be followed as closely as possible to prior scans. Body scans 
should be performed with breath-hold scanning techniques, if possible. 
PET- CT At present, the low dose or attenuation correction CT portion of a combined 
PET-CT is not always of optimal diagnostic CT quality for use with RECIST 
measurements. However, if the site can document that the CT performed as part of a PET- CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), 
then the CT portion of the PET- CT can be used for RECIST measurements and can be 
used interchangeably with conventional CT in accurately measuring cancer lesions over time. Note, however, that the PET portion of the CT introduces additional data which may bias an investigator if it is not routinely or serially performed. 
Ultrasound Ultrasound is not useful in assessment of lesion size and should not be used 
as a method of measurement. Ultrasound examinations cannot be reproduced in their 
entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to the next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
Endoscopy, Laparoscopy The utiliza
 tion of these techniques for objective tumor 
evaluation is not advised. However, such techniques may be useful to confirm complete 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
98 pathological response when biopsies are obtained or to determine relapse in trials where 
recurrence after  CR or surgical resection is an endpoint. 
Tumor markers  Tumor marker s alone cannot be used to assess response. If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response. Specific guidelines for both CA-125 response (in recurrent ovarian cancer) [Rustin 2004] and PSA response (in recurrent prostate cancer) [ Bubley 
1999; Scher 2008] have been published. In addition, the Gynecologic Cancer Intergroup 
has developed CA-125 progression criteria which are to be integrated with objective tumor assessment for use in first- line trials in ovarian cancer [ Vergote 2000 ]. 
Cytology, Histology These techniques can be used to differentiate between PR and CR in 
rare cases ( e.g., residual lesions in tumor types, such as germ cell tumors, where known 
residual benign tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during t
reatment when the measurable tumor has met criteria for response or 
stable disease is mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) and PD . 
FDG -PET While FDG -P
 ET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible 'new' disease). New lesions on the basis of FDG -PET imaging can be identified according to the following algorithm: 
a. Negative FDG -PET at ba
 seline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion. 
b. No FDG -PET at baseline and a positive FDG- PET at follow -up: If the positive FDG-
PET at follow -up corresponds to a new site of disease confirmed by CT, this is PD. If 
the positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, 
additio nal follow-up CT scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG -PET scan). If the positive FDG- PET at follow -up corresponds to a pre-existing 
site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD. 
c. FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring. The use of FDG-PET in this circumstance should be prospectively described in the protocol and supported by disease- specific medical literature for the indication. 
However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy resolution/sensitivity. 
Note : A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image. 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
99 
 Response Criteria  
11.1.4.1 Evaluation of Target Lesions 
Complete Response (CR): Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to 
<10 mm (<1  cm).  
Partial Response (PR): At least a 30% de crease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters.  
Progressive Disease (PD) : At least a 20% incr ease in the sum of the diameters of 
target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonst rate an absolute increase of at least 5 mm (0.5  cm). 
(Note: the appearance of one or more new lesions is also considered progressions). 
Stable Disease (SD) : Neither suffi
 cient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 
study. 
11.1.4.2 Evaluation of Non-Tar get Lesions 
Complete Response (CR) : Disappearance of  all non -target lesions and normalization 
of tumor marker level. All lymph nodes must be non -pathological in size (<10  mm 
[<1 cm] short axis).  
Note : If tumor markers are initially above the upper normal limit, they must 
normalize for
 a patient to be considered in complete clinical response.  
Non-CR/Non -PD: Persiste nce of one or more non- target lesion(s) and/or maintenance 
of tumor marker level above the normal limits.  
Progressive Disease (PD) : Appearance of  one or more new lesions and/or 
unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.  
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating phys
ician should prevail in such circumstances, and the progression 
status should be confirmed at a later time by the review panel (or PI ). 
11.1.4.3 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and 
confirmation criteria.   -----
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
100 For Patients with Measurable Disease ( i.e., Target Disease) 
Target 
Lesions  Non-Target Lesions  New 
Lesions  Overall 
Response  Best Overall Response 
when Confirmation is 
Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non-CR/Non -PD No PR >4 wks. Confirmation**  
CR Not evaluated  No PR  
PR Non-CR/Non -PD/not 
evaluated  No PR  
SD Non-CR/Non -PD/not 
evaluated  No SD Documented at least once 
>4 wks. from baseline** 
PD Any Yes or No  PD no prior SD, PR , or CR  
Any PD***  Yes or No  PD  
Any Any Yes PD  
 See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
** Only for non-randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in non- target lesions may be accepted as 
disease progression.  
Note: Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as “symptomatic 
deterioration.” Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
 
For Patients with Non -Measurable Disease ( i.e., Non -Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is increasingly 
used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions 
can be measured is not advised  
 
 Duration of Response 
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).   ------
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
101 The duration of overall CR is measured from the time measurement criteria are first met 
for CR until the first date that progressive disease is objectively documented.  
Duration of stable disease: SD is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.  
 Progression -Free Survival  
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. 
 Response Review  
Radiological images will be collected for a possible review of response by an expert(s) independent of the study. Measurement of tumor response by a trained radiologist/nuclear medicine physician at each clinical site will be chronicled and reported unless  or until a 
central expert review takes place.  
11.2 Other Response Parameters: Immune -Related Response Criteria (irRC)  
See Appendix C  for a detailed description of the evaluation criteria. 
12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY REQUIREMENTS  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements). 
12.1 Study Oversight  
This protocol is
 monitored at several levels, as described elsewhere in this section. The Protocol 
PI is responsible for monitoring the conduct and progress of the clinical trial, including the 
ongoing review of accrual, patient-specific clinical and laboratory data, and routine and serious AEs; reporting of expedited AEs ; and accumulation of reported AEs from other trials testing the 
same drug(s). The Protocol PI and statistician have access to the data at all times.  
All Study Investigators at participating sites who register/enroll patients on a given protocol are responsible for timely submission of data via the mechanism described elsewhere in this section. All studies are also reviewed in accordance with the enroll ing institution’s data safety monitoring 
plan. 
12.2 Data Submission/Reporting  
Medidata Rave is a clinical data management system being used for data collection for this 
trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.    --------
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
102 Requirements to access Rave via iMedidata:  
• A valid CTEP -IAM account; and  
• Assigned a Rave role on the LPO or PO roster at the enrolling site of: Rave CRA, Rave 
Read Only, Rave CRA (LabAdmin), Rave SLA, or Rave Investigator.  
 
Rave role requirements:  
• Rave CRA or Rave CRA (Lab Admin) role must have a minimum of an Associate Plus (AP) registration type; 
• Rave Investigator role must be registered as an  Non-Physician Investigator (NPIVR) or 
Investigator (IVR); and 
• Rave Read Only role must have at a minimum an Associates (A) registration type.  
 
Refer to https://ctep.cancer.gov/investigatorResources/default.htm  for registration types and 
documentation required.  
 This study has a De
legation of Tasks Log (DTL). Therefore, those requiring write access to Rave 
must also be assigned the appropriate Rave tasks on the DTL.  
 
Upon initial site registration approval for the study in Regulatory Support System ( RSS), all 
persons with Rave roles assigned on the appropriate roster will be sent a study invitation email  
from iMedidata . To accept the invitation, site users must either click on the link in the email or 
log in to iMedidata via the CTSU members’ website  under Data Management > Rave Home and 
click to accept the invitation in the Tasks pane located in the upper right  corner of the iMedidata 
screen . Site staff will not be able to access the study in Rave until all required Medidata and 
study specific trainings are completed. Trainings will be in the form of electronic learnings (eLearnings ) and  can be accessed by clicking on the eLearning  link in the Tasks  pane located in 
the upper right corner  of the iMedidata screen.  If an eLearning is required for a study and has not 
yet been taken, the link to the eLearning will appear under the study name in the Studies pane located in the center of the iMedidata screen; once the successful completion of the eLearning has been recorded, access to the study in Rave will be granted, and a Rave EDC  link will replace 
the eLearning link under the study name.
 
Site staff that have not previously activated their iMedidata/Rave account at the time of initial site registration approval for the study in RSS will also receive a separate invitation from iMedidata to activate their account. Account activation instructions are located on the CTSU website, Rave tab under the Rave resource materials (Medidata Account Activation and Study Invitation Acceptance). Additional information on iMedidata/Rave is available on the CTSU members’ website under the Rave tab at www.ctsu.org/RAVE/  or by contacting the CTSU Help 
Desk at 1 -888-823-5923 or by email  at ctsucontact@westat.com . 
 Method 
This study will be monitored by the CTMS. Data will be submitted to CTMS at least once every 2 weeks via Medidata Rave (or other modality if approved by CTEP). Information on CTMS reporting is available at: http://www.theradex.com/clinicalTechnologies/?National- Cancer -Institute -NCI-11.   --
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
103 For CTMS monitored studies, after users have activated their accounts, please contact the 
Theradex Help Desk at (609) 619-7862 or by email at CTMSSupport@theradex.com  for 
additional support with Rave and completion of CRFs. 
 Responsibility for Data Submission 
For trials monitored by CTMS, a quarterly report of data will be provided by Theradex to the Coordinating Center. 
12.3 CTEP Multicenter Guidelines  
This protocol will adhere to the policies and requirements of the CTEP Multicenter Guidelines. The specific responsibilities of the P I and the Coordinating Center (Study Coordinator) and the 
procedures for auditing are presented in Appendix B . 
• The Principal Investigator/Coordinating Center is responsible for distributing all IND Action 
Letters or Safety Reports received from CTEP to all participating institutions for submission to their individual IRBs for action as required. 
 
• Except in very unusual circumstances, each participating institution will order DCTD-
supplied agents directly from CTEP. Agents may be ordered by a participating site only after the initial IRB approval for the site has been forwarded by the Coordinating C enter to the 
CTEP PIO ( PIO@ctep.nci.nih.gov) except for Group studies. 
12.4 Collaborative Agreements Language 
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cance r 
Treatment and Diagnosis. Therefore, the following obligations/guidelines, in addition to the provisions in the “Intellectual Property Option to Collaborator” (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ) contained within the 
terms of award, apply to the use of the Agent(s) in this study: 
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor can 
Agent(s) be tra
nsferred or licensed to any party not participating in the clinical study. 
Collaborator(s) data for Agent(s) are confidential and proprietary to Collabor ator(s) and 
shall be maintained as such by the investigators. The protocol documents for studies utilizing Agents contain confidential information and should not be shared or distributed without the permission of the NCI. If a copy of this protocol is requested by a patient or patient’s family member participating on the study, the individual should sign a confidentiality agreement. A suitable model agreement can be downloaded from: http://ctep.cancer.gov. 
2. For a clinical protocol where there is an investigational Agent used in combination with 
(an)other Agent(s), each the subject of different Collaborative Agreements, the access to and use of data by each Collaborator shall be as follows (data pertaining to such combination use shall hereinafter be referred to as "Multi- Party Data”):   ----------
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
104 a. NCI will provide all Collaborators with prior written notice regarding the existence 
and nature of any agreements governing their collaboration with NCI, the design of the proposed combination protocol, and the existence of any obligations that would tend to restrict NCI's participation in the proposed combination protocol. 
b. Each Collaborator shall agree to permit use of the Multi- Party Data from the clinical 
trial by any other Collaborator solely to the extent necessary to allow said other Collaborator to develop, obtain regulatory approval, or commercialize its own Agent.  
c. Any Collaborator having the right to use the Multi- Party Data from these trials must 
agree in writing before the commencement of the trials that it will use the Multi- Party 
Data solely for development, regulatory approval, and commercialization of its own Agent. 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless additional disclosure is required by law or court order as described in the IP Option to Collaborator (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ). Additionally, 
all Clinical Data and Results and Raw Data will be collected, used and disclosed consistent with all applicable federal statutes and regulations for the protection of human subjects, including, if applicable, the Standards for Privacy of Individually Identifiable Health Information set forth in 45 C.F.R. Part 164. 
4. When a Collaborator wishes to initiate a data request, the request should first be sent to 
the NCI, who w
ill then notify the appropriate investigators (Group Chair for Cooperative 
Group studies, or PI for other studies) of Collaborator's wish to contact them.  
5. Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for this clinical trial.  
6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP by 
the Group office for Cooperative Group studies or by the PI  for non –Cooperative Group 
studies for immediate delivery to Collaborator(s) for advisory review and comment before  submission for publication. Collaborator(s) will have 30 days from the date of 
receipt for review. Collaborator shall have the right to request that publication be delayed for up to an additional 30 days in order to ensure that Collaborator’s confidential and proprietary data, in addition to Collaborator(s)’s intellectual property rights, are protected. Copies of abstracts must be provided to CTEP for forwarding to Collaborator(s) for courtesy review as soon as possible and preferably at least three (3) days before submission, but in any case, before  presentation at the meeting or publication 
in the proceedings. Press releases and other media presentations must also be forwarded to CTEP before  release. Copies of any manuscript, abstract and/or pre ss release/ media 
presentation should be sent to: 
Email: ncicteppubs@mail.nih.gov 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
105 The Regulatory Affairs Branch will then distribute them to Collaborator(s). No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator’s confidential/ proprietary information. 
12.5 Genomic Data Sharing Plan: N/A 
13. STATISTICAL CONSIDERATIONS  
This section outlines the statistical analysis strategy and methods for the study. If, after the study 
has begun, but before the conduct of any analysis, changes are made to primary and/or key secondary hypotheses or the statistical methods related to those hypotheses, then the protocol will be amended (consistent with ICH Guideline E -9). Changes to exploratory or other non-
confirmatory  analyses made after the protocol has been finalized, along with an explanation as to 
when and why they occurred, will be listed in the Clinical Study Report (CSR) for the study. Post hoc exploratory analyses will be clearly identified in the CSR. No separate Statistical Analysis Plan (SAP) will be issued for this study. 
13.1 Responsibility for Analyses 
The statistical analysis of the data obtained from this study will be the responsibility of Fred 
Hutch  as part of the CITN.  
13.2 Study Design/Objectives  
This is a phase II trial of atezolizumab (MPDL3280A) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma. The trial follows a randomized, controlled trial design, with an initial ‘Safety Run- In’ phase d esigned to evaluate 
the acute safety profile of the investigational treatment combination. The Safety Run- In phase is 
designed to demonstrate that the incidence of DLTs is 16.7% or less in 6 patients receiving the 
investigational combination. These patient s will not be included as part of the overall analysis 
since they are not randomized.  Due to the non-randomized nature of the enrollment for these six 
patients, the inclusion of these patients in the overall analysis could confound and bias results of 
any randomized comparisons. Hence, these 6 patients will be analyzed and reported separately both for safety and for efficacy. However, toxicity data from all patients will be reviewed in the aggregate at the time of the interim and final analysis to evaluate overall patterns.  
The randomized trial is designed to evaluate the improvement in the objective response rate (ORR) of CYT107 + atezolizumab compared to atezolizumab alone in patients with advanced/unresectable bladder cancer who have progressive disease after  a platinum- based 
chemotherapy regimen. An interim futility analysis will be conducted when 50% of planned 
sample size have their  first disease assessment  and survival information. An exploratory analysis 
will be conducted to evaluate the ORR after all patients have been followed up for 2 years.  
 Primary Objective  
The primary endpoint will be the ORR, defined by CR or PR as measured by RECIST v1.1.  -----
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
106 For patients with disease that progressed after at least one platinum- based treatment 
regimen, the ORR for atezolizumab monotherapy is 14.8%.  
The Cochran Mantel Haenszel test will be conducted to compare ORR in the 
experimental arm (atezolizumab + CYT107) to the ORR in the control arm (atezolizumab monotherapy). A one- sided significance level of 0.10 will be considered for the test.  
13.3 Sample Size/Accrual Rate  
During the Safety Run-In phase, 6 patients will be assigned to the experimental arm (atezolizumab + CYT107)  with staggered enrollment (refer to Section 5  for details) . The AEs  
will be assessed by the Toxicity Evaluation Committee. If , at any time,  2 or more patients 
experience a protocol -defined DLT (refer to Section 5.2), further enrollment into the trial will be 
suspended. 
If the treatment combination of the experimental arm demonstrates an acceptable safety profile 
in the Safety Run- I
n (1 or fewer patient experiences a protocol -defined DLT), randomized 
enrollment into the trial will begin.  
A total of 54 patients will be enrolled in this study; 6 patients in the Safety Run -In and 48 
patients in the randomized portion of the study. The expected accrual is 4 patients per month total at approximately 8 CITN  sites. A study with 48 randomly assigned patients (1:1 
randomization) will meet the following statistical parameters: H
null = 14.8%; H alt = 45%; one-
sided alpha of 0.10; power 88%. 
The interim futility analysis will be conducted when 24 randomized patients have their first 
disease assessment and survival information. The futility analysis is based on an O’Brien-Fleming boundary, and the futility boundary will be considered to be crossed when the difference of ORR in the experimental arm – ORR in the control arm is less than -0.0063. Under the null hypothesis, the probability of crossing the futility boundary is 48.2%.   
Safety Population: All patients who receive at least 1 dose of the investigational regimen will be considered evaluable for safety and included in the overall safety analysis. For the Safety Run-in phase, in the absence of a DLT, patients must complete the full 28- day DLT wi ndow period to be 
considered evaluable for DLTs. Patients who discontinue from the study before the completion of the full 28-day DLT window for reasons other than the occurrence of a DLT ( e.g., withdrawal 
of consent, rapid tumor progression, death due to rapid tumor progression, AE that does not meet DLT criteria) will not be considered evaluable for DLTs and will be replaced.  
Efficacy Population: The efficacy analysis will be conducted on all random ized patients, based 
upon the intent- to-treat population. 
 
PLANNED ENROLLMENT REPORT  
Racial Categories  Ethnic Categories   
Not Hispanic or Latino  Hispanic or Latino  Totals   
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
108 The endpoints will include the evaluation of the effect of the investigation treatment 
combination on the immune-bias of the tumor microenvironment, based upon baseline and post-baseline tumor biopsy comparisons of: 
• Number, distribution, and phenotype of tumor- infiltrating cells  
• PD-L1 expression 
• Expression of Interferon γ (IFNγ) and associated proinflammatory  gene expression in 
the tumor microenvironment 
Analyses may be also performed to explore the effect of the investigational treatment combination on the number and phenotype of tumor- specific T  cells in the peripheral 
blood, investigate for evidence that the investigational treatment combination increases the exposure of bladder cancer- specific antigens ( e.g., Cancer/Testis Antigens or 
neoantigens), and investigate changes in tumor microenvironment that correlate with response or provide information on potential actionable causes for lack of clinical benefit.  
The effect of CYT107 on the infiltrating T cells will be assessed using the paired baseline and post- baseline results of the patients. The patient’s baseline result will serve as the 
control for the comparison. Log-transformed values will be considered for the comparison of the number of infiltrating T cells.   It was established that the CYT107 dose regimen can double the number of peripheral blood T cells. There had been no prior information on the effect of CYT107 on infiltrating T cells. Assuming the CYT107 dose regimen also similarly doubles the number of infiltrating T cells, standard error of the effect size in the log scale (i.e. log(post- baseline) – log(baseline)) being 1, and a two-sided alpha of 0.10, a sample size 
of 13 paired samples will have 80% power to detect any difference between baseline and post-baseline.  
 
13.6 Reporting and Exclusions  
 Evaluation of Toxicity 
All patients will be evaluable for toxicity from the time of their first treatment with atezolizumab and/or CYT107. 
 Evaluation of Response 
All patients included in the study must be assessed for response to treatment, even if there are major protocol treatment deviations or if they are ineligible. Each patient will be assigned one of the following categories: ( 1) complete response, ( 2) partial response, 
(3) stable disease, ( 4) progressive disease, ( 5) early death from malignant disease, 
(6) early death from toxicity, (7) early death because of other cause, or (9) unknown (not assessable, insufficient data). [Note: By arbitrary convention, category 9 usually designates the “unknown” status of any type of data in a clinical database.] 
All of the patients who met the eligibility criteria (with the possible exception of those 
who received no study medication) should be included in the main analysis of the  
 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
109 response rate. Patients in response categories 4 -9 should be considered to have a 
treatment failure (disease progression). Thus, an incorrect treatment schedule or drug 
administration does not result in exclusion from the analysis of the response rate. Pre cise 
definitions for categories 4-9 will be protocol specific. 
All conclusions should be based on all eligible patients. Subanalyses may then be 
performed on the basis of a subset of patients, excluding those for whom major protocol deviations have been identified (early death due to other reasons, early discontinuation of treatment, major protocol violations, etc. ). However, these subanalyses may not serve as 
the basis for drawing conclusions concerning treatment efficacy, and the reasons for excluding patients from the analysis should be clearly reported. The 95% confidence intervals should also be provided. 
  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
110 14. REFERENCES  
 
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced 
Urothelial Carcinoma. N Engl J Med  2017;376(11):1015-1026.  
Bhindi B, Hermanns T, Wei Y, et al. Identification of the best complete blood count- based predictors for 
bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer  2016;114(2):207-212.  
Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor- specific T 
cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol 
Immunother . 2005;54:307-314.  
Blank C, Mackensen A. Contribution of the PD- L1/PD -1 pathway to T-cell exhaustion: an update on 
implications for chronic infections and tumor evasion. Cancer Immunol Immunother  2007;56(5):739-745.  
Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in 
androgen- independent prostate cancer: recommendations from the Prostate-Specific Antigen Working 
Group. J Clin Oncol  1999;17(11):3461-3467.  
CYT107 Investigator's Brochure. Recombinant interleukin-7 (CYT107), Cytheris SA.  
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti- CTLA -4 antibodies across 
clinical indications. Semin Oncol  2010;37(5):499-507.  
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.  
Fry TJ, Moniuszko M, Creekmore S, et al. IL- 7 therapy dramatically alters peripheral T -cell homeostasis 
in normal and SIV-infected nonhuman primates. Blood 2003;101(6):2294-2299.  
Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor- infiltrating CD8+ 
T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A  
2007;104(9):3360-3365.  
Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death -1 ligand 1 is a 
prognostic factor for malignant melanoma. Cancer  2010;116(7):1757-1766.  
Investigators's Brochure. Atezolizumab (MPDL3280A) -  RO5541267 - Atezolizumab 
(MPDL5543280A) - 5541207-5541215-Ver5541267.pdf.  
Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD- L1 on tumor cells in the escape from host immune 
system and tumor immunotherapy by PD -L1 blockade. Proc Natl Acad Sci U S A  2002;99(19):12293-
12297.  
Kaech SM, Tan JT, Wherry EJ, et al. Selective expression of the interleukin 7 receptor identifies effector 
CD8 T cells that give rise to long- lived memory cells. Nat Immunol  2003;4(12):1191-1198.  
Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr Urol Rep  2001;2(1):62-69.  
Keir ME, Butte MJ, Freeman GJ, et al. PD -1 and its ligands in tolerance and immunity. Annu Rev 
Immunol  2008;26:677-704.  
Kim JM, Chen DS. Immune escape to PD- L1/PD -1 blockade: seven steps to success (or failure). Ann 
Oncol  2016;27(8):1492-1504.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
111 Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 
treatment. J Clin Invest 2009;119(4):997-1007.  
Levy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T- cell recovery and 
thymic output in HIV -infected patients receiving antiretroviral therapy: results of a phase I/IIa 
randomized, placebo- controlled, multicenter study. Clin Infect Dis  2012;55(2):291-300.  
Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive 
function of human CD4+ T reg cells. J Exp Med  2006;203(7):1701-1711.  
Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL -7 for therapeutic application. Nat Rev 
Immunol  2011;11(5):330-342.  
Melchionda F, Fry TJ, Milliron MJ, et al. Adjuvant IL-7 or IL- 15 overcomes immunodominance and 
improves survival of the CD8+ memory cell pool. J Clin Invest  2005;115(5):1177-1187.  
Okazaki T, Honjo T. PD-1 and PD- 1 ligands: from discovery to clinical application. Int Immunol 
2007;19(7):813-824.  
Package Insert. Tecetriq (atezolizumab) [prescribing information]. San Francisco, CA, Genentech, Inc. 
2017.  
Park JH, Yu Q, Erman B, et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival 
cytokines: a novel mechanism for maximizing IL -7-dependent T cell survival. Immunity  2004;21(2):289-
302.  
Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability 
of reinvigoration by PD-1 blockade. Science 2016;354(6316):1160-1165.  
Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin -7 (CYT107) promotes T- cell 
recovery after allogeneic stem cell transplantation. Blood  2012;120(24):4882-4891.  
Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally 
advanced or metastatic urothelial cancer (KEYNOTE -012): a non- randomised, open-label, phase 1b 
study. Lancet Oncol  2017;18(2):212-220.  
Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti- PD-L1) treatment leads to clinical activity in 
metastatic bladder cancer. Nature  2014;515(7528):558-562.  
Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst  2004;96(6):487-488.
 
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol  2008;26(7):1148-1159.
 
Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL- 7 receptors 
discriminates between human regulatory and activated T cells. J Exp Med  2006;203(7):1693-1700.  
Sereti I, Estes JD, Thompson WL, et al. Gut mucosa T lymphocyte restoration in chronically HIV-
infected patients treated with recombinant human interleukin- 7 (rhIL -7). Conference on Retrovirus and 
Opportunistic Infections . Seattle, WA. 2012.  
Sheikh V, Porter BO, DerSimonian R, et al. Administration of interleukin- 7 increases CD4 T cells in 
idiopathic CD4 lymphocytopenia. Blood  2016;127(8):977-988.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
112 Shi LZ, Fu T, Guan B, et al. Interdependent IL-7 and IFN-gamma signalling in T- cell controls tumour 
eradication by combined alpha- CTLA -4+alpha- PD-1 therapy. Nat Commun 2016;7:12335.  
Shindo Y, Unsinger J, Burnham CA, et al. Interleukin-7 and anti-programmed cell death 1 antibody have 
differing effects to reverse sepsis- induced immunosuppression. Shock  2015;43(4):334-343.  
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin  2014;64(1):9-29.  
Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL -7 in humans increases in vivo TCR 
repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med  2008;205(7):1701-1714.  
Sportes C, Babb RR, Krumlauf MC, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010;16(2):727-735.
 
Strome SE, Dong H, Tamura H, et al. B7 -H1 blockade augments adoptive T- cell immunotherapy for 
squamous cell carcinoma. Cancer Res 2003;63(19):6501-6505.  
Swainson L, Kinet S, Mongellaz C, et al. IL-7- induced proliferation of recent thymic emigrants requires 
activation of the PI3K pathway. Blood  2007;109(3):1034-1042.  
Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev 
Immunol  2009;9(12):823-832.  
Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta -analysis. Cancer Epidemiol Biomarkers Prev 2014;23(7):1204-
1212.
 
Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long -term follow -up. Cancer Res 2006;66(7):3381-3385.
 
Tredan O, Menetrier- Caux C, Ray -Coquard I, et al. ELYPSE-7: a randomized placebo-controlled phase 
IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol  2015;26(7):1353-1362.
 
Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst  2000;92(18):1534-
1535.
 
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol  2000;18(17):3068-3077.
 
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid 
tumors: immune -related response criteria. Clin Cancer Res  2009;15(23):7412-7420.  
 
  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
113 APPENDIX A  PERFORMANCE STATUS CRITERIA 
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able to 
carry on all pre- disease performance 
without restriction.  100 Normal, no complaints, no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to 
carry out work of a light or sedentary 
nature ( e.g., light housework, office 
work). 80 Normal activity with effort; some signs 
or symptoms of disease.  
70 Cares for self, unable to carry on normal activity or to do active work.  
2 In bed <50% of the time.  Ambulatory 
and capable of all self- care, but 
unable to carry out any work activities.  Up and about more than 
50% of waking hours. 60 Requires occasional assistance but  is 
able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable of 
only limited self -care, confined to bed 
or chair more than 50% of waking 
hours. 40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated.  Death not imminent.  
4 100% bedridden.  Completely disabled.  Cannot carry on any self -
care.  Totally confined to bed or chair. 20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes progressing 
rapidly. 
5 Dead.  0 Dead.  
  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
114 APPENDIX B  CTEP MULTICENTER GUIDELINES  
If an institution wishes to collaborate with other participating institutions in performing a CTEP -
sponsored research protocol, then the guidelines below must be followed. 
Responsibility of the Protocol Chair 
• The Protocol Chair will be the single liaison with the CTEP Protocol and Information Office 
(PIO). The Protocol Chair is responsible for the coordination, development, submission, and 
approval of the protocol as well as its subsequent amendments. The protocol must not be rewritten or modified by anyone other than the Protocol Chair. There will be only one 
version of the protocol, and each participating institution will use that document. The 
Protocol Chair is responsible for assuring that all participating institutions are using the correct version of the protocol. 
• The Protocol Chair is responsible for the overall conduct of the study at all participating 
institutions and for monitoring its progress. All reporting requirements to CTEP are the 
responsibility of the Protocol Chair. 
• The Protocol Chair is responsible for the timely review of AE to ensure safety of the patients. 
• The Protocol Chair will be responsible for the review of and timely submission of data for 
study analysis. 
Responsibilities of the Coordinating Center 
• Each participating institution will have an appropriate assurance on file with the Office for Human Research Protection (OHRP), NIH. The Coordinating Center is responsible for 
assuring that each participating institution has an OHRP assurance and must maintain copies of IRB approvals from each participating site. 
• Before the activation of the protocol at each participating institution, an OHRP form 310 
(documentation of IRB approval) must be submitted to the CTEP PIO. 
• The Coordinating Center is responsible for central patient registration. The Coordinating Center is responsible for ensuring that IRB approval has been obtained at each participating 
site before the first patient registration from that site.  
• The Coordinating Center is responsible for the preparation of all submitted data for review by 
the Protocol Chair. 
• The Coordinating Center will maintain documentation of AE reports. There are 2 options for 
AE reporting: (1) participating institutions may report directly to CTEP with a copy to the Coordinating Center, or (2) participating institutions report to the Coordinating Center who in turn report to CTEP. The Coordinating Center will submit AE reports to the Protocol Chair for timely review.  
• Audits may be accomplished in one of 2 ways: (1) source documents and research records for 
selected patients are brought from participating sites to the Coordinating Center for audit, or 
(2) selected patient records may be audited on- site at participating sites. If the NCI chooses to 
have an audit at the Coordinating Center, then the Coordinating Center is responsible for 
having all source documents, research records, all IRB approval documents, NCI Drug 
Accountability Record forms, patient registration lis ts, response assessments scans, x -rays, 
etc., available for the audit.  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
115 Inclusion of Multicenter Guidelines in the Protocol 
• The protocol must include the following minimum information: 
 The title page must include the name and address of each participating institution and the 
name, telephone number , and  email  address of the responsible investigator at each 
participating institution.  
 The Coordinating Center must be designated on the title page. 
 Central registration of patients is required. The procedures for registration must be stated in the protocol. 
 Data collection forms should be of a common format. Sample forms should be submitted with the protocol. The frequency and timing of data submission forms to the Coordinating Center should be stated. 
 Describe how AEs will be reported from the participating institutions, either directly to CTEP or through the Coordinating Center. 
 Describe how Safety Reports and Action Letters from CTEP will be distributed to participating institutions.  
Agent Ordering 
• Except in very unusual circumstances, each participating institution will order DCTD-
supplied investigational agents directly from CTEP. Investigational agents may be ordered by 
a participating site only after the initial IRB approval for the site has been  forwarded by the 
Coordinating Center to the CTEP PIO. 
  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
116 APPENDIX C IMMUNE -RELATED RESPONSE CRITERIA 
Introduction 
Increasing clinical experience indicates that traditional response criteria ( e.g., Response 
Evaluation Criteria in Solid Tumors, Version 1.1 [RECIST v1.1][ Eisenhauer 2009] and World 
Health Organization [WHO]) may not be sufficient to fully characterize activity in the new era of target therapies and/or biologics. In studies with cytokines, cancer vaccines, and monoclonal antibodies, CR, PR, or SD has been shown to occur aft er an increase in tumor burden as 
characterized by progressive disease by traditional response criteria. Therefore, conventional response criteria may not adequately assess the activity of immunotherapeutic agents because progressive disease (by initial radiographic evaluation) does not necessarily reflect therapeutic failure. Long term effect on the target disease must also be captured. The immune- related 
response criteria (irRC) are criteria that attempt to do that by enhancing characterization of new response patterns that have been observed with immunotherapeutic agents ( i.e., ipilimumab) 
[Wolchok 2009] . (Note:  The irRC only index and measurable new lesions are taken into 
account.) 
Glossary 
Term  Definition  
SPD sum of the products of the 2 largest perpendicular diameters  
Tumor burden  SPD index lesions  + SPD new, measurable lesions  
Nadir  minimally recorded tumor burden  
irCR  immune -related complete response  
irPD  immune -related progressive disease  
irPR immune -related partial response  
irSD  immune -related stable disease  
irBOR  immune -related best overall response  
 
Baseline Assessment Using irRC  
Step 1. Identify the index lesions (5 lesions per organ, up to 10 visceral lesions and 5 cutaneous lesions). 
Step 2. Calculate the SPD of all of these index lesions: 
× (Second largest diameter of lesion i)"  SPD = 
Post-Baseline Assessments Using irRC  
Step 1. Calculate the SPD of the index lesions. Step 2. Identify new, measurable lesions ( ≥5 × 5 mm; up to 5 new lesions per organ: 5 new 
cutaneous lesions and 10 visceral lesions). Step 3. Calculate the SPD of the new, measurable lesions.  �(Largest diameter of lesion i)
i 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
117 Step 4. Calculate the tumor burden: 
Tumor burden = SPD index lesions  + SPD new, measurable lesions  
Step 5. Calculate the change in tumor burden relative to baseline and the change in tumor burden 
relative to nadir.  
Step 6. Derive the overall response using the table below. 
Overall Response  Criterion  
irCR  Complete disappearance of all lesions (whether measurable or not, and no new 
lesions) confirmed by a repeat, consecutive assessment ≥ 4 weeks from the date 
first documented  
irPR Decrease in tumor burden ≥50% relative to baseline confirmed by a consecutive 
assessment ≥ 4 weeks from the date first documented  
irSD  Criteria for irCR, irPR, and irPD are not met; does not require confirmation  
irPD  Increase in tumor burden ≥25% relative to nadir confirmed by a consecutive 
assessment ≥ 4 weeks from the date first documented  
irCR = immune -related complete response; irPD = immune -related progressive disease; irPR = 
immune -related partial response; irSD = immune -related stable disease.  
Determination of irBOR  
Once a patient has completed all tumor assessments, his/her irBOR may be determined:  
Condition  irBOR  
At least one irCR  irCR  
At least one irPR and no irCR  irPR 
At least one irSD and no irCR and no irPR  irSD  
At least one irPD and no irCR, no irPR, and no irSD  irPD  
irBOR = immune -related best overall response; irCR = immune -related complete response; 
irPD  = immune -related progressive disease; irPR = immune -related partial response; 
irSD  = immune -related stable disease.  
Use of this document is governed by the terms of use on the first page of this document 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
119 If BMI >30, proceed with the following steps: 
• Determine Ideal Weight (1  kg = 2.2 lbs)  
Males:  50 kg + (2.3 kg/inch over 5 feet) 
Females: 45.5 kg + (2.3 kg/inch over 5 feet) 
(Patients less than 5 feet: subtract 2.3  kg/inch) 
•  Determine Adjusted Body Weight:  
Ideal Weight + 0.25 (actual weight – ideal weight) = Adjusted Body Weight 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
120 APPENDIX E MICROBIOME SAMPLE COLLECTION  
Patient Instructions: The clinical research team  will provide you wi th fecal swab/storage devices 
and the instructions sheet at the screening  visit and at the Cycle 3  (Week 8 ) visit.   
1. Collect the sample at home using the standardized fecal swab/storage devices  provided.  
2. Stor
e the sample in the freezer at home.  
3. Return the sample to the clinical research team  at your next study visit.     
 
     
      
  
             
       
      
        
       
  
   
   
       
   
      
      
   
      
     
    
      
       
 
    
             
  
        
    
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
121 APPENDIX F ABBREVIATIONS LIST  
AE  adverse event  
AP  Associate Plus  
BAL   bronchoscopic alveolar lavage 
CAEPR  Comprehensive Adverse Events and Potential Risks 
CBR   clinic al benefit rate  
CDUS   Clinical Data Update System  
CIML   CITN Immune Monitoring Laboratory 
CITN   Cancer Immunotherapy Trials Network  
CNS   central  nervous system 
COPD  chronic obstructive pulmonary disease 
COSC   Central Operating and Statistical Center  
CR  complete response 
CRF   case report form  
CRS   clinical research site  
CSR   clinical study report 
CT  computed tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP   Cancer Therapy Evaluation Program  
CTMS   Clinical Trials Monitoring Service  
CTSU   Cancer Trials Support Unit 
DLT   dose- limiting toxicities  
DMC   data monitoring committee  
DOR   duration of response 
FDA   Food and Drug Administration 
FDF  financial disclosure form 
FFPE   formalin -fixed paraffin -embedded 
FWA   Federal Wide Assurance  
HAART  highly active antiretroviral therapy  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV  human immunodeficiency virus 
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
122 HSCT   hematopoietic stem cell transplantation  
IAM   Identity and Access Management  
ICF  informed consent form 
IDF  Investigator Data Form  
IME  important medical events  
IRB  Institutional Review Board  
LCMV   lymphocytic choriomeningitis virus 
LPO   Lead Protocol Organization  
MDSC   myel oid-derived suppressor cells 
MTD   maximum tolerated dose 
NCI  National Cancer Institute  
NK  natural killer  (cells)  
OAOP   Online Agent Order Processing 
OHRP   Office for Human Research Protection  
OPEN  Oncology Patient Enrollment Network 
ORR   objective response rate  
OS  overal l survival 
PCR   polymer ase chain reaction  
PD  progressive disease  
PFS  progression- free survival  
PI  principal investigator 
PIO  Protocol and Information Office 
PMB   Pharmaceutical Management Branch  
PR  partial response 
PSA  prostate-specific antigen  
RCC   renal cell carcinoma  
RCR   Registration and Credential Repository 
RECIST  Response Evaluation Criteria in Solid Tumors 
RSS  Regulatory Support System 
SAP  statistical analysis plan  
SD  stable  disease  
SOC   syste m organ class  
Use of this document is governed by the terms of use on the first page of this document 
NCI Protocol #: CITN -14 
Version Date:  October 12, 2022  
 
123 SPEER  Specific Protocol Exceptions to Expedited Reporting 
TCR   T- cell receptor 
TIL  tumor- infiltrating lymphocyte  
TNBC   triple -negative breast cancer  
TSH   thyroid -stimulating hormone 
UBC   urothelial bladder cancer  
UC  urothelial carcinoma  
ULN   upper limit of normal 
WGS   whole genome shotgun 
Use of this document is governed by the terms of use on the first page of this document 